[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"SurgiSmoke Solutions\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":404},{"warningLetters":4,"total":403},[5,31,53,73,96,114,139,157,177,201,219,238,256,274,293,313,329,350,369,386],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},1227,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-10-01T13:20:00Z\">10\u002F01\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-09-06T04:00:00Z\">09\u002F06\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fclean-solutions-llc-686995-09062024\">Clean Solutions LLC\u003C\u002Fa>","Division of Pharmaceutical Quality Operations I","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Asim Ozcan\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Clean Solutions LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>791 Paulison Ave., Suite 5\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Clifton\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07011-3608\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:asim@cleansolutionsnj.com\"> asim@cleansolutionsnj.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong>\u003Cbr>\nCMS #686995\u003C\u002Fp>\n\n\u003Cp>9\u002F6\u002F2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Ozcan:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Clean Solutions LLC, FEI 3012305678, at 791 Paulison Ave., Suite 5, Clifton, NJ, from May 6 to 10, 2024.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your May 29, 2024 response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supportive documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures over-the-counter (OTC) topical drug products, such as antibacterial hand soaps containing benzalkonium chloride. You failed to perform adequate identity testing of each component lot used in the manufacture of your drug products. You also relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\u003C\u002Fp>\n\n\u003Cp>Without adequate testing, you do not have scientific evidence that the components conform to appropriate specifications before use in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and conduct for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to perform appropriate testing on your hand sanitizer and antibacterial hand soap drug products prior to release for distribution. Specifically, during the inspection, you stated that no chemical or microbiological analyses are performed on your finished drug products.\u003C\u002Fp>\n\n\u003Cp>Testing is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Because you lacked adequate testing of each batch of your drug products, you do not know whether they conform to all appropriate finished product specifications and are suitable for release to consumers.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to validate the processes used to manufacture your drug products. You also failed to qualify the equipment used to manufacture your drug products.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure that you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>Without adequate process validation, incorporating all manufacturing inputs and parameters that can affect product quality, your firm lacks basic assurance that you can reproducibly deliver products that meet specifications. See FDA's guidance for industry, \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\n\n\u003Cp>• Establishment of adequate procedures describing complaint handling, change control, and employee training procedures (21 CFR 211.22(d)).\u003Cbr>\n• Establishment of an adequate ongoing stability program (21 CFR 211.166(a)).\u003Cbr>\n• Performance of periodic (i.e., at least annual) product reviews (21 CFR 211.180(e)).\u003Cbr>\n• Adequate equipment cleaning and cleaning procedures, as well as appropriate cleaning validation (21 CFR 211.67(a) and 67(b)).\u003Cbr>\n• Appropriate batch production and control records that include documentation of the accomplishment of each significant step in manufacturing of your drug products (21 CFR 211.188(b)).\u003C\u002Fp>\n\n\u003Cp>An adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document Quality Systems approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In response to this letter, clarify whether you intend to continue manufacturing drugs at this or any other facility.\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if you continue manufacturing drugs. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003Cbr>\n\u003Cbr>\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic response to orapharm1_responses@fda.hhs.gov. Your written notification should refer to Warning Letter CMS # 686995 and include FEI: 3012305678.\u003C\u002Fp>\n\n\u003Cp>If you have any questions, contact Compliance Officer Barbara Wilimczyk-Macri at barbara.wilimczyk@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lisa Harlan\u003Cbr>\nProgram Division Director\u003Cbr>\nOPQO Division I\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Asim Ozcan\n\nRecipient Title\n\nPresident\n\nClean Solutions LLC\n\n791 Paulison Ave., Suite 5\n\nClifton, NJ 07011-3608\n\nUnited States\n\nasim@cleansolutionsnj.com\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nWarning Letter\n\nCMS #686995\n\n9\u002F6\u002F2024\n\nDear Mr. Ozcan:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Clean Solutions LLC, FEI 3012305678, at 791 Paulison Ave., Suite 5, Clifton, NJ, from May 6 to 10, 2024.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your May 29, 2024 response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supportive documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nYour firm manufactures over-the-counter (OTC) topical drug products, such as antibacterial hand soaps containing benzalkonium chloride. You failed to perform adequate identity testing of each component lot used in the manufacture of your drug products. You also relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\n\nWithout adequate testing, you do not have scientific evidence that the components conform to appropriate specifications before use in the manufacture of your drug products.\n\n2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and conduct for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\n\nYour firm failed to perform appropriate testing on your hand sanitizer and antibacterial hand soap drug products prior to release for distribution. Specifically, during the inspection, you stated that no chemical or microbiological analyses are performed on your finished drug products.\n\nTesting is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Because you lacked adequate testing of each batch of your drug products, you do not know whether they conform to all appropriate finished product specifications and are suitable for release to consumers.\n\n3. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYou failed to validate the processes used to manufacture your drug products. You also failed to qualify the equipment used to manufacture your drug products.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure that you maintain a stable manufacturing operation throughout the product lifecycle.\n\nWithout adequate process validation, incorporating all manufacturing inputs and parameters that can affect product quality, your firm lacks basic assurance that you can reproducibly deliver products that meet specifications. See FDA's guidance for industry, Process Validation: General Principles and Practices for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\n\n• Establishment of adequate procedures describing complaint handling, change control, and employee training procedures (21 CFR 211.22(d)).\n\n• Establishment of an adequate ongoing stability program (21 CFR 211.166(a)).\n\n• Performance of periodic (i.e., at least annual) product reviews (21 CFR 211.180(e)).\n\n• Adequate equipment cleaning and cleaning procedures, as well as appropriate cleaning validation (21 CFR 211.67(a) and 67(b)).\n\n• Appropriate batch production and control records that include documentation of the accomplishment of each significant step in manufacturing of your drug products (21 CFR 211.188(b)).\n\nAn adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document Quality Systems approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nCGMP Consultant Recommended\n\nIn response to this letter, clarify whether you intend to continue manufacturing drugs at this or any other facility.\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if you continue manufacturing drugs. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic response to orapharm1_responses@fda.hhs.gov. Your written notification should refer to Warning Letter CMS # 686995 and include FEI: 3012305678.\n\nIf you have any questions, contact Compliance Officer Barbara Wilimczyk-Macri at barbara.wilimczyk@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nLisa Harlan\n\nProgram Division Director\n\nOPQO Division I\n\nU.S. Food and Drug Administration","Clean Solutions LLC","clean-solutions-llc-686995-09062024","2026-08-18T06:42:28.856152+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fclean-solutions-llc-686995-09062024","2026-10-26T08:08:15.745138+00:00","Warning Letter","Issued","2024-10-01","686995","Drugs","Mr. Asim Ozcan","2026-08-19T22:31:53.814+00:00","VIA Electronic Mail","2024-09-06",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":18,"fei_number":19,"letter_url":43,"updated_at":44,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":46,"product_type":47,"closeout_date":19,"issuing_office":37,"recipient_name":48,"body_fetched_at":49,"delivery_method":50,"recipient_title":19,"reference_number":51,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},1183,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2024-10-31T04:00:00Z\">10\u002F31\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-10-24T04:00:00Z\">10\u002F24\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmodern-smoking-solutions-llc-693233-10242024\">Modern Smoking Solutions, LLC\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>ER2401076\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Erika Petrosky\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Modern Smoking Solutions, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1921 Commonwealth Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Charlottesville\u003C\u002Fspan>, \u003Cspan>VA\u003C\u002Fspan> \u003Cspan>22901\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 24, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>To Whom It May Concern:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Modern Smoking Solutions, LLC sells and\u002For distributes e-liquid products to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States e-liquid products that lack a marketing authorization order, including: Modern Vape Klown Resurrection 3 MG 100 ML, and Coastal Clouds Apple Watermelon 3MG 60 ML.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2401076, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>John E. Verbeten\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>CC:\u003C\u002Fp>\n\n\u003Cp>DC Laboratories, Inc.\u003Cbr>\n80 13th Ave\u003Cbr>\nRonkonkoma, NY 11779\u003C\u002Fp>\n\n\u003Cp>Coastal Clouds LLC\u003Cbr>\nPO Box 16032\u003Cbr>\nIrvine, CA 92623\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nER2401076\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nErika Petrosky\n\nRecipient Title\n\nOwner\n\nModern Smoking Solutions, LLC\n\n1921 Commonwealth Drive\n\nCharlottesville, VA 22901\n\nUnited States\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nOctober 24, 2024\n\nWARNING LETTER\n\nTo Whom It May Concern:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Modern Smoking Solutions, LLC sells and\u002For distributes e-liquid products to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you offer for sale or distribution to customers in the United States e-liquid products that lack a marketing authorization order, including: Modern Vape Klown Resurrection 3 MG 100 ML, and Coastal Clouds Apple Watermelon 3MG 60 ML.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\n\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2401076, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nJohn E. Verbeten\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nCC:\n\nDC Laboratories, Inc.\n\n80 13th Ave\n\nRonkonkoma, NY 11779\n\nCoastal Clouds LLC\n\nPO Box 16032\n\nIrvine, CA 92623","Modern Smoking Solutions, LLC","modern-smoking-solutions-llc-693233-10242024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmodern-smoking-solutions-llc-693233-10242024","2026-10-26T08:09:27.004411+00:00","2024-10-31","693233","Tobacco","Erika Petrosky","2026-08-19T20:15:39.348+00:00","VIA UPS and Electronic Mail","ER2401076","2024-10-24",{"id":54,"raw":55,"subject":60,"body_html":61,"body_text":62,"firm_name":63,"letter_id":64,"created_at":65,"fei_number":19,"letter_url":66,"updated_at":67,"action_type":22,"case_status":23,"posted_date":68,"marcs_cms_no":69,"product_type":70,"closeout_date":19,"issuing_office":59,"recipient_name":19,"body_fetched_at":71,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":72,"medical_device_id":19,"response_letter_date":19},3127,[56,57,58,59,60,13,13,13],"\u003Ctime datetime=\"2021-10-05T13:20:00Z\">10\u002F05\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-08-09T04:00:00Z\">08\u002F09\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpairon-solutions-llc-616392-08092021\">Pairon Solutions LLC\u003C\u002Fa>","Center for Devices and Radiological Health","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Pairon Solutions LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>13970 SW 72nd Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Portland\u003C\u002Fspan>, \u003Cspan>OR\u003C\u002Fspan> \u003Cspan>97223\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:melissa@paironsolutions.com\"> melissa@paironsolutions.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>DATE: August 9, 2021\u003Cbr>\n\u003Cbr>\nRe: “Arun KN95 Folding Face Mask,” “Deming Surgical Mask,” and “Pairon 3Ply Face Mask” (Blue, White &amp; Black)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.paironsolutionsppe.com\u002F on July 14, 2021. The FDA has observed that your website offers the “Arun KN95 Folding Face Mask,” the “Deming Surgical Mask”, and the “Pairon 3Ply Face Mask” (Blue, White &amp; Black) for sale in the United States. Based on our review, these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>FDA’s review of your website revealed the following statements that establish that the Arun KN95 Folding Face Mask, Deming Surgical Mask, and Pairon 3Ply Face Mask (Blue, White &amp; Black) are intended for the mitigation, prevention, treatment, diagnosis, or cure of disease, including but not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Statements made alongside an image of the Arun KN95 Folding Face Mask that it is “listed on FDA EUA for Non-NIOSH Devices” and representing compliance with “GB2626-2006” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\u003C\u002Fli>\n\t\u003Cli>Statements alongside an image of the Deming Surgical Mask that it provides “99% bacterial efficiency” and “complies ASTM F2100”. The name also incorporates the word “surgical” as well as “medical” written on the box packaging [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\u003C\u002Fli>\n\t\u003Cli>Statements made on the packaging and alongside the images of the Pairon 3Ply Face Mask (Blue, White &amp; Black) that they provide “&gt;95% bacterial efficiency” and “helps filter out … bacteria” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-facemask], [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3ply-face-mask-black], [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fwhite-pairon-3ply-face-mask]\u003C\u002Fli>\n\t\u003Cli>Statements on your firm’s customer blog page representing that the BLUE – Pairon 3Ply Face Mask has been supplied to nursing home facilities [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fblogs\u002Fnews]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Based on our review, your website is offering for sale in the United States, the Arun KN95 Folding Face Mask (which your website represents is manufactured by Dongguan Arun Industrial Co. Ltd.), the Deming Surgical Mask (which your website represents is manufactured by Xiantao Deming Healthcare Products Co., Ltd.), and the Pairon 3Ply Face Mask - Blue, White &amp; Black (which your website represents is manufactured by Wuxi Hingdou Sports Co., Ltd) without marketing approval or clearance from the FDA. Accordingly, these products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\n\n\u003Cp>In addition, these products are misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because their labeling is false or misleading. FDA registration of a device establishment or assignment of a registration number does not denote FDA approval of the establishment or the device. Thus, references to a firm’s establishment registration and registration number that create an impression of official FDA approval, clearance, authorization, certification, endorsement or other evaluation of the establishment or the devices are misleading and constitute misbranding. See 21 CFR 807.39.\u003C\u002Fp>\n\n\u003Cp>Your website contains a number of false or misleading representations, including but not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Representations that the Arun KN95 Folding Face Masks are “Certified: … FDA” and unauthorized display of what appears to be FDA’s logo\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> on inner packaging of the product [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\u003C\u002Fli>\n\t\u003Cli>Representations that the Deming Surgical Masks are “Certified: FDA” and unauthorized display of what appears to be FDA’s logo on packaging [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\u003C\u002Fli>\n\t\u003Cli>Representations that Pairon 3Ply Face Masks (Blue, White &amp; Black) are “FDA Registered” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-face-mask] [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3ply-face-mask-black][https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fwhite-pairon-3ply-face-mask]\u003C\u002Fli>\n\t\u003Cli>Unauthorized display of what appears to be FDA’s logo alongside the BLACK – Pairon&nbsp;3Ply Face Mask [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3plyface-mask-black]\u003C\u002Fli>\n\t\u003Cli>Displaying a “Certificate of FDA Registration” issued by “UCL-REGSERVICE INC” (UCL-REGSERVICE Certificate) alongside Arun KN95 Folding Face Mask product information. The UCL-REGSERVICE Certificate “certifies that Dongguan Arun Industrial Co. Ltd., …has completed the FDA Establishment Registration and Device Listing with the US Food &amp; Drug Administration…” The UCL-REGSERVICE Certificate has the look of an official government document, and incorporates unauthorized use of the FDA logo\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and an illustration of an eagle with a U.S. flag (or a similar flag) [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\u003C\u002Fli>\n\t\u003Cli>Displaying a “Certification of Registration” issued by “Sungo Technical Services Inc.” (Sungo Technical Certificate) alongside Deming Surgical Mask product information. The Sungo Technical Certificate “certifies that Xiantao Deming Healthcare Products Co., Ltd., … has completed the FDA Establishment Registration and Device Listing with the US Food &amp; Drug Administration…” The Sungo Technical Certificate has the look of an official government document, and incorporates unauthorized use of the FDA logo and an illustration of an eagle with a U.S. flag (or a similar flag) [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\u003C\u002Fli>\n\t\u003Cli>Displaying a “Certification of Registration” issued by “Wayborn Quality &amp; Technology Services” (Wayborn Certificate) alongside the BLUE – Pairon 3Ply Face Mask product information. The Wayborn Certificate “certifies that … Wuxi Hingdou Sports Co., Ltd., …has completed U.S. FOOD And DRUG Administration Medical Device Registration…” The Wayborn Certificate has the look of an official government document and incorporates unauthorized use of the FDA logo and an illustration of an eagle with a U.S. flag (or a similar flag). [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-face-mask]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>To date, FDA has not cleared, approved, authorized or “Certified” the Arun KN95 Folding Face Mask or the Deming Surgical Mask offered for sale by your firm, and so statements to the contrary are false. In addition, display of the FDA logo on packaging and near images of and information about the Arun KN95 Folding Face Mask, the Deming Surgical Mask, and the Pairon 3Ply Face Mask (Blue, White &amp; Black), combined with statements such as, “Certified: FDA” and “FDA Registered”, are misleading because it creates the impression of official FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the devices and\u002For your establishment.. The UCL-REGSERVICE Certificate bearing the FDA logo, positioned near images of and information about the Arun KN95 Folding Face Mask is misleading because it implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishment based on the representations that Dongguan Arun Industrial, Co., Ltd. is or was registered with FDA and that the firm is or was in possession of a registration number. In addition, the display of Sungo Technical Certificate bearing the FDA logo positioned near images of and information about the Deming Surgical Mask is misleading because such display implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishments based on the existence of Xiantao Deming Healthcare Products Co., Ltd. registration and possession of a registration number. Furthermore, display of the Wayborn Certificate bearing the FDA logo, near information about the BLUE – Pairon 3Ply Face Mask is misleading because such display implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishments based on the existence of Wuxi Hingdou Sports Co., Ltd registration and possession of a registration number. Although the Arun KN95 Folding Face Mask, Deming Surgical Mask, and BLUE – Pairon 3Ply Face Mask Certificates contain legible language that appears to be intended to function as a disclaimer, including a statement that the Certificates do not denote FDA endorsement or approval, statements that FDA does not issue or recognize certificates of registration, and a statement that quotes 21 CFR 807.39, the small font size and overall placement of such language could be easily overlooked and does not limit or otherwise mitigate the misleading impression created by the use of the Certificates. Such representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA.\u003C\u002Fp>\n\n\u003Cp>We remind you that FDA’s Center for Devices and Radiological Health (CDRH) does not issue device registration certificates to medical device establishments, including to sellers and manufacturers. When an establishment registers and lists its devices, the resulting entry in FDA’s Establishment Registration &amp; Device Listing Database merely denotes that the establishment has provided certain information to FDA.\u003C\u002Fp>\n\n\u003Cp>This letter is not meant to be an all-inclusive list of violations that exist in connection with the products or your operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your website, product labels, and other labeling and promotional materials to ensure that you do not make representations that misbrand the product(s) in violation of the Act.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. Please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of any actions your firm has taken. If your firm’s planned actions will occur over time, please include a timetable for implementation of those activities. Your firm’s response should be comprehensive and address all violations included in this letter. If you believe that the products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to:\u003C\u002Fp>\n\n\u003Cp>Food and Drug Administration\u003Cbr>\nCenter for Devices and Radiological Health\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nDivision of Regulatory Programs 2: Establishment Support\u003Cbr>\nRegulatory Inspections and Audits Team\u003Cbr>\nWhite Oak Building 66\u003Cbr>\n10903 New Hampshire Ave.\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Refer to the Document number CMS Case# 616392 or CTS Number CPT2001233 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Assistant Director, Paola Barnett at 301-796-5462 or Paola.Barnett@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Donna Engleman, MS, BSN\u003Cbr>\nDirector\u003Cbr>\nDivision of Market Intelligence\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>Cc:\u003C\u002Fp>\n\n\u003Cp>Yabo Zhang\u003Cbr>\nDongguan Arun Industrial, Co., Ltd.\u003Cbr>\nNO.18Xingfeng St, Changlong, Huangjiang\u003Cbr>\nDongguan, CN 523766\u003C\u002Fp>\n\n\u003Cp>US Agent:\u003Cbr>\nSimcal\u003Cbr>\nUCL-REG SERVICE INC.\u003Cbr>\n3907 Prince Street Suite 6F\u003Cbr>\nFlushing, NY 11354\u003Cbr>\nEmail: gbstandard@163.com\u003C\u002Fp>\n\n\u003Cp>UCL-Reg Service\u003Cbr>\n602 ROCKWOOD ROAD, WILMINGTON\u003Cbr>\nNew Castle, DE, 19802\u003C\u002Fp>\n\n\u003Cp>XIANTAO DEMING HEALTHCARE PRODUCTS CO., LTD.\u003Cbr>\nNo.198, Pengchang Ave. Pengchang Town, Xiantao City\u003Cbr>\nHubei Province, P.R. China\u003Cbr>\nXiantao, CN 433018\u003C\u002Fp>\n\n\u003Cp>Leeyeo Kee\u003Cbr>\nRegrek LLC\u003Cbr>\n19 Holly Cove Ln.\u003Cbr>\nDover, DE 19901\u003Cbr>\nEmail: regrek.cs@hotmail.com\u003C\u002Fp>\n\n\u003Cp>Sungo Technical Services Inc.\u003Cbr>\n6050 W Eastwood Ave Apt. 201 Chicago Illinois 60630\u003Cbr>\nE-mail：sungo.group@yahoo.com\u003Cbr>\nEmail: Shage2008@126.com\u003C\u002Fp>\n\n\u003Cp>WUXI HINGDOU SPORTS CO., LTD\u003Cbr>\nHongdou Industrial Park, Donggang Town\u003Cbr>\nWuxi, Jiangsu, 214000, China\u003C\u002Fp>\n\n\u003Cp>Director: Crane Yu\u003Cbr>\nWayborn Quality &amp; Technology Services\u003Cbr>\n306, Xincheng International Main Building,\u003Cbr>\nNo.535 Qingshuiqiao Road, Ningbo High-tech Zone\u003Cbr>\nEmail: wayborn@wayb.org\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>The FDA logo is for official use by FDA and not for private use on labeling of FDA-regulated products. See FDA Logo Policy (available at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy\">https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy\u003C\u002Fa>)\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nPairon Solutions LLC\n\n13970 SW 72nd Ave\n\nPortland, OR 97223\n\nUnited States\n\nmelissa@paironsolutions.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDATE: August 9, 2021\n\nRe: “Arun KN95 Folding Face Mask,” “Deming Surgical Mask,” and “Pairon 3Ply Face Mask” (Blue, White & Black)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.paironsolutionsppe.com\u002F on July 14, 2021. The FDA has observed that your website offers the “Arun KN95 Folding Face Mask,” the “Deming Surgical Mask”, and the “Pairon 3Ply Face Mask” (Blue, White & Black) for sale in the United States. Based on our review, these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nFDA’s review of your website revealed the following statements that establish that the Arun KN95 Folding Face Mask, Deming Surgical Mask, and Pairon 3Ply Face Mask (Blue, White & Black) are intended for the mitigation, prevention, treatment, diagnosis, or cure of disease, including but not limited to:\n\nStatements made alongside an image of the Arun KN95 Folding Face Mask that it is “listed on FDA EUA for Non-NIOSH Devices” and representing compliance with “GB2626-2006” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\n\nStatements alongside an image of the Deming Surgical Mask that it provides “99% bacterial efficiency” and “complies ASTM F2100”. The name also incorporates the word “surgical” as well as “medical” written on the box packaging [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\n\nStatements made on the packaging and alongside the images of the Pairon 3Ply Face Mask (Blue, White & Black) that they provide “>95% bacterial efficiency” and “helps filter out … bacteria” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-facemask], [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3ply-face-mask-black], [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fwhite-pairon-3ply-face-mask]\n\nStatements on your firm’s customer blog page representing that the BLUE – Pairon 3Ply Face Mask has been supplied to nursing home facilities [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fblogs\u002Fnews]\n\nBased on our review, your website is offering for sale in the United States, the Arun KN95 Folding Face Mask (which your website represents is manufactured by Dongguan Arun Industrial Co. Ltd.), the Deming Surgical Mask (which your website represents is manufactured by Xiantao Deming Healthcare Products Co., Ltd.), and the Pairon 3Ply Face Mask - Blue, White & Black (which your website represents is manufactured by Wuxi Hingdou Sports Co., Ltd) without marketing approval or clearance from the FDA. Accordingly, these products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\n\nIn addition, these products are misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because their labeling is false or misleading. FDA registration of a device establishment or assignment of a registration number does not denote FDA approval of the establishment or the device. Thus, references to a firm’s establishment registration and registration number that create an impression of official FDA approval, clearance, authorization, certification, endorsement or other evaluation of the establishment or the devices are misleading and constitute misbranding. See 21 CFR 807.39.\n\nYour website contains a number of false or misleading representations, including but not limited to:\n\nRepresentations that the Arun KN95 Folding Face Masks are “Certified: … FDA” and unauthorized display of what appears to be FDA’s logo1 on inner packaging of the product [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\n\nRepresentations that the Deming Surgical Masks are “Certified: FDA” and unauthorized display of what appears to be FDA’s logo on packaging [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\n\nRepresentations that Pairon 3Ply Face Masks (Blue, White & Black) are “FDA Registered” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-face-mask] [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3ply-face-mask-black][https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fwhite-pairon-3ply-face-mask]\n\nUnauthorized display of what appears to be FDA’s logo alongside the BLACK – Pairon 3Ply Face Mask [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3plyface-mask-black]\n\nDisplaying a “Certificate of FDA Registration” issued by “UCL-REGSERVICE INC” (UCL-REGSERVICE Certificate) alongside Arun KN95 Folding Face Mask product information. The UCL-REGSERVICE Certificate “certifies that Dongguan Arun Industrial Co. Ltd., …has completed the FDA Establishment Registration and Device Listing with the US Food & Drug Administration…” The UCL-REGSERVICE Certificate has the look of an official government document, and incorporates unauthorized use of the FDA logo1 and an illustration of an eagle with a U.S. flag (or a similar flag) [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\n\nDisplaying a “Certification of Registration” issued by “Sungo Technical Services Inc.” (Sungo Technical Certificate) alongside Deming Surgical Mask product information. The Sungo Technical Certificate “certifies that Xiantao Deming Healthcare Products Co., Ltd., … has completed the FDA Establishment Registration and Device Listing with the US Food & Drug Administration…” The Sungo Technical Certificate has the look of an official government document, and incorporates unauthorized use of the FDA logo and an illustration of an eagle with a U.S. flag (or a similar flag) [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\n\nDisplaying a “Certification of Registration” issued by “Wayborn Quality & Technology Services” (Wayborn Certificate) alongside the BLUE – Pairon 3Ply Face Mask product information. The Wayborn Certificate “certifies that … Wuxi Hingdou Sports Co., Ltd., …has completed U.S. FOOD And DRUG Administration Medical Device Registration…” The Wayborn Certificate has the look of an official government document and incorporates unauthorized use of the FDA logo and an illustration of an eagle with a U.S. flag (or a similar flag). [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-face-mask]\n\nTo date, FDA has not cleared, approved, authorized or “Certified” the Arun KN95 Folding Face Mask or the Deming Surgical Mask offered for sale by your firm, and so statements to the contrary are false. In addition, display of the FDA logo on packaging and near images of and information about the Arun KN95 Folding Face Mask, the Deming Surgical Mask, and the Pairon 3Ply Face Mask (Blue, White & Black), combined with statements such as, “Certified: FDA” and “FDA Registered”, are misleading because it creates the impression of official FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the devices and\u002For your establishment.. The UCL-REGSERVICE Certificate bearing the FDA logo, positioned near images of and information about the Arun KN95 Folding Face Mask is misleading because it implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishment based on the representations that Dongguan Arun Industrial, Co., Ltd. is or was registered with FDA and that the firm is or was in possession of a registration number. In addition, the display of Sungo Technical Certificate bearing the FDA logo positioned near images of and information about the Deming Surgical Mask is misleading because such display implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishments based on the existence of Xiantao Deming Healthcare Products Co., Ltd. registration and possession of a registration number. Furthermore, display of the Wayborn Certificate bearing the FDA logo, near information about the BLUE – Pairon 3Ply Face Mask is misleading because such display implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishments based on the existence of Wuxi Hingdou Sports Co., Ltd registration and possession of a registration number. Although the Arun KN95 Folding Face Mask, Deming Surgical Mask, and BLUE – Pairon 3Ply Face Mask Certificates contain legible language that appears to be intended to function as a disclaimer, including a statement that the Certificates do not denote FDA endorsement or approval, statements that FDA does not issue or recognize certificates of registration, and a statement that quotes 21 CFR 807.39, the small font size and overall placement of such language could be easily overlooked and does not limit or otherwise mitigate the misleading impression created by the use of the Certificates. Such representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA.\n\nWe remind you that FDA’s Center for Devices and Radiological Health (CDRH) does not issue device registration certificates to medical device establishments, including to sellers and manufacturers. When an establishment registers and lists its devices, the resulting entry in FDA’s Establishment Registration & Device Listing Database merely denotes that the establishment has provided certain information to FDA.\n\nThis letter is not meant to be an all-inclusive list of violations that exist in connection with the products or your operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your website, product labels, and other labeling and promotional materials to ensure that you do not make representations that misbrand the product(s) in violation of the Act.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. Please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of any actions your firm has taken. If your firm’s planned actions will occur over time, please include a timetable for implementation of those activities. Your firm’s response should be comprehensive and address all violations included in this letter. If you believe that the products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to:\n\nFood and Drug Administration\n\nCenter for Devices and Radiological Health\n\nOffice of Regulatory Programs\n\nDivision of Regulatory Programs 2: Establishment Support\n\nRegulatory Inspections and Audits Team\n\nWhite Oak Building 66\n\n10903 New Hampshire Ave.\n\nSilver Spring, MD 20993\n\nRefer to the Document number CMS Case# 616392 or CTS Number CPT2001233 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Assistant Director, Paola Barnett at 301-796-5462 or Paola.Barnett@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nDonna Engleman, MS, BSN\n\nDirector\n\nDivision of Market Intelligence\n\nOffice of Regulatory Programs\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCc:\n\nYabo Zhang\n\nDongguan Arun Industrial, Co., Ltd.\n\nNO.18Xingfeng St, Changlong, Huangjiang\n\nDongguan, CN 523766\n\nUS Agent:\n\nSimcal\n\nUCL-REG SERVICE INC.\n\n3907 Prince Street Suite 6F\n\nFlushing, NY 11354\n\nEmail: gbstandard@163.com\n\nUCL-Reg Service\n\n602 ROCKWOOD ROAD, WILMINGTON\n\nNew Castle, DE, 19802\n\nXIANTAO DEMING HEALTHCARE PRODUCTS CO., LTD.\n\nNo.198, Pengchang Ave. Pengchang Town, Xiantao City\n\nHubei Province, P.R. China\n\nXiantao, CN 433018\n\nLeeyeo Kee\n\nRegrek LLC\n\n19 Holly Cove Ln.\n\nDover, DE 19901\n\nEmail: regrek.cs@hotmail.com\n\nSungo Technical Services Inc.\n\n6050 W Eastwood Ave Apt. 201 Chicago Illinois 60630\n\nE-mail：sungo.group@yahoo.com\n\nEmail: Shage2008@126.com\n\nWUXI HINGDOU SPORTS CO., LTD\n\nHongdou Industrial Park, Donggang Town\n\nWuxi, Jiangsu, 214000, China\n\nDirector: Crane Yu\n\nWayborn Quality & Technology Services\n\n306, Xincheng International Main Building,\n\nNo.535 Qingshuiqiao Road, Ningbo High-tech Zone\n\nEmail: wayborn@wayb.org\n\n___________________________\n\n1 The FDA logo is for official use by FDA and not for private use on labeling of FDA-regulated products. See FDA Logo Policy (available at: https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy)","Pairon Solutions LLC","pairon-solutions-llc-616392-08092021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpairon-solutions-llc-616392-08092021","2026-10-26T08:09:39.952179+00:00","2021-10-05","616392","Medical Devices","2026-08-20T02:35:05.169+00:00","2021-08-09",{"id":74,"raw":75,"subject":80,"body_html":81,"body_text":82,"firm_name":83,"letter_id":84,"created_at":85,"fei_number":19,"letter_url":86,"updated_at":87,"action_type":22,"case_status":23,"posted_date":88,"marcs_cms_no":89,"product_type":90,"closeout_date":19,"issuing_office":79,"recipient_name":91,"body_fetched_at":92,"delivery_method":93,"recipient_title":19,"reference_number":94,"action_taken_date":95,"medical_device_id":19,"response_letter_date":19},22012,[76,77,78,79,80,13,13,13],"\u003Ctime datetime=\"2026-10-27T04:00:00Z\">10\u002F27\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-22T04:00:00Z\">10\u002F22\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftsp-solutions-pte-ltd-735071-10222026\">TSP Solutions Pte. Ltd.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Request for Records\u002FCGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-27-07\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Min-tsek Lau\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>TSP Solutions Pte. Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Block 998 Toa Payoh North\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>#05-05\u002F06 Mapletree Industrial\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>318993\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Singapore\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:mintsek@tspsolutions.co\"> mintsek@tspsolutions.co\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 22, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: 320-27-07\u003C\u002Fp>\u003Cp>To Mr. Min-tsek Lau:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of records submitted from your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during review of your drug manufacturing facility, TSP Solutions Pte. Ltd., FDA Establishment Identifier (FEI) 3023093622. This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\u003C\u002Fp>\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our September 9, 2025, request and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release; and, your firm failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures sunscreen drug products.\u003C\u002Fp>\u003Cp>Based on the records and information you provided, you did not demonstrate that you conduct adequate finished drug product testing on your drug products. Specifically, neither the certificate of analysis (COA) reports nor the batch records that you provided include an appropriate assay test for active ingredient content or impurity testing. In addition, your records do not include appropriate microbiological testing.\u003C\u002Fp>\u003Cp>Full release testing, including strength and identity testing of the active ingredient, as well as appropriate microbiological testing, must be performed before drug product release and distribution. Without adequate testing, you do not have adequate scientific evidence to ensure that your drug products conform to appropriate specifications before release.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a lot disposition decision.\u003C\u002Fli>\u003Cli>An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003C\u002Fli>\u003Cli>A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided, you did not demonstrate that you are adequately testing the identity of incoming components used in the manufacture of your drug products. Your response also indicated that you accept your supplier’s COA without verifying the test results at appropriate intervals. Verification of component quality is performed only by reviewing the COAs and material safety data sheets provided by the suppliers.\u003C\u002Fp>\u003Cp>Without adequate testing and without establishing the reliability of your component suppliers’ test analyses at appropriate intervals, you do not have scientific evidence that your raw materials conform to appropriate specifications before you use them in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before you use them in production to ensure adequate quality.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your material system, including but not limited to:\u003Cbr>o evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified\u003Cbr>o an assessment of all materials to determine whether they are consistently of acceptable quality based on thorough historical review\u003Cbr>o a review to ensure assigned expiration or retest dates are appropriate (supported by data)\u003Cbr>o adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions\u003Cbr>o vigilant lifecycle monitoring of all suppliers using sound quality risk management practices\u003Cbr>o based on this thorough review, summarize a systemic CAPA that remediates the materials system to ensure ongoing lifecycle oversight of vendor performance and prevents use of unsuitable components (ingredients), containers and closures.\u003C\u002Fli>\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the components and drug products you manufacture.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm’s quality unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided, your firm failed to establish an adequate quality unit (QU) with the responsibilities and authority to oversee the manufacturing of drug products. For example, your QU failed to ensure:\u003C\u002Fp>\u003Cul>\u003Cli>Adequate procedures ensuring appropriate production and process controls for drug product manufacturing and qualification of equipment used to manufacture drug products (21 CFR 211.100(a)).\u003C\u002Fli>\u003Cli>Adequate laboratory control procedures to ensure drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fli>\u003Cli>The establishment of an adequate, ongoing stability program (21 CFR 211.166(a)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA’s guidance documents \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified in your response, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on August 14, 2026.\u003C\u002Fp>\u003Cp>FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at TSP Solutions Pte. Ltd., at Block 998 Toa Payoh North, #05-05\u002F06 Mapletree Industrial, Singapore 318993, Singapore, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within 15 business days of receipt of this letter. Identify your written response with FEI 3023093622 and ATTN: Bryce Hammer in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA posts warning letters to www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>Cc: Registered U.S. Agent\u003Cbr>Mr. David Lennarz\u003Cbr>Registrar Corp\u003Cbr>drugs@registrarcorp.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nReference #:\n\n320-27-07\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Min-tsek Lau\n\nRecipient Title\n\nManaging Director\n\nTSP Solutions Pte. Ltd.\n\nBlock 998 Toa Payoh North\n\n#05-05\u002F06 Mapletree Industrial\n\n318993\n\nSingapore\n\nmintsek@tspsolutions.co\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 22, 2026\nWARNING LETTER\nReference number: 320-27-07\nTo Mr. Min-tsek Lau:\nThis warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of records submitted from your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice.\nFDA Review\nViolations were identified and documented during review of your drug manufacturing facility, TSP Solutions Pte. Ltd., FDA Establishment Identifier (FEI) 3023093622. This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our September 9, 2025, request and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations at your facility.\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release; and, your firm failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\nYour firm manufactures sunscreen drug products.\nBased on the records and information you provided, you did not demonstrate that you conduct adequate finished drug product testing on your drug products. Specifically, neither the certificate of analysis (COA) reports nor the batch records that you provided include an appropriate assay test for active ingredient content or impurity testing. In addition, your records do not include appropriate microbiological testing.\nFull release testing, including strength and identity testing of the active ingredient, as well as appropriate microbiological testing, must be performed before drug product release and distribution. Without adequate testing, you do not have adequate scientific evidence to ensure that your drug products conform to appropriate specifications before release.\nIn response to this letter, provide:\nA list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a lot disposition decision.\nAn action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\nA summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nBased on the records and information you provided, you did not demonstrate that you are adequately testing the identity of incoming components used in the manufacture of your drug products. Your response also indicated that you accept your supplier’s COA without verifying the test results at appropriate intervals. Verification of component quality is performed only by reviewing the COAs and material safety data sheets provided by the suppliers.\nWithout adequate testing and without establishing the reliability of your component suppliers’ test analyses at appropriate intervals, you do not have scientific evidence that your raw materials conform to appropriate specifications before you use them in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before you use them in production to ensure adequate quality.\nIn response to this letter, provide:\nA comprehensive, independent review of your material system, including but not limited to:\no evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified\no an assessment of all materials to determine whether they are consistently of acceptable quality based on thorough historical review\no a review to ensure assigned expiration or retest dates are appropriate (supported by data)\no adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions\no vigilant lifecycle monitoring of all suppliers using sound quality risk management practices\no based on this thorough review, summarize a systemic CAPA that remediates the materials system to ensure ongoing lifecycle oversight of vendor performance and prevents use of unsuitable components (ingredients), containers and closures.\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\nA summary of your program for qualifying and overseeing contract facilities that test the components and drug products you manufacture.\n3. Your firm’s quality unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nBased on the records and information you provided, your firm failed to establish an adequate quality unit (QU) with the responsibilities and authority to oversee the manufacturing of drug products. For example, your QU failed to ensure:\nAdequate procedures ensuring appropriate production and process controls for drug product manufacturing and qualification of equipment used to manufacture drug products (21 CFR 211.100(a)).\nAdequate laboratory control procedures to ensure drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\nThe establishment of an adequate, ongoing stability program (21 CFR 211.166(a)).\nYour firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA’s guidance documents Quality Systems Approach to Pharmaceutical CGMP Regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified in your response, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nFDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on August 14, 2026.\nFDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at TSP Solutions Pte. Ltd., at Block 998 Toa Payoh North, #05-05\u002F06 Mapletree Industrial, Singapore 318993, Singapore, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within 15 business days of receipt of this letter. Identify your written response with FEI 3023093622 and ATTN: Bryce Hammer in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nFDA posts warning letters to www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\nCc: Registered U.S. Agent\nMr. David Lennarz\nRegistrar Corp\ndrugs@registrarcorp.com","TSP Solutions Pte. Ltd.","tsp-solutions-pte-ltd-735071-10222026","2026-11-03T01:02:17.615107+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftsp-solutions-pte-ltd-735071-10222026","2026-11-17T01:02:03.701861+00:00","2026-10-27","735071","Drugs Over-the-Counter Drugs","Mr. Min-tsek Lau","2026-11-03T01:03:12.526+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","320-27-07","2026-10-22",{"id":97,"raw":98,"subject":12,"body_html":103,"body_text":104,"firm_name":105,"letter_id":106,"created_at":18,"fei_number":19,"letter_url":107,"updated_at":108,"action_type":22,"case_status":23,"posted_date":109,"marcs_cms_no":110,"product_type":26,"closeout_date":19,"issuing_office":102,"recipient_name":111,"body_fetched_at":112,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":113,"medical_device_id":19,"response_letter_date":19},1431,[99,100,101,102,12,13,13,13],"\u003Ctime datetime=\"2024-06-11T13:20:00Z\">06\u002F11\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-05-31T04:00:00Z\">05\u002F31\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcosmetic-solutions-llc-670486-05312024\">Cosmetic Solutions, LLC\u003C\u002Fa>","Division of Pharmaceutical Quality Operations II","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. John Puckett\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and COO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Cosmetic Solutions, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6101 Park of Commerce Blvd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Boca Raton\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33487-8208\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:johnp@csinnovationlabs.com\"> johnp@csinnovationlabs.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>DATE: 5\u002F31\u002F2024\u003C\u002Fp>\n\n\u003Cp>Case #: 670486\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Mr. Puckett:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Cosmetic Solutions, LLC, FEI 3002692859, at 6101 Park of Commerce Blvd., Boca Raton, from September 12 to 21, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>In addition, the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>We reviewed your October 11, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit and to follow such written procedures (21 CFR 211.22(d)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) did not provide adequate oversight to ensure procedures for manufacturing your over-the-counter (OTC) drug products were established and followed. For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>You failed to follow your stability testing procedure. You manufactured multiple batches of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> but have not placed samples of either product into your stability program as required by your procedure (21 CFR 211.166(a) and (b)).\u003C\u002Fli>\n\t\u003Cli>You failed to establish the reliability of your component suppliers’ test analyses at appropriate intervals. You also failed to follow your written procedure for incoming sampling, inspection, and release of raw materials. Without adequate testing, you do not have scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products (21 CFR 211.84(d)(2)).\u003C\u002Fli>\n\t\u003Cli>You failed to follow your written change control procedure. During the manufacture of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you noted the batch became crystallized when cooling to the target temperature range after the addition of phase B ingredients. You then expanded the target temperature range of this batch and subsequent batches outside of the predetermined manufacturing process range. In addition, you added a step to heat a later batch after the addition of phase C ingredients. These changes were executed without following the steps required in your change control procedure (21 CFR 211.100(a)).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In your response, you state \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;will be placed on stability. You also explain your supplier qualification procedure has been revised to require sampling and testing of raw materials for comparison with your suppliers’ certificate of analysis (COA). Further, you state you have revised your change control procedure, and you consider this issue closed.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>You fail to provide a comprehensive assessment of your stability program that extends to all drug products you manufacture. Further, your response does not include a retrospective assessment of the impact your stability deficiencies have on marketed drug batches within their expiry period.\u003C\u002Fli>\n\t\u003Cli>You fail to assess how the lack of supplier qualification impacts the quality of your marketed drug batches.\u003C\u002Fli>\n\t\u003Cli>You fail to evaluate the quality impact of changes you made outside your change control system to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing process. Furthermore, you fail to assess the scope of this issue to determine if manufacturing changes to other drug products were made outside your change control system.\u003C\u002Fli>\n\t\u003Cli>You lack an adequate investigation, including a detailed corrective action and preventive action (CAPA) plan to remediate your firm’s failure to follow approved procedures.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>An adequate QU overseeing all elements of CGMP is necessary to consistently ensure drug product quality.\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fqualitysystems-approach-pharmaceutical-current-good-manufacturing-practice-regulations for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;A comprehensive independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Stability indicating methods\u003Cbr>\n&nbsp; &nbsp; o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>\n&nbsp; &nbsp; o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>\n&nbsp; &nbsp; o Detailed definition of the specific attributes to be tested at each station (timepoint)\u003Cbr>\n&nbsp; &nbsp; o Improved procedures that describe the listed elements above and any other elements of your remediated stability program\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive independent review of your material system to determine whether all suppliers of components, containers, and closures are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>A comprehensive assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your QU. Your change management program should also include provisions for determining change effectiveness.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100 (a) and 211.100 (b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>A. Lack of Water System Qualification and Validation\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You failed to qualify your purified water system. You use water from this system as a component in manufacturing drug products, but failed to ensure it consistently produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> water that meets appropriate microbial limits. For example, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water failed microbial testing on several occasions throughout August 2023. Multiple drug batches were manufactured with \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>water during this period. Your investigation failed to identify and quantify the microbial contamination. Routine monitoring of microbial counts and identity of contamination in the system is integral to maintaining a state of control and suitability of water for use in drug manufacturing operations.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>You also failed to adequately validate your alternative rapid microbiological test methods. For example, you use the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system for rapid microbiological testing of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water. You stated this system was validated by the manufacturer, but you failed to verify it upon installation at your facility. Furthermore, you did not demonstrate the system adequately quantifies and identifies objectionable microbes, and you failed to demonstrate it was equivalent to, or better than United States Pharmacopeia (USP) compendial methods, and suitable for its intended use.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cem>B. Lack of Cleaning Validation\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your cleaning validation is inadequate because you did not include all products you manufacture, and all pieces of product-contact equipment currently used for manufacturing your drug products. For example, your cleaning validation protocol did not include various kettles, fillers, and mixers you currently use to manufacture drug products. You also manufacture drug products using the same equipment that you use to manufacture nonpharmaceutical products, such as cosmetics. Chemical and microbiological residues on equipment from previous manufacturing activities can adversely impact the purity, quality, and safety of drug products also manufactured on that equipment.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In your response, you state batches manufactured while the water system failed microbial testing were released only after finished product results from an outside laboratory passed.\u003C\u002Fp>\n\n\u003Cp>Additionally, you explain batches manufactured with water from a port that demonstrates microbial contamination will be held until “results” from an outside laboratory are within specification. You also commit to decommissioning a failing port until the investigation and corrective actions are complete. Furthermore, you provide approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> of microbial testing results of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water to show validation of your microbial monitoring system, yet this documentation was not available at the time of the inspection.\u003C\u002Fp>\n\n\u003Cp>You also explain future cleaning validations will be modified by using a revised equipment list, and you will include equipment in contact with active pharmaceutical ingredients (APIs). You will also use \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning verification system where applicable. Furthermore, you state you have engaged a consultant to help implement an enhanced cleaning and sanitization program.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>You fail to address the lack of qualification and validation of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system.\u003C\u002Fli>\n\t\u003Cli>You lack sound scientific data to demonstrate your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water testing methods are adequate for your firm’s operations. Furthermore, your response does not include identification of the microbes present in your failing water samples and lacks a comprehensive investigation of your water system’s impact on the quality of your drug products. Microbiological contamination is not uniformly distributed, and your plan to test batches until samples are within specification does not scientifically prove your products are free of contaminants. It is essential that stringent upstream controls be employed to assure the quality of a batch.\u003C\u002Fli>\n\t\u003Cli>Additionally, you do not provide an assessment of the impact of your deficient cleaning validation on the quality of your drug products in the market within expiry.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive remediation plan for the design, control, and maintenance of the water system.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your total microbial count limits to monitor whether this system is producing water suitable for the intended uses for each of your products.\u003C\u002Fli>\n\t\u003Cli>A detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\n\t\u003Cli>A procedure for your water system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fli>\n\t\u003Cli>The current action\u002Falert limits for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water system. Ensure that the total count limits for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water are appropriately stringent in view of the intended use of each of the products produced by your firm.\u003C\u002Fli>\n\t\u003Cli>A procedure governing your program for monitoring that ensures the system consistently produces water that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> monograph specifications and appropriate microbial limits.\u003C\u002Fli>\n\t\u003Cli>A validation study of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> microbiological testing system, or other testing system to show it consistently quantifies and identifies microbes as described in \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water monograph.\u003C\u002Fli>\n\t\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Drugs with higher toxicities\u003Cbr>\n&nbsp; &nbsp; o Drugs with higher drug potencies\u003Cbr>\n&nbsp; &nbsp; o Drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; &nbsp; o Drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Maximum hold times before cleaning\u003C\u002Fp>\n\n\u003Cp>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cu>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> product labels and labeling, including the product websites, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003Cbr>\n\u003Cbr>\n\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the products’ labeled intended uses, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> products are not generally recognized as safe and effective (GRASE) for their above referenced uses. We are not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that these products are generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. Therefore, these products are “new drugs” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). In general, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Thus, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to case #\u003Cstrong> 670486\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Please electronically submit your reply, on company letterhead, to Mark W. Rivero, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, you may contact Mr. Rivero via phone at (504) 759-7718 or email at mark.rivero@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Monica R. Maxwell\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations,\u003Cbr>\nDivision II\u003C\u002Fp>\n\n\u003Cp>____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We note your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product is an external analgesic, and your \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>product is a combination external analgesic and skin protectant drug product, both of which are subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. However, there is no basis under the FD&amp;C Act under which these products would be legally marketed without an approved application. Specifically, with respect to external analgesic drug products, such products are deemed to be generally recognized as safe and effective (GRASE) and not new drugs if, among other things, they conform to the conditions of use set forth in Over-the-Counter (OTC) Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use (henceforth “M017”) and for combination external analgesic and skin protectant drug products, they must conform to the conditions of use set forth in both M017 and OTC Monograph M016: Skin Protectant Drug Products for Over-the-Counter Human Use (henceforth “M016”). However,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> do not conform to the conditions specified in the relevant orders. Neither product is formulated in a manner that is consistent with the applicable final administrative orders and \u003Cstrong>(b)(4)\u003C\u002Fstrong> includes intended uses outside both monographs. Specifically, \u003Cstrong>(b)(4)\u003C\u002Fstrong> is formulated to contain eucalyptus oil, which falls under section 505G(a)(5) of the FD&amp;C Act because FDA has determined that no counterirritant external analgesic products containing eucalyptus oil as an active ingredient are GRASE under a final determination issued under 21 CFR part 330. In addition, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> labeling purports to promote cell repair, which is an intended use not permitted under any OTC Monograph or relevant rulemaking. Although you do not distinguish between active and inactive ingredients for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product, no combination of the labeled ingredients is permitted by M017 and M016 for a combination external analgesic and skin protectant drug product.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. John Puckett\n\nRecipient Title\n\nPresident and COO\n\nCosmetic Solutions, LLC\n\n6101 Park of Commerce Blvd.\n\nBoca Raton, FL 33487-8208\n\nUnited States\n\njohnp@csinnovationlabs.com\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations II\n\nUnited States\n\nDATE: 5\u002F31\u002F2024\n\nCase #: 670486\n\nWARNING LETTER\n\nDear Mr. Puckett:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Cosmetic Solutions, LLC, FEI 3002692859, at 6101 Park of Commerce Blvd., Boca Raton, from September 12 to 21, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nIn addition, the (b)(4), and (b)(4) drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). These violations are described in more detail below.\n\nWe reviewed your October 11, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\nCGMP Violations\n\n1. Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit and to follow such written procedures (21 CFR 211.22(d)).\n\nYour quality unit (QU) did not provide adequate oversight to ensure procedures for manufacturing your over-the-counter (OTC) drug products were established and followed. For example:\n\nYou failed to follow your stability testing procedure. You manufactured multiple batches of (b)(4), and (b)(4) but have not placed samples of either product into your stability program as required by your procedure (21 CFR 211.166(a) and (b)).\n\nYou failed to establish the reliability of your component suppliers’ test analyses at appropriate intervals. You also failed to follow your written procedure for incoming sampling, inspection, and release of raw materials. Without adequate testing, you do not have scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products (21 CFR 211.84(d)(2)).\n\nYou failed to follow your written change control procedure. During the manufacture of (b)(4), you noted the batch became crystallized when cooling to the target temperature range after the addition of phase B ingredients. You then expanded the target temperature range of this batch and subsequent batches outside of the predetermined manufacturing process range. In addition, you added a step to heat a later batch after the addition of phase C ingredients. These changes were executed without following the steps required in your change control procedure (21 CFR 211.100(a)).\n\nIn your response, you state (b)(4), and (b)(4) will be placed on stability. You also explain your supplier qualification procedure has been revised to require sampling and testing of raw materials for comparison with your suppliers’ certificate of analysis (COA). Further, you state you have revised your change control procedure, and you consider this issue closed.\n\nYour response is inadequate.\n\nYou fail to provide a comprehensive assessment of your stability program that extends to all drug products you manufacture. Further, your response does not include a retrospective assessment of the impact your stability deficiencies have on marketed drug batches within their expiry period.\n\nYou fail to assess how the lack of supplier qualification impacts the quality of your marketed drug batches.\n\nYou fail to evaluate the quality impact of changes you made outside your change control system to the (b)(4) manufacturing process. Furthermore, you fail to assess the scope of this issue to determine if manufacturing changes to other drug products were made outside your change control system.\n\nYou lack an adequate investigation, including a detailed corrective action and preventive action (CAPA) plan to remediate your firm’s failure to follow approved procedures.\n\nAn adequate QU overseeing all elements of CGMP is necessary to consistently ensure drug product quality.\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fqualitysystems-approach-pharmaceutical-current-good-manufacturing-practice-regulations for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nA comprehensive independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\n\no Stability indicating methods\n\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\n\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\n\no Detailed definition of the specific attributes to be tested at each station (timepoint)\n\no Improved procedures that describe the listed elements above and any other elements of your remediated stability program\n\nA comprehensive independent review of your material system to determine whether all suppliers of components, containers, and closures are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nA comprehensive assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your QU. Your change management program should also include provisions for determining change effectiveness.\n\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100 (a) and 211.100 (b)).\n\nA. Lack of Water System Qualification and Validation\n\nYou failed to qualify your purified water system. You use water from this system as a component in manufacturing drug products, but failed to ensure it consistently produces (b)(4) water that meets appropriate microbial limits. For example, your (b)(4) water failed microbial testing on several occasions throughout August 2023. Multiple drug batches were manufactured with (b)(4) water during this period. Your investigation failed to identify and quantify the microbial contamination. Routine monitoring of microbial counts and identity of contamination in the system is integral to maintaining a state of control and suitability of water for use in drug manufacturing operations.\n\nYou also failed to adequately validate your alternative rapid microbiological test methods. For example, you use the (b)(4) system for rapid microbiological testing of your (b)(4) water. You stated this system was validated by the manufacturer, but you failed to verify it upon installation at your facility. Furthermore, you did not demonstrate the system adequately quantifies and identifies objectionable microbes, and you failed to demonstrate it was equivalent to, or better than United States Pharmacopeia (USP) compendial methods, and suitable for its intended use.\n\nB. Lack of Cleaning Validation\n\nYour cleaning validation is inadequate because you did not include all products you manufacture, and all pieces of product-contact equipment currently used for manufacturing your drug products. For example, your cleaning validation protocol did not include various kettles, fillers, and mixers you currently use to manufacture drug products. You also manufacture drug products using the same equipment that you use to manufacture nonpharmaceutical products, such as cosmetics. Chemical and microbiological residues on equipment from previous manufacturing activities can adversely impact the purity, quality, and safety of drug products also manufactured on that equipment.\n\nIn your response, you state batches manufactured while the water system failed microbial testing were released only after finished product results from an outside laboratory passed.\n\nAdditionally, you explain batches manufactured with water from a port that demonstrates microbial contamination will be held until “results” from an outside laboratory are within specification. You also commit to decommissioning a failing port until the investigation and corrective actions are complete. Furthermore, you provide approximately (b)(4) of microbial testing results of your (b)(4) water to show validation of your microbial monitoring system, yet this documentation was not available at the time of the inspection.\n\nYou also explain future cleaning validations will be modified by using a revised equipment list, and you will include equipment in contact with active pharmaceutical ingredients (APIs). You will also use (b)(4) cleaning verification system where applicable. Furthermore, you state you have engaged a consultant to help implement an enhanced cleaning and sanitization program.\n\nYour response is inadequate.\n\nYou fail to address the lack of qualification and validation of your (b)(4) water system.\n\nYou lack sound scientific data to demonstrate your (b)(4) water testing methods are adequate for your firm’s operations. Furthermore, your response does not include identification of the microbes present in your failing water samples and lacks a comprehensive investigation of your water system’s impact on the quality of your drug products. Microbiological contamination is not uniformly distributed, and your plan to test batches until samples are within specification does not scientifically prove your products are free of contaminants. It is essential that stringent upstream controls be employed to assure the quality of a batch.\n\nAdditionally, you do not provide an assessment of the impact of your deficient cleaning validation on the quality of your drug products in the market within expiry.\n\nIn response to this letter, provide:\n\nA comprehensive remediation plan for the design, control, and maintenance of the water system.\n\no A (b)(4) water system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\n\nYour total microbial count limits to monitor whether this system is producing water suitable for the intended uses for each of your products.\n\nA detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\n\nA procedure for your water system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\n\nThe current action\u002Falert limits for total counts and objectionable organisms used for your (b)(4) Water system. Ensure that the total count limits for your (b)(4) water are appropriately stringent in view of the intended use of each of the products produced by your firm.\n\nA procedure governing your program for monitoring that ensures the system consistently produces water that meets (b)(4) monograph specifications and appropriate microbial limits.\n\nA validation study of your (b)(4) microbiological testing system, or other testing system to show it consistently quantifies and identifies microbes as described in (b)(4) Water monograph.\n\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\n\no Drugs with higher toxicities\n\no Drugs with higher drug potencies\n\no Drugs of lower solubility in their cleaning solvents\n\no Drugs with characteristics that make them difficult to clean\n\no Swabbing locations for areas that are most difficult to clean\n\no Maximum hold times before cleaning\n\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\n\nA summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\nUnapproved New Drug Violations\n\nExamples of claims observed on the (b)(4), and (b)(4) product labels and labeling, including the product websites, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\n\n(b)(4):\n\n(b)(4)\n\n(b)(4):\n\n(b)(4)\n\n(b)(4):\n\n(b)(4)\n\n(b)(4):\n\n(b)(4)\n\nBased on the products’ labeled intended uses, (b)(4), and (b)(4) are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\n\nYour (b)(4), and (b)(4)1 products are not generally recognized as safe and effective (GRASE) for their above referenced uses. We are not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that these products are generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. Therefore, these products are “new drugs” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p). In general, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for (b)(4), and (b)(4).\n\nThus, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days2. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour written notification should refer to case # 670486.\n\nPlease electronically submit your reply, on company letterhead, to Mark W. Rivero, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov.\n\nIf you have questions regarding the contents of this letter, you may contact Mr. Rivero via phone at (504) 759-7718 or email at mark.rivero@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMonica R. Maxwell\n\nProgram Division Director\n\nOffice of Pharmaceutical Quality Operations,\n\nDivision II\n\n____________________\n\n1 We note your (b)(4) product is an external analgesic, and your (b)(4) product is a combination external analgesic and skin protectant drug product, both of which are subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. However, there is no basis under the FD&C Act under which these products would be legally marketed without an approved application. Specifically, with respect to external analgesic drug products, such products are deemed to be generally recognized as safe and effective (GRASE) and not new drugs if, among other things, they conform to the conditions of use set forth in Over-the-Counter (OTC) Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use (henceforth “M017”) and for combination external analgesic and skin protectant drug products, they must conform to the conditions of use set forth in both M017 and OTC Monograph M016: Skin Protectant Drug Products for Over-the-Counter Human Use (henceforth “M016”). However, (b)(4) and (b)(4) do not conform to the conditions specified in the relevant orders. Neither product is formulated in a manner that is consistent with the applicable final administrative orders and (b)(4) includes intended uses outside both monographs. Specifically, (b)(4) is formulated to contain eucalyptus oil, which falls under section 505G(a)(5) of the FD&C Act because FDA has determined that no counterirritant external analgesic products containing eucalyptus oil as an active ingredient are GRASE under a final determination issued under 21 CFR part 330. In addition, your (b)(4) labeling purports to promote cell repair, which is an intended use not permitted under any OTC Monograph or relevant rulemaking. Although you do not distinguish between active and inactive ingredients for your (b)(4) product, no combination of the labeled ingredients is permitted by M017 and M016 for a combination external analgesic and skin protectant drug product.\n\n2 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Cosmetic Solutions, LLC","cosmetic-solutions-llc-670486-05312024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcosmetic-solutions-llc-670486-05312024","2026-10-26T08:08:18.507651+00:00","2024-06-11","670486","Mr. John Puckett","2026-08-20T00:02:51.223+00:00","2024-05-31",{"id":115,"raw":116,"subject":123,"body_html":124,"body_text":125,"firm_name":126,"letter_id":127,"created_at":128,"fei_number":19,"letter_url":129,"updated_at":130,"action_type":22,"case_status":131,"posted_date":132,"marcs_cms_no":133,"product_type":26,"closeout_date":134,"issuing_office":11,"recipient_name":135,"body_fetched_at":136,"delivery_method":137,"recipient_title":19,"reference_number":19,"action_taken_date":138,"medical_device_id":19,"response_letter_date":19},2025,[117,118,119,120,121,13,122,13],"\u003Ctime datetime=\"2023-06-27T13:20:00Z\">06\u002F27\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-08T04:00:00Z\">06\u002F08\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsafe-chain-solutions-llc-636044-06082023\">Safe Chain Solutions, LLC\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations I","Drug Product\u002FAdulterated\u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsafe-chain-solutions-llc-636044-03102025\">\u003Ctime datetime=\"2025-03-17T04:00:00Z\">03\u002F17\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","Drug Product\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Charles D. Boyd\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder and Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Safe Chain Solutions, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>822 Chesapeake Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Cambridge\u003C\u002Fspan>, \u003Cspan>MD\u003C\u002Fspan> \u003Cspan>21613-9408\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter #636044\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 08, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Boyd:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your wholesale drug distribution facility, Safe Chain Solutions, LLC (Safe Chain), FEI 3009729473, at 822 Chesapeake Drive, Cambridge, Maryland from April 11 to May 11, 2022.\u003C\u002Fp>\n\n\u003Cp>The Drug Supply Chain Security Act (DSCSA) (Title II of Public Law 113-54), enacted by Congress on November 27, 2013, added Section 582 to the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act). Section 582 of the FD&amp;C Act (21 U.S.C. 360eee-1) states the requirements that certain entities in the pharmaceutical distribution supply chain (including wholesale drug distributors) must follow related to product tracing, verification, and authorized trading partners. This warning letter summarizes significant violations of the requirements found in section 582(c) of the FD&amp;C Act. These requirements are intended to help preserve the security of the supply chain for certain prescription drug products, thereby protecting patients from exposure to drugs that may be counterfeit, stolen, contaminated, or otherwise harmful.\u003C\u002Fp>\n\n\u003Cp>FDA issued a Form FDA 483 to Safe Chain at its Cambridge, MD headquarters on May 10, 2022. FDA reviewed your firm’s response, dated June 1, 2022.\u003C\u002Fp>\n\n\u003Cp>FDA has observed that Safe Chain did not have adequate verification systems in place in violation of section 582(c)(4)(A) &amp; (B) of the FD&amp;C Act. FDA observed that Safe Chain failed to maintain records regarding suspect product investigations in violation of section 582(c)(4)(A)(iii) of the FD&amp;C Act, and failed to respond to a notification of illegitimate product in violation of section 582(c)(4)(B)(iii) of the FD&amp;C Act. In addition, Safe Chain engaged in transactions with unauthorized trading partners in violation of section 582(c)(3) of the FD&amp;C Act. Failure to comply with any of the requirements under section 582 of the FD&amp;C Act is a prohibited act under section 301(t) of the FD&amp;C Act (21 U.S.C. 331(t)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>DSCSA Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During FDA’s inspection, our investigators observed that your firm failed to comply with various requirements of the DSCSA. Specific violations include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to have systems in place to enable compliance with the verification requirements of the DSCSA (FD&amp;C Act Section 582(c)(4)(A) &amp; (B)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Under section 582(c)(4)(A) &amp; (B) of the FD&amp;C Act, wholesale drug distributors must have systems in place to enable the wholesale distributor to comply with the verification requirements of the DSCSA.\u003C\u002Fp>\n\n\u003Cp>Your firm was not able to demonstrate systems that would enable Safe Chain to comply with a number of verification requirements required by the DSCSA. For example, your document, “Standard Operating Procedure for Suspect &amp; Illegitimate Product” (Suspect &amp; Illegitimate Product SOP) (re-issue date 3\u002F15\u002F21) lacked sufficient detail or instruction to enable Safe Chain to adequately:\u003C\u002Fp>\n\n\u003Cp>o Identify suspect product,\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003Cbr>\no Conduct an investigation (including validating any applicable transaction history and transaction information) to determine whether a suspect product is an illegitimate product in coordination with trading partners,\u003Cbr>\no Handle an illegitimate product notification,\u003Cbr>\no Handle a request for verification of a suspect product from FDA,\u003Cbr>\no Make notifications of cleared product, and\u003Cbr>\no Maintain adequate records relating to the investigation of suspect product or the disposition of illegitimate product.\u003C\u002Fp>\n\n\u003Cp>Your firm’s failure to establish and implement systems to enable your compliance with these DSCSA requirements may have resulted in suspect product entering the supply chain rather than the product being quarantined as required by section 582(c)(4)(A)(i)(I) of the FD&amp;C Act. For example, an email from February 6, 2021 from the California Board of Pharmacy to Safe Chain, explains that Safe Chain distributed Gentek lot CCXKVA (discussed in more detail in section 2 below) to White Cross Pharmacy and that this lot lacked the required&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> and the original induction seal had been removed and replaced with a non-genuine seal.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> A physical examination of the product may have prevented the lot from being distributed.\u003C\u002Fp>\n\n\u003Cp>Your firm’s Suspect &amp; Illegitimate Product SOP also contained information inconsistent with the DSCSA. Specifically, the SOP stated that if “SCS [Safe Chain Solutions] receives confirmation the product is illegitimate or potentially fraudulent an FDA form 3911 will be filed. Disposition of the product will depend on guidance received from the FDA.” As written, this SOP indicated that the firm is expecting guidance from FDA upon submission of a 3911, and disposition of the product depends on such guidance. However, disposition of illegitimate product is your responsibility and is not dependent on FDA’s response to a FDA Form 3911. (FD&amp;C Act section 582(c)(4)(B)).\u003C\u002Fp>\n\n\u003Cp>In addition, your document “Standard Operating Procedures for Vendor and Transaction History Authentication” (re-issue date 4\u002F1\u002F21) contained information inconsistent with the DSCSA. The document indicated that in case of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” your firm should contact the Maryland Board of Pharmacy and the FDA within 3 days. However, the DSCSA requires a trading partner that determines a product in its possession or control is an illegitimate product to notify the FDA within 24 hours of making such a determination. (FD&amp;C Act section 582(c)(4)(B)(ii)). (FDA understands “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Your lack of sufficient written procedures, or other systems related to compliance with the verification requirements of the DSCSA, rendered your firm unable to demonstrate compliance with the verification requirements of the section 582(c)(4) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm conducted transactions with trading partners that were not authorized (FD&amp;C Act Section 582(c)(3)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The DSCSA requires that trading partners of wholesale distributors meet the applicable requirements for being \u003Cem>authorized\u003C\u002Fem> trading partners. (FD&amp;C Act Section 582(c)(3)). To be authorized, a wholesale drug distributor must have a valid license under State law or section 583 of the FD&amp;C Act, in accordance with section 582(a)(6) of the FD&amp;C Act, and comply with the licensure reporting requirements in section 503(e) of the FD&amp;C Act. (FD&amp;C Act Section 581(2)(B)). Under section 503(e)(2)(A) of the FD&amp;C Act, wholesale distributors must report to FDA, on an annual basis, “each State by which the person is licensed and the appropriate identification number of each such license; the name, address, and contact information of each facility at which, and all trade names under which, the person conducts business;” and “any significant disciplinary actions.”\u003C\u002Fp>\n\n\u003Cp>Your firm has a written procedure to verify a trading partner’s status, “Standard Operating Procedures for Trading Partner Validation” (re-issue date of 3\u002F15\u002F21) (Trading Partner Validation SOP). This procedure recognizes that \u003Cstrong>(b)(4)\u003C\u002Fstrong> as defined by the DSCSA. Your Trading Partner Validation SOP even goes so far as to provide the link to FDA’s publicly accessible database of WDDs and 3PLs that have reported their state licensure status to FDA: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fwdd3plreporting\u002Findex.cfm. Your firm, however, did not adhere to this SOP and failed to verify that all of your trading partners reported licensure information to FDA.\u003C\u002Fp>\n\n\u003Cp>Between July, 2020 and March, 2021, your firm purchased drug products from wholesale drug distributors that were not authorized trading partners according to sections 581(2) and 503(e) of the FD&amp;C Act. For example, your firm purchased prescription drug products from wholesale distributors Gentek and Boulevard 9229 LLC. However, FDA has no record of Gentek or Boulevard 9229 LLC ever submitting the required annual reports to FDA regarding state licensure as required by section 503(e) of the FD&amp;C Act. In addition, Boulevard 9229 LLC provided your firm with a fraudulent license. Therefore, Boulevard 9229 LLC not only failed to report to FDA, but it was also never appropriately licensed as required by section 503(e)(1)(A) and 582(a)(6) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>The importance of the requirement that trading partners of wholesale distributors be authorized is highlighted by the fact that, on multiple occasions, your firm was notified that it had received prescription drug products containing different medication than was purported to be present based on the product labeling, making those products suspect product and unfit for distribution. For example, on multiple occasions your firm was notified by trading partners that patients reported receiving bottles of a product labeled as Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide) that in fact contained different tablets instead of the Biktarvy tablets.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm purchased Biktarvy (lot CCXKVA) from Gentek on July 28, 2020. Subsequently, on July 29, 2020, your firm sold bottles from this lot to pharmacy trading partner White Cross. On November 23, 2020, Gilead Sciences, Inc., the manufacturer of Biktarvy, notified your firm that a bottle from lot CCXKVA that was dispensed by White Cross to a patient contained different tablets instead of Biktarvy tablets.\u003C\u002Fli>\n\t\u003Cli>On September 30, 2020, your firm purchased Biktarvy from Gentek (lot CDFYCA) and subsequently sold it to Medicine Shoppe Pharmacy #1802. On October 14, 2020, your firm was notified through an email from World Wide Pharma Sales that a patient returned a bottle of Biktarvy (lot CDFYCA) to the pharmacy because it contained a different medication than was purported to be present based on the product labeling. Furthermore, in another email from World Wide Pharma Sales, from November 24, 2020, you were notified of yet another patient complaint concerning lot CDFYCA. A second patient had retuned a bottle of Biktarvy (lot CDFYCA) to the same pharmacy because it also contained a different medication than was purported to be present based on the product labeling.\u003C\u002Fli>\n\t\u003Cli>On January 7, 2021, your firm purchased Biktarvy from Gentek for a third time (lot CCZCFA), having already been informed that two prior lots purchased from this firm contained bottles of a medication that was different than what was purported to be present based on the product labeling. Safe Chain subsequently sold the product to Medicine Shoppe Pharmacy #1802. Safe Chain discovered that the drug product purchased in this third lot also contained multiple tablets of a different product than should have been present based on the product’s label. A letter from Safe Chain to Gilead indicates that your firm knew of the issue with this third lot by February 12, 2021.\u003C\u002Fli>\n\t\u003Cli>On March 1, 2021, your firm purchased Biktarvy (lot CDSFFA) from Boulevard 9229 LLC. In a letter to your customer, dated March 27, 2021, Safe Chain reported a quality complaint regarding this product. The drug product purchased contained multiple tablets of a different product than should have been present based on the product’s label.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>These instances are especially concerning from a public health perspective given that Biktarvy is indicated to treat a serious health condition, HIV-1 infection, and the recommended dosage for adult and pediatric patients is one pill daily. As explained in the Patient Counseling Information section of the Prescribing Information for Biktarvy, “it is important to take BIKTARVY on a regular dosing schedule with or without food and to avoid missing doses as it can result in development of resistance.” Patients who receive the wrong drug product from the pharmacy may not be able to take the prescribed dose in a timely manner which can cause serious adverse health consequences. In addition, FDA-approved Biktarvy bears a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious and even life-threatening adverse effects. The boxed warning addresses risks including post treatment acute exacerbation of Hepatitis B.\u003C\u002Fp>\n\n\u003Cp>Your firm continued to purchase product from the same unauthorized trading partners, which resulted in acquiring more suspect product from those entities after they had previously sold you suspect product. This is extremely concerning from a public health perspective given the serious health condition Biktarvy is indicated for. In FDA’s 2016 final guidance \u003Cem>Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification\u003C\u002Fem>, FDA warns trading partners that purchasing from a source that a trading partner knows or has reason to believe has engaged in questionable business practices could significantly increase the chance of suspect product entering the pharmaceutical distribution supply chain.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to maintain records of suspect product investigations (FD&amp;C Act Section 582(c)(4)(A)(iii)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The DSCSA requires that wholesale distributors maintain records of investigations of suspect product for not less than 6 years. (FD&amp;C Act section 582(c)(4)(A)(iii)). Your firm was both unable to provide any written documentation of what products were held in or released from quarantine, and unable to provide records explaining how suspect product was quarantined. In addition, while you were able to produce some correspondence pertaining to the various lots of suspect product, you were unable to provide records about when and how investigations took place to determine whether suspect product was illegitimate.\u003C\u002Fp>\n\n\u003Cp>For example, in a letter from Safe Chain’s outside counsel to Gilead, dated February 12, 2021, you indicate that you would quarantine Biktarvy lot CCZCFA when it was returned to you by the dispenser. The letter explains that Safe Chain notified your immediate trading partner, but does not clarify whether you were referring to a dispenser trading partner or your supplier, Gentek. Your letter also explains that Gentek advised you to destroy the product. However, you were not able to produce records demonstrating that you quarantined the product, any notice you shared about the suspect product with Gentek or other immediate trading partners, or records of the disposition of the product.\u003C\u002Fp>\n\n\u003Cp>Also, your firm could not produce adequate records pertaining to three other suspect product investigations for which Safe Chain made notifications of illegitimate product to the FDA using Form FDA 3911. These Form FDA 3911s were submitted on March 25, 2021 (lots CCXKVA and CDFYCA), March 27, 2021 (lot CDSFFA), and April 7, 2021. (Lot CCZCFA was included on the March 25, 2021 Form FDA 3911 as well.) While these FDA Form 3911s provide some insight into actions Safe Chain claims to have taken, you were not able to provide documentation supporting these actions. As a result, FDA is unable to determine if, or at what point, the drugs referred to in the FDA Form 3911s were appropriately quarantined, as required by section 582(c)(4)(A)(i)(I) of the FD&amp;C Act, and whether investigations were conducted in coordination with trading partners, as required by section 582(c)(4)(A)(i)(II) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to respond to a notification of illegitimate product (FD&amp;C Act Section 582(c)(4)(B)(iii)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Upon receiving a notification of illegitimate product, a wholesale distributor must identify all illegitimate product subject to such notification in its possession or control, including any product that is subsequently received. (FD&amp;C Act section 582(c)(4)(B)(iii)). You are also required to quarantine such product within your possession or control from product intended for distribution (FD&amp;C Act sections 582(c)(4)(A)(i)(I) and 582(c)(4)(B)(i)(I)) and investigate the product as suspect product (FD&amp;C Act sections 582(c)(4)(A)(i)(II) and 582(c)(4)(B)(iii)). You were not able to provide evidence that you appropriately responded to notifications of illegitimate product.\u003C\u002Fp>\n\n\u003Cp>For example, you emailed Gilead regarding Biktarvy Lot CDGXKA in October 2020. You were informed in an email response from Gilead to Safe Chain dated October 9, 2020, that the transaction history in your records was inconstant with Gilead’s records and that Gilead considers the product to be illegitimate product. You were not able to provide any further information about Lot CDGXKA and whether your firm investigated or quarantined the product.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Your Response to the FDA Form 483\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has reviewed your June 1, 2022 response to our Form FDA 483 in detail and your response is inadequate for the following reasons:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>FDA understands that your firm hired a third-party consulting firm after FDA’s inspection to assist in reviewing and enhancing all the company’s SOPs. However, your firm’s new SOP, “Handling and Reporting Suspect and\u002For Illegitimate Products” (effective 5\u002F5\u002F22) contains information not consistent with the DSCSA. For example, the SOP indicates that immediate trading partners be notified \u003Cstrong>(b)(4)\u003C\u002Fstrong> after Safe Chain makes a determination that product in its possession or control is illegitimate product. FDA reiterates that the DSCSA requires immediate trading partners to be notified within 24 hours of an illegitimate product determination. (FD&amp;C Act section 582(c)(4)(B)(ii)). FDA notes that the revised SOP you provided, “Vendor and Transaction History Authentication” (effective 5\u002F9\u002F15) is updated with the correct time-frame. However, the inconsistency between the two SOPs creates the potential for significant confusion and untimely notification.\u003C\u002Fli>\n\t\u003Cli>In your response you state that you have: “…NEVER knowingly purchased illegitimate products from any of our Vendors…” (emphasis in original). You explain that you continued to purchase products from Gentek, and did not cease sales of the product, even after becoming aware of issues with product received from the firm because the products were part of an ongoing investigation and you believed the issue was at the retailer\u002Fpharmacy level.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your response is inadequate because you failed to provide any documentation demonstrating the rationale for your belief that the issue was at the retailer\u002Fpharmacy level. If your firm had conducted the required investigations, which would have included your firm’s knowledge of reported issues with the drug, you may have recognized the inherent risk of these Gentek products to the supply chain. Furthermore, your response appears to acknowledge that your efforts to look into the problematic product was limited to Safe Chain and Safe Chain’s attorneys. If this is the case, this is inadequate because the DSCSA requires that investigations of suspect product take place in coordination with trading partners. (FD&amp;C Act section 582(c)(4)(A)(i)(II)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>DSCSA Resources\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As explained above, your firm has failed to comply with a number of DSCSA provisions. Please see the FDA guidance documents listed below for additional information about the DSCSA requirements noted above:\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification, Final Guidance, June 2021, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F88790\u002Fdownload\u003C\u002Fli>\n\t\u003Cli>Definitions of Suspect Product and Illegitimate Product for Verification Obligations Under the Drug Supply Chain Security Act, Final Guidance for Industry, March 2023, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F111468\u002Fdownload.\u003C\u002Fli>\n\t\u003Cli>Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs, Draft Guidance for Industry, March 2022, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F117950\u002Fdownload.\u003C\u002Fli>\n\t\u003Cli>Identifying Trading Partners Under the Drug Supply Chain Security Act, Draft Guidance for Industry, July 2022, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F159621\u002Fdownload.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Safe Chain’s response to FDA Form 483 does not indicate that sufficient remediation efforts have been taken. FDA is sending this compliance letter to Safe Chain because of the inherent risk to the supply chain when firms do not comply with the provisions of the DSCSA.\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address these violations may result in regulatory or legal action without further notice, including seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please send your electronic reply to ORAPHARM1_Responses@FDA.HHS.GOV and “cc” Compliance Officer, Emmanuel Ramos (Emmanuel.Ramos@fda.hhs.gov). Your written notification should refer to the Warning Letter #636044 and include FEI number 3009729473.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Emmanuel Ramos, Compliance Officer, via email at Emmanuel.Ramos@fda.hhs.gov or by telephone at 240-507-7119.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lisa Harlan\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations, Division I\u003Cbr>\nU.S. Food &amp; Drug Administration\u003C\u002Fp>\n\n\u003Cp>_______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> “Suspect product” and “illegitimate product” are defined in sections 581(21) and (8) of the FD&amp;C Act, respectively.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Trading partners should be mindful of product that is missing required information or security features, as that may indicate the product should be considered suspect. See FDA’s 2016 final \u003Cem>guidance Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Draft guidances, when finalized, will represent the agency's current thinking on the topic.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Charles D. Boyd\n\nRecipient Title\n\nFounder and Chief Executive Officer\n\nSafe Chain Solutions, LLC\n\n822 Chesapeake Drive\n\nCambridge, MD 21613-9408\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nWarning Letter #636044\n\nJune 08, 2023\n\nDear Mr. Boyd:\n\nThe U.S. Food and Drug Administration (FDA) inspected your wholesale drug distribution facility, Safe Chain Solutions, LLC (Safe Chain), FEI 3009729473, at 822 Chesapeake Drive, Cambridge, Maryland from April 11 to May 11, 2022.\n\nThe Drug Supply Chain Security Act (DSCSA) (Title II of Public Law 113-54), enacted by Congress on November 27, 2013, added Section 582 to the Federal Food, Drug, and Cosmetic Act (FD&C Act). Section 582 of the FD&C Act (21 U.S.C. 360eee-1) states the requirements that certain entities in the pharmaceutical distribution supply chain (including wholesale drug distributors) must follow related to product tracing, verification, and authorized trading partners. This warning letter summarizes significant violations of the requirements found in section 582(c) of the FD&C Act. These requirements are intended to help preserve the security of the supply chain for certain prescription drug products, thereby protecting patients from exposure to drugs that may be counterfeit, stolen, contaminated, or otherwise harmful.\n\nFDA issued a Form FDA 483 to Safe Chain at its Cambridge, MD headquarters on May 10, 2022. FDA reviewed your firm’s response, dated June 1, 2022.\n\nFDA has observed that Safe Chain did not have adequate verification systems in place in violation of section 582(c)(4)(A) & (B) of the FD&C Act. FDA observed that Safe Chain failed to maintain records regarding suspect product investigations in violation of section 582(c)(4)(A)(iii) of the FD&C Act, and failed to respond to a notification of illegitimate product in violation of section 582(c)(4)(B)(iii) of the FD&C Act. In addition, Safe Chain engaged in transactions with unauthorized trading partners in violation of section 582(c)(3) of the FD&C Act. Failure to comply with any of the requirements under section 582 of the FD&C Act is a prohibited act under section 301(t) of the FD&C Act (21 U.S.C. 331(t)).\n\nDSCSA Violations\n\nDuring FDA’s inspection, our investigators observed that your firm failed to comply with various requirements of the DSCSA. Specific violations include, but may not be limited to, the following:\n\n1. Your firm failed to have systems in place to enable compliance with the verification requirements of the DSCSA (FD&C Act Section 582(c)(4)(A) & (B)).\n\nUnder section 582(c)(4)(A) & (B) of the FD&C Act, wholesale drug distributors must have systems in place to enable the wholesale distributor to comply with the verification requirements of the DSCSA.\n\nYour firm was not able to demonstrate systems that would enable Safe Chain to comply with a number of verification requirements required by the DSCSA. For example, your document, “Standard Operating Procedure for Suspect & Illegitimate Product” (Suspect & Illegitimate Product SOP) (re-issue date 3\u002F15\u002F21) lacked sufficient detail or instruction to enable Safe Chain to adequately:\n\no Identify suspect product,1\n\no Conduct an investigation (including validating any applicable transaction history and transaction information) to determine whether a suspect product is an illegitimate product in coordination with trading partners,\n\no Handle an illegitimate product notification,\n\no Handle a request for verification of a suspect product from FDA,\n\no Make notifications of cleared product, and\n\no Maintain adequate records relating to the investigation of suspect product or the disposition of illegitimate product.\n\nYour firm’s failure to establish and implement systems to enable your compliance with these DSCSA requirements may have resulted in suspect product entering the supply chain rather than the product being quarantined as required by section 582(c)(4)(A)(i)(I) of the FD&C Act. For example, an email from February 6, 2021 from the California Board of Pharmacy to Safe Chain, explains that Safe Chain distributed Gentek lot CCXKVA (discussed in more detail in section 2 below) to White Cross Pharmacy and that this lot lacked the required (b)(4) and the original induction seal had been removed and replaced with a non-genuine seal.2 A physical examination of the product may have prevented the lot from being distributed.\n\nYour firm’s Suspect & Illegitimate Product SOP also contained information inconsistent with the DSCSA. Specifically, the SOP stated that if “SCS [Safe Chain Solutions] receives confirmation the product is illegitimate or potentially fraudulent an FDA form 3911 will be filed. Disposition of the product will depend on guidance received from the FDA.” As written, this SOP indicated that the firm is expecting guidance from FDA upon submission of a 3911, and disposition of the product depends on such guidance. However, disposition of illegitimate product is your responsibility and is not dependent on FDA’s response to a FDA Form 3911. (FD&C Act section 582(c)(4)(B)).\n\nIn addition, your document “Standard Operating Procedures for Vendor and Transaction History Authentication” (re-issue date 4\u002F1\u002F21) contained information inconsistent with the DSCSA. The document indicated that in case of “(b)(4),” your firm should contact the Maryland Board of Pharmacy and the FDA within 3 days. However, the DSCSA requires a trading partner that determines a product in its possession or control is an illegitimate product to notify the FDA within 24 hours of making such a determination. (FD&C Act section 582(c)(4)(B)(ii)). (FDA understands “(b)(4).\n\nYour lack of sufficient written procedures, or other systems related to compliance with the verification requirements of the DSCSA, rendered your firm unable to demonstrate compliance with the verification requirements of the section 582(c)(4) of the FD&C Act.\n\n2. Your firm conducted transactions with trading partners that were not authorized (FD&C Act Section 582(c)(3)).\n\nThe DSCSA requires that trading partners of wholesale distributors meet the applicable requirements for being authorized trading partners. (FD&C Act Section 582(c)(3)). To be authorized, a wholesale drug distributor must have a valid license under State law or section 583 of the FD&C Act, in accordance with section 582(a)(6) of the FD&C Act, and comply with the licensure reporting requirements in section 503(e) of the FD&C Act. (FD&C Act Section 581(2)(B)). Under section 503(e)(2)(A) of the FD&C Act, wholesale distributors must report to FDA, on an annual basis, “each State by which the person is licensed and the appropriate identification number of each such license; the name, address, and contact information of each facility at which, and all trade names under which, the person conducts business;” and “any significant disciplinary actions.”\n\nYour firm has a written procedure to verify a trading partner’s status, “Standard Operating Procedures for Trading Partner Validation” (re-issue date of 3\u002F15\u002F21) (Trading Partner Validation SOP). This procedure recognizes that (b)(4) as defined by the DSCSA. Your Trading Partner Validation SOP even goes so far as to provide the link to FDA’s publicly accessible database of WDDs and 3PLs that have reported their state licensure status to FDA: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fwdd3plreporting\u002Findex.cfm. Your firm, however, did not adhere to this SOP and failed to verify that all of your trading partners reported licensure information to FDA.\n\nBetween July, 2020 and March, 2021, your firm purchased drug products from wholesale drug distributors that were not authorized trading partners according to sections 581(2) and 503(e) of the FD&C Act. For example, your firm purchased prescription drug products from wholesale distributors Gentek and Boulevard 9229 LLC. However, FDA has no record of Gentek or Boulevard 9229 LLC ever submitting the required annual reports to FDA regarding state licensure as required by section 503(e) of the FD&C Act. In addition, Boulevard 9229 LLC provided your firm with a fraudulent license. Therefore, Boulevard 9229 LLC not only failed to report to FDA, but it was also never appropriately licensed as required by section 503(e)(1)(A) and 582(a)(6) of the FD&C Act.\n\nThe importance of the requirement that trading partners of wholesale distributors be authorized is highlighted by the fact that, on multiple occasions, your firm was notified that it had received prescription drug products containing different medication than was purported to be present based on the product labeling, making those products suspect product and unfit for distribution. For example, on multiple occasions your firm was notified by trading partners that patients reported receiving bottles of a product labeled as Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide) that in fact contained different tablets instead of the Biktarvy tablets.\n\nYour firm purchased Biktarvy (lot CCXKVA) from Gentek on July 28, 2020. Subsequently, on July 29, 2020, your firm sold bottles from this lot to pharmacy trading partner White Cross. On November 23, 2020, Gilead Sciences, Inc., the manufacturer of Biktarvy, notified your firm that a bottle from lot CCXKVA that was dispensed by White Cross to a patient contained different tablets instead of Biktarvy tablets.\n\nOn September 30, 2020, your firm purchased Biktarvy from Gentek (lot CDFYCA) and subsequently sold it to Medicine Shoppe Pharmacy #1802. On October 14, 2020, your firm was notified through an email from World Wide Pharma Sales that a patient returned a bottle of Biktarvy (lot CDFYCA) to the pharmacy because it contained a different medication than was purported to be present based on the product labeling. Furthermore, in another email from World Wide Pharma Sales, from November 24, 2020, you were notified of yet another patient complaint concerning lot CDFYCA. A second patient had retuned a bottle of Biktarvy (lot CDFYCA) to the same pharmacy because it also contained a different medication than was purported to be present based on the product labeling.\n\nOn January 7, 2021, your firm purchased Biktarvy from Gentek for a third time (lot CCZCFA), having already been informed that two prior lots purchased from this firm contained bottles of a medication that was different than what was purported to be present based on the product labeling. Safe Chain subsequently sold the product to Medicine Shoppe Pharmacy #1802. Safe Chain discovered that the drug product purchased in this third lot also contained multiple tablets of a different product than should have been present based on the product’s label. A letter from Safe Chain to Gilead indicates that your firm knew of the issue with this third lot by February 12, 2021.\n\nOn March 1, 2021, your firm purchased Biktarvy (lot CDSFFA) from Boulevard 9229 LLC. In a letter to your customer, dated March 27, 2021, Safe Chain reported a quality complaint regarding this product. The drug product purchased contained multiple tablets of a different product than should have been present based on the product’s label.\n\nThese instances are especially concerning from a public health perspective given that Biktarvy is indicated to treat a serious health condition, HIV-1 infection, and the recommended dosage for adult and pediatric patients is one pill daily. As explained in the Patient Counseling Information section of the Prescribing Information for Biktarvy, “it is important to take BIKTARVY on a regular dosing schedule with or without food and to avoid missing doses as it can result in development of resistance.” Patients who receive the wrong drug product from the pharmacy may not be able to take the prescribed dose in a timely manner which can cause serious adverse health consequences. In addition, FDA-approved Biktarvy bears a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious and even life-threatening adverse effects. The boxed warning addresses risks including post treatment acute exacerbation of Hepatitis B.\n\nYour firm continued to purchase product from the same unauthorized trading partners, which resulted in acquiring more suspect product from those entities after they had previously sold you suspect product. This is extremely concerning from a public health perspective given the serious health condition Biktarvy is indicated for. In FDA’s 2016 final guidance Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification, FDA warns trading partners that purchasing from a source that a trading partner knows or has reason to believe has engaged in questionable business practices could significantly increase the chance of suspect product entering the pharmaceutical distribution supply chain.\n\n3. Your firm failed to maintain records of suspect product investigations (FD&C Act Section 582(c)(4)(A)(iii)).\n\nThe DSCSA requires that wholesale distributors maintain records of investigations of suspect product for not less than 6 years. (FD&C Act section 582(c)(4)(A)(iii)). Your firm was both unable to provide any written documentation of what products were held in or released from quarantine, and unable to provide records explaining how suspect product was quarantined. In addition, while you were able to produce some correspondence pertaining to the various lots of suspect product, you were unable to provide records about when and how investigations took place to determine whether suspect product was illegitimate.\n\nFor example, in a letter from Safe Chain’s outside counsel to Gilead, dated February 12, 2021, you indicate that you would quarantine Biktarvy lot CCZCFA when it was returned to you by the dispenser. The letter explains that Safe Chain notified your immediate trading partner, but does not clarify whether you were referring to a dispenser trading partner or your supplier, Gentek. Your letter also explains that Gentek advised you to destroy the product. However, you were not able to produce records demonstrating that you quarantined the product, any notice you shared about the suspect product with Gentek or other immediate trading partners, or records of the disposition of the product.\n\nAlso, your firm could not produce adequate records pertaining to three other suspect product investigations for which Safe Chain made notifications of illegitimate product to the FDA using Form FDA 3911. These Form FDA 3911s were submitted on March 25, 2021 (lots CCXKVA and CDFYCA), March 27, 2021 (lot CDSFFA), and April 7, 2021. (Lot CCZCFA was included on the March 25, 2021 Form FDA 3911 as well.) While these FDA Form 3911s provide some insight into actions Safe Chain claims to have taken, you were not able to provide documentation supporting these actions. As a result, FDA is unable to determine if, or at what point, the drugs referred to in the FDA Form 3911s were appropriately quarantined, as required by section 582(c)(4)(A)(i)(I) of the FD&C Act, and whether investigations were conducted in coordination with trading partners, as required by section 582(c)(4)(A)(i)(II) of the FD&C Act.\n\n4. Your firm failed to respond to a notification of illegitimate product (FD&C Act Section 582(c)(4)(B)(iii)).\n\nUpon receiving a notification of illegitimate product, a wholesale distributor must identify all illegitimate product subject to such notification in its possession or control, including any product that is subsequently received. (FD&C Act section 582(c)(4)(B)(iii)). You are also required to quarantine such product within your possession or control from product intended for distribution (FD&C Act sections 582(c)(4)(A)(i)(I) and 582(c)(4)(B)(i)(I)) and investigate the product as suspect product (FD&C Act sections 582(c)(4)(A)(i)(II) and 582(c)(4)(B)(iii)). You were not able to provide evidence that you appropriately responded to notifications of illegitimate product.\n\nFor example, you emailed Gilead regarding Biktarvy Lot CDGXKA in October 2020. You were informed in an email response from Gilead to Safe Chain dated October 9, 2020, that the transaction history in your records was inconstant with Gilead’s records and that Gilead considers the product to be illegitimate product. You were not able to provide any further information about Lot CDGXKA and whether your firm investigated or quarantined the product.\n\nYour Response to the FDA Form 483\n\nFDA has reviewed your June 1, 2022 response to our Form FDA 483 in detail and your response is inadequate for the following reasons:\n\nFDA understands that your firm hired a third-party consulting firm after FDA’s inspection to assist in reviewing and enhancing all the company’s SOPs. However, your firm’s new SOP, “Handling and Reporting Suspect and\u002For Illegitimate Products” (effective 5\u002F5\u002F22) contains information not consistent with the DSCSA. For example, the SOP indicates that immediate trading partners be notified (b)(4) after Safe Chain makes a determination that product in its possession or control is illegitimate product. FDA reiterates that the DSCSA requires immediate trading partners to be notified within 24 hours of an illegitimate product determination. (FD&C Act section 582(c)(4)(B)(ii)). FDA notes that the revised SOP you provided, “Vendor and Transaction History Authentication” (effective 5\u002F9\u002F15) is updated with the correct time-frame. However, the inconsistency between the two SOPs creates the potential for significant confusion and untimely notification.\n\nIn your response you state that you have: “…NEVER knowingly purchased illegitimate products from any of our Vendors…” (emphasis in original). You explain that you continued to purchase products from Gentek, and did not cease sales of the product, even after becoming aware of issues with product received from the firm because the products were part of an ongoing investigation and you believed the issue was at the retailer\u002Fpharmacy level.\n\nYour response is inadequate because you failed to provide any documentation demonstrating the rationale for your belief that the issue was at the retailer\u002Fpharmacy level. If your firm had conducted the required investigations, which would have included your firm’s knowledge of reported issues with the drug, you may have recognized the inherent risk of these Gentek products to the supply chain. Furthermore, your response appears to acknowledge that your efforts to look into the problematic product was limited to Safe Chain and Safe Chain’s attorneys. If this is the case, this is inadequate because the DSCSA requires that investigations of suspect product take place in coordination with trading partners. (FD&C Act section 582(c)(4)(A)(i)(II)).\n\nDSCSA Resources\n\nAs explained above, your firm has failed to comply with a number of DSCSA provisions. Please see the FDA guidance documents listed below for additional information about the DSCSA requirements noted above:3\n\nDrug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification, Final Guidance, June 2021, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F88790\u002Fdownload\n\nDefinitions of Suspect Product and Illegitimate Product for Verification Obligations Under the Drug Supply Chain Security Act, Final Guidance for Industry, March 2023, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F111468\u002Fdownload.\n\nVerification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs, Draft Guidance for Industry, March 2022, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F117950\u002Fdownload.\n\nIdentifying Trading Partners Under the Drug Supply Chain Security Act, Draft Guidance for Industry, July 2022, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F159621\u002Fdownload.\n\nConclusion\n\nSafe Chain’s response to FDA Form 483 does not indicate that sufficient remediation efforts have been taken. FDA is sending this compliance letter to Safe Chain because of the inherent risk to the supply chain when firms do not comply with the provisions of the DSCSA.\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address these violations may result in regulatory or legal action without further notice, including seizure and injunction.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease send your electronic reply to ORAPHARM1_Responses@FDA.HHS.GOV and “cc” Compliance Officer, Emmanuel Ramos (Emmanuel.Ramos@fda.hhs.gov). Your written notification should refer to the Warning Letter #636044 and include FEI number 3009729473.\n\nIf you have questions regarding the contents of this letter, please contact Emmanuel Ramos, Compliance Officer, via email at Emmanuel.Ramos@fda.hhs.gov or by telephone at 240-507-7119.\n\nSincerely,\n\n\u002FS\u002F\n\nLisa Harlan\n\nProgram Division Director\n\nOffice of Pharmaceutical Quality Operations, Division I\n\nU.S. Food & Drug Administration\n\n_______________________\n\n1 “Suspect product” and “illegitimate product” are defined in sections 581(21) and (8) of the FD&C Act, respectively.\n\n2 Trading partners should be mindful of product that is missing required information or security features, as that may indicate the product should be considered suspect. See FDA’s 2016 final guidance Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification.\n\n3 Draft guidances, when finalized, will represent the agency's current thinking on the topic.","Safe Chain Solutions, LLC","safe-chain-solutions-llc-636044-06082023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsafe-chain-solutions-llc-636044-06082023","2026-10-26T08:09:52.58375+00:00","Closed Out","2023-06-27","636044","2025-03-17","Mr. Charles D. Boyd","2026-08-20T01:00:46.064+00:00","Via Email","2023-06-08",{"id":140,"raw":141,"subject":145,"body_html":146,"body_text":147,"firm_name":148,"letter_id":149,"created_at":18,"fei_number":19,"letter_url":150,"updated_at":151,"action_type":22,"case_status":23,"posted_date":152,"marcs_cms_no":153,"product_type":26,"closeout_date":19,"issuing_office":79,"recipient_name":154,"body_fetched_at":155,"delivery_method":137,"recipient_title":19,"reference_number":19,"action_taken_date":156,"medical_device_id":19,"response_letter_date":19},1338,[142,143,144,79,145,13,13,13],"\u003Ctime datetime=\"2024-07-30T13:20:00Z\">07\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-07-25T04:00:00Z\">07\u002F25\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fskin-beauty-solutions-683006-07252024\">Skin Beauty Solutions\u003C\u002Fa>","Finished Pharmaceuticals\u002FUnapproved New Drugs","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Cassandra Pryor\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Skin Beauty Solutions\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>P.O. Box 25527\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saint Paul\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55125-0527\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@skinbeautysolutions.com\"> info@skinbeautysolutions.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>July 25, 2024\u003C\u002Fp>\n\n\u003Cp>RE: 683006\u003C\u002Fp>\n\n\u003Cp>Dear Cassandra Pryor:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website, at the internet address https:\u002F\u002Fwww.skinbeautysolutions.com\u002F in April 2024 and has observed that your website offers numerous chemical peel drug products; including, multiple strengths of lactic acid, glycolic acid, combination glycolic and lactic acid, and salicylic acid products\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>, including “LACTIC Acid Skin Chemical Peel 90%,” “GLYCOLIC ACID Skin Cosmetic Grade Peel 70%,” “Combination Peel GLYCOLIC 35% LACTIC 45%,” and “SALICYLIC ACID Skin Chemical Peel 30%” (hereinafter referred to as your “chemical peels”) for sale in the United States. As described below, your chemical peels are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>The Agency is concerned about potent chemical peel products that are available to be purchased and used by consumers. Such products pose a public health risk because they can cause skin injuries such as burns on the area of application, wounds, pain, swelling, and scarring. FDA has received adverse event reports of injuries involving use of such products, some of which required emergency room care, specialty care from a dermatologist, and\u002For surgical intervention.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on a review of your website, your firm’s chemical peels are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on your website https:\u002F\u002Fwww.skinbeautysolutions.com\u002F that establish the intended use of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cu>LACTIC Acid Skin Chemical Peel 90%\u003C\u002Fu>\u003Cbr>\n• “lactic acid skin peel 90%\u003Cbr>\nClears Acne &amp; Scars\u003Cbr>\nRemoves Dead Skin Cells”\u003C\u002Fp>\n\n\u003Cp>• “Chemical peels work by loosening and gently sloughing off the damaged, unattractive skin cells. . .. Lactic Peels can also work on the deeper layers of skin to accelerate the skin’s natural production of collagen and elastin.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>GLYCOLIC ACID Skin Cosmetic Grade Peel 70%\u003C\u002Fu>\u003Cbr>\n• “glycolic acid skin peel 70%\u003Cbr>\nClears Acne &amp; Scars\u003Cbr>\nRemoves Dead Skin Cells\u003Cbr>\nPrevents Fine lines &amp; Wrinkles”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Combination Peel GLYCOLIC 35% LACTIC 45%\u003C\u002Fu>\u003Cbr>\n• “combination peel\u003Cbr>\nGlycolic Acid 35%\u003Cbr>\nLactic Acid 45%\u003Cbr>\nClears Acne &amp; Scars\u003Cbr>\nRemoves Dead Skin Cells\u003Cbr>\nSmoothes [sic] Fine lines &amp; Wrinkles”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>SALICYLIC ACID Skin Chemical Peel 30%\u003C\u002Fu>\u003Cbr>\n• “salicylic acid skin peel 30%\u003Cbr>\nRemoves Blackheads\u003Cbr>\nClears Acne &amp; Scars”\u003C\u002Fp>\n\n\u003Cp>• “SALICYLIC ACID SKIN CHEMICAL PEEL W\u002F BETA HYDROXY (BHA) BY SKIN BEAUTY SOLUTIONS – IDEAL FOR ACNE, BLACKHEADS, DERMATITIS, WHITEHEADS, CLOGGED PORES.”\u003C\u002Fp>\n\n\u003Cp>Your chemical peels are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction. Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTina Smith, M.S.\u003Cbr>\nCaptain, U.S. Public Health Service\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>___________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We have observed that your website offers Lactic Acid skin peel 35%, 50%, 70%, 90% strengths, Glycolic Acid skin peel buffered and unbuffered 35%, 50%, 70% strengths, combination Glycolic Acid 35% and Lactic Acid 45% strength, and Salicylic Acid skin chemical peels 10%, 20%, and 30% strengths.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nCassandra Pryor\n\nRecipient Title\n\nManager\n\nSkin Beauty Solutions\n\nP.O. Box 25527\n\nSaint Paul, MN 55125-0527\n\nUnited States\n\ninfo@skinbeautysolutions.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\n\nJuly 25, 2024\n\nRE: 683006\n\nDear Cassandra Pryor:\n\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website, at the internet address https:\u002F\u002Fwww.skinbeautysolutions.com\u002F in April 2024 and has observed that your website offers numerous chemical peel drug products; including, multiple strengths of lactic acid, glycolic acid, combination glycolic and lactic acid, and salicylic acid products1, including “LACTIC Acid Skin Chemical Peel 90%,” “GLYCOLIC ACID Skin Cosmetic Grade Peel 70%,” “Combination Peel GLYCOLIC 35% LACTIC 45%,” and “SALICYLIC ACID Skin Chemical Peel 30%” (hereinafter referred to as your “chemical peels”) for sale in the United States. As described below, your chemical peels are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d).\n\nThe Agency is concerned about potent chemical peel products that are available to be purchased and used by consumers. Such products pose a public health risk because they can cause skin injuries such as burns on the area of application, wounds, pain, swelling, and scarring. FDA has received adverse event reports of injuries involving use of such products, some of which required emergency room care, specialty care from a dermatologist, and\u002For surgical intervention.\n\nUnapproved New Drugs\n\nBased on a review of your website, your firm’s chemical peels are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body.\n\nExamples of claims observed on your website https:\u002F\u002Fwww.skinbeautysolutions.com\u002F that establish the intended use of these products as drugs include, but may not be limited to, the following:\n\nLACTIC Acid Skin Chemical Peel 90%\n\n• “lactic acid skin peel 90%\n\nClears Acne & Scars\n\nRemoves Dead Skin Cells”\n\n• “Chemical peels work by loosening and gently sloughing off the damaged, unattractive skin cells. . .. Lactic Peels can also work on the deeper layers of skin to accelerate the skin’s natural production of collagen and elastin.”\n\nGLYCOLIC ACID Skin Cosmetic Grade Peel 70%\n\n• “glycolic acid skin peel 70%\n\nClears Acne & Scars\n\nRemoves Dead Skin Cells\n\nPrevents Fine lines & Wrinkles”\n\nCombination Peel GLYCOLIC 35% LACTIC 45%\n\n• “combination peel\n\nGlycolic Acid 35%\n\nLactic Acid 45%\n\nClears Acne & Scars\n\nRemoves Dead Skin Cells\n\nSmoothes [sic] Fine lines & Wrinkles”\n\nSALICYLIC ACID Skin Chemical Peel 30%\n\n• “salicylic acid skin peel 30%\n\nRemoves Blackheads\n\nClears Acne & Scars”\n\n• “SALICYLIC ACID SKIN CHEMICAL PEEL W\u002F BETA HYDROXY (BHA) BY SKIN BEAUTY SOLUTIONS – IDEAL FOR ACNE, BLACKHEADS, DERMATITIS, WHITEHEADS, CLOGGED PORES.”\n\nYour chemical peels are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction. Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nTina Smith, M.S.\n\nCaptain, U.S. Public Health Service\n\nDirector\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n___________________\n\n1 We have observed that your website offers Lactic Acid skin peel 35%, 50%, 70%, 90% strengths, Glycolic Acid skin peel buffered and unbuffered 35%, 50%, 70% strengths, combination Glycolic Acid 35% and Lactic Acid 45% strength, and Salicylic Acid skin chemical peels 10%, 20%, and 30% strengths.","Skin Beauty Solutions","skin-beauty-solutions-683006-07252024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fskin-beauty-solutions-683006-07252024","2026-10-26T08:09:58.469498+00:00","2024-07-30","683006","Cassandra Pryor","2026-08-19T23:55:45.859+00:00","2024-07-25",{"id":158,"raw":159,"subject":163,"body_html":165,"body_text":166,"firm_name":167,"letter_id":168,"created_at":65,"fei_number":19,"letter_url":169,"updated_at":170,"action_type":22,"case_status":131,"posted_date":171,"marcs_cms_no":172,"product_type":70,"closeout_date":173,"issuing_office":59,"recipient_name":174,"body_fetched_at":175,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":176,"medical_device_id":19,"response_letter_date":19},3478,[160,161,162,59,163,13,164,13],"\u003Ctime datetime=\"2021-03-05T18:00:00Z\">03\u002F05\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-04T05:00:00Z\">03\u002F04\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcreativestar-solutions-613535-03042021\">CreativeStar Solutions\u003C\u002Fa>","Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcreativestar-solutions-613535-07202023\">\u003Ctime datetime=\"2023-07-24T04:00:00Z\">07\u002F24\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Steven Gao\u002FDan Xiao\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>CreativeStar Solutions\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1601 Trapelo Road, Suite 260\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Waltham\u003C\u002Fspan>, \u003Cspan>MA\u003C\u002Fspan> \u003Cspan>02451\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:steven.gao@cssinco.com\"> steven.gao@cssinco.com \u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:dan.xiao@cssinco.com\"> dan.xiao@cssinco.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>WARNING LETTER\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Date:&nbsp; March , 2021\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>RE: &nbsp;&nbsp;&nbsp;&nbsp;Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fcssinco.com\u002F on February 12, 2021. The FDA has observed that your website offers products for measuring human body temperature, specifically the “Artemis TI-CS-T11 Thermal Scanner” and “Artemis Gateway” (collectively referred to as “Thermal Scanners”), for sale in the United States. Based on our review, these products are intended to mitigate, prevent, treat, diagnose or cure COVID-19\u003Ca>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[1]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa> in people, and thus are devices under section 201(h) of the Federal, Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>FDA’s review of your website revealed the following statements that establish that the Thermal Scanners are intended for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, including: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“The T-Series can be used as a prevention solution for COVID-19” [Published on an undated blog post on your website, https:\u002F\u002Fcssinco.com\u002Fblog\u002Four-blog-1\u002Fpost\u002Fartemis-t-series-thermal-scanners-31]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“The Artemis Gateway is a leading solution in COVID-19 prevention.” [Published on your website, https:\u002F\u002Fwww.cssinco.com\u002Fartemis-gateway] \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>The Thermal Scanners are offered for sale\u003C\u002Fspan>\u003Cspan> in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. §&nbsp;351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce these products into interstate commerce for commercial distribution as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>[\u003Ca>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[2]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>]\u003C\u002Fsup> In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19\u003C\u002Fspan>\u003Cspan>.\u003Csup>[\u003Ca>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[3]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>]\u003C\u002Fsup> \u003C\u002Fspan>\u003Cspan>Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you offer for sale products that are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of such adulterated and misbranded products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Use of telethermographic devices for the assessment of human body temperature can present potentially serious public health risks. Such risks may include, but are not limited to, the device incorrectly detecting a normal human body temperature when a person has an elevated temperature and incorrectly assessing a person to have an elevated body temperature when they do not. A person with an undetected elevated temperature who was subject to temperature assessment using a telethermographic device may, as a result, be less likely to adhere to infection prevention and control guidelines, such as social distancing and using personal protective equipment. These risks are more likely to be present where telethermographic devices scan multiple individuals simultaneously. Your website, https:\u002F\u002Fcssinco.com\u002F, includes statements that indicate that the Thermal Scanners are intended to scan multiple individuals simultaneously, including:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Scan up to 10 persons at a time for rapid screening” [Published on your “Artemis Thermal Scanner” webpage under the subheading “TI-CS-11”, https:\u002F\u002Fcssinco.com\u002Fartemis-thermalscanner] \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“This model can scan up to 10 individuals at a single time.” [Published on your TI-CS-11 webpage, https:\u002F\u002Fcssinco.com\u002Fti-cs-t11-detail] \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>For more information \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>about FDA’s regulation of\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan> devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, \u003Cspan>visit our website at\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">\u003Cspan>\u003Cspan>https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>\u003Cspan>\u003Cspan>. In addition, the guidance titled “Enforcement Policy for Telethermographic Systems During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency”\u003Csup>[\u003C\u002Fsup>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Ca>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[4]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Csup>\u003Cspan>\u003Cspan>\u003Cspan>]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fsup>\u003Cspan>\u003Cspan>\u003Cspan> provides information about FDA’s \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>policies intended to help expand the availability of telethermographic systems used for body temperature measurements for triage use during the COVID-19 public health emergency. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>You should take action to address the\u003C\u002Fspan>\u003Cspan> violations\u003C\u002Fspan>\u003Cspan> cited in this letter\u003C\u002Fspan>\u003Cspan>. \u003C\u002Fspan>\u003Cspan>This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that misbrand the products in violation of the Act. \u003Cb>Within 48 hours, please send an email to \u003C\u002Fb>\u003C\u002Fspan>\u003Ca href=\"mailto:COVID-19-Task-Force-CDRH@fda.hhs.gov\">\u003Cb>\u003Cspan>COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fa>\u003Cb> \u003C\u002Fb>\u003Cspan>\u003Cspan>describing the specific steps you have taken to address these\u003C\u002Fspan>\u003C\u002Fspan> \u003Cspan>\u003Cspan>violations, using CMS # 613535 as reference\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>. \u003Cspan>Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>Failure to \u003C\u002Fspan>\u003Cspan>adequately \u003C\u002Fspan>\u003Cspan>prevent \u003C\u002Fspan>\u003Cspan>address any\u003C\u002Fspan>\u003Cspan> violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.&nbsp;Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act.&nbsp;This list can be found at \u003C\u002Fspan>\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">\u003Cspan>https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>\u003Cspan>. \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>Once you have taken actions to&nbsp;\u003C\u002Fspan>\u003Cspan>address\u003C\u002Fspan>\u003Cspan> the sale of \u003C\u002Fspan>\u003Cspan>unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, \u003C\u002Fspan>\u003Cspan>and \u003C\u002Fspan>\u003Cspan>any appropriate corrective\u003C\u002Fspan>\u003Cspan> actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken \u003C\u002Fspan>\u003Cspan>such\u003C\u002Fspan>\u003Cspan> corrective \u003C\u002Fspan>\u003Cspan>actions.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>This letter notifies you of our concerns and provides you with an opportunity to address them. \u003C\u002Fspan>\u003Cspan>\u003Cspan>If you cannot \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>take action to address this matter \u003C\u002Fspan>\u003Cspan>\u003Cspan>completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Please direct any inquiries to FDA at \u003C\u002Fspan>\u003Ca href=\"mailto:COVID-19-Task-Force-CDRH@fda.hhs.gov\">\u003Cspan>COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>.&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Sincerely, \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Courtney H. Lias, Ph.D.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Acting Office Director\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>OHT3: Office of GastroRenal, ObGyn,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>&nbsp; &nbsp; General Hospital and Urology Devices\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Office of Product Evaluation and Quality\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Center for Devices and Radiological Health\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cdiv>&nbsp;\n\u003Chr>\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Csup>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[1]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fsup>\u003Cspan>&nbsp;As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Csup>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[2]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fsup>&nbsp;Secretary of Health and Human Services Alex M. Azar II, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), \u003Ci>available at\u003C\u002Fi> \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">\u003Cspan>https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Csup>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[3]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fsup>\u003Csup>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fsup>\u003Cspan>President Donald J. Trump, Proclamation\u003C\u002Fspan>\u003Cspan> on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19\u003C\u002Fspan>\u003Cspan>) Outbreak (\u003C\u002Fspan>\u003Cspan>Mar. 13, 2020\u003C\u002Fspan>\u003Cspan>), \u003Ci>available at\u003C\u002Fi> \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">\u003Cspan>https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[4]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003Cspan>Accessible\u003Ci> \u003C\u002Fi>at \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F137079\u002Fdownload\">\u003Cspan>https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F137079\u002Fdownload\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nSteven Gao\u002FDan Xiao\n\nCreativeStar Solutions\n\n1601 Trapelo Road, Suite 260\n\nWaltham, MA 02451\n\nUnited States\n\nsteven.gao@cssinco.com\n\ndan.xiao@cssinco.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDate: March , 2021\n\nRE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fcssinco.com\u002F on February 12, 2021. The FDA has observed that your website offers products for measuring human body temperature, specifically the “Artemis TI-CS-T11 Thermal Scanner” and “Artemis Gateway” (collectively referred to as “Thermal Scanners”), for sale in the United States. Based on our review, these products are intended to mitigate, prevent, treat, diagnose or cure COVID-19[1] in people, and thus are devices under section 201(h) of the Federal, Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nFDA’s review of your website revealed the following statements that establish that the Thermal Scanners are intended for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, including:\n\n“The T-Series can be used as a prevention solution for COVID-19” [Published on an undated blog post on your website, https:\u002F\u002Fcssinco.com\u002Fblog\u002Four-blog-1\u002Fpost\u002Fartemis-t-series-thermal-scanners-31]\n\n“The Artemis Gateway is a leading solution in COVID-19 prevention.” [Published on your website, https:\u002F\u002Fwww.cssinco.com\u002Fartemis-gateway]\n\nThe Thermal Scanners are offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce these products into interstate commerce for commercial distribution as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.[[2]] In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.[[3]] Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you offer for sale products that are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of such adulterated and misbranded products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nUse of telethermographic devices for the assessment of human body temperature can present potentially serious public health risks. Such risks may include, but are not limited to, the device incorrectly detecting a normal human body temperature when a person has an elevated temperature and incorrectly assessing a person to have an elevated body temperature when they do not. A person with an undetected elevated temperature who was subject to temperature assessment using a telethermographic device may, as a result, be less likely to adhere to infection prevention and control guidelines, such as social distancing and using personal protective equipment. These risks are more likely to be present where telethermographic devices scan multiple individuals simultaneously. Your website, https:\u002F\u002Fcssinco.com\u002F, includes statements that indicate that the Thermal Scanners are intended to scan multiple individuals simultaneously, including:\n\n“Scan up to 10 persons at a time for rapid screening” [Published on your “Artemis Thermal Scanner” webpage under the subheading “TI-CS-11”, https:\u002F\u002Fcssinco.com\u002Fartemis-thermalscanner]\n\n“This model can scan up to 10 individuals at a single time.” [Published on your TI-CS-11 webpage, https:\u002F\u002Fcssinco.com\u002Fti-cs-t11-detail]\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Enforcement Policy for Telethermographic Systems During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency”[[4]] provides information about FDA’s policies intended to help expand the availability of telethermographic systems used for body temperature measurements for triage use during the COVID-19 public health emergency.\n\nYou should take action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address these violations, using CMS # 613535 as reference. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately prevent address any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nActing Office Director\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n[1] As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n[2] Secretary of Health and Human Services Alex M. Azar II, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n[3] President Donald J. Trump, Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\n\n[4] Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F137079\u002Fdownload.","CreativeStar Solutions","creativestar-solutions-613535-03042021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcreativestar-solutions-613535-03042021","2026-10-26T08:08:19.208588+00:00","2021-03-05","613535","2023-07-24","Steven Gao\u002FDan Xiao","2026-08-20T03:18:27.385+00:00","2021-03-04",{"id":178,"raw":179,"subject":184,"body_html":186,"body_text":187,"firm_name":188,"letter_id":189,"created_at":190,"fei_number":19,"letter_url":191,"updated_at":192,"action_type":22,"case_status":131,"posted_date":193,"marcs_cms_no":194,"product_type":195,"closeout_date":196,"issuing_office":183,"recipient_name":197,"body_fetched_at":198,"delivery_method":199,"recipient_title":19,"reference_number":19,"action_taken_date":200,"medical_device_id":19,"response_letter_date":19},1623,[180,181,182,183,184,13,185,13],"\u003Ctime datetime=\"2024-02-06T14:20:00Z\">02\u002F06\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-01-30T05:00:00Z\">01\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finmar-supply-chain-solutions-llc-666158-01302024\">Inmar Supply Chain Solutions, LLC\u003C\u002Fa>","Division of Human and Animal Food Operations West III","CGMP\u002FManufacturing, Packing or Holding Human Food\u002FAdulterated\u002FInsanitary Conditions","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finmar-supply-chain-solutions-llc-666158-08022024\">\u003Ctime datetime=\"2024-11-04T05:00:00Z\">11\u002F04\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS Overnight\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages\u003Cbr>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Spencer Baird\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Inmar Supply Chain Solutions, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1 W. 4th St., Suite 500\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Winston-Salem\u003C\u002Fspan>, \u003Cspan>NC\u003C\u002Fspan> \u003Cspan>27101\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations West III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>January 30, 2024\u003C\u002Fp>\n\n\u003Cp>CMS# 666158\u003C\u002Fp>\n\n\u003Cp>Dear Spencer Baird:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) inspected your facility, Inmar Supply Chain Solutions, LLC, located at 1131 W Bardin Rd. Ste 131, Arlington, TX 76017 from June 22, 2023 through July 19, 2023. Your facility holds and distributes various human foods; cosmetics; over-the-counter drugs (OTC drugs); and devices. Based on the inspectional findings, we have identified serious violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations.\u003C\u002Fp>\n\n\u003Cp>Under section 301(a) of the Act [21 U.S.C. § 331(a), the introduction or delivery for introduction into interstate commerce of any food, drug, device, or cosmetic that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the Act [21 U.S.C. § 331(k)] to do any act with respect to a food, drug, device, or cosmetic, if such act is done while the products are held for sale after shipment in interstate commerce and results in the products being adulterated. You can find the Act and FDA regulations through links on the FDA’s home page at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your firm initiated a voluntary recall of certain products regulated by the FDA that were stored and shipped to interstate customers from January 1, 2023 through July 19, 2023 due to the presence of rodents and rodent activity at your firm. At the close of the inspection, you were issued a Form FDA 483, Inspectional Observations, dated July 19, 2023. FDA received your written responses to those observations on August 10, 2023 and September 11, 2023. We have reviewed your responses and we discuss your significant violations and your corrective actions below.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Adulterated Human Foods\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>The inspection of your facility revealed serious violations of FDA’s regulations for Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Foods under Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). These violations cause your human food and dietary supplement products to be adulterated within the meaning of section 402(a)(3) of the Act [21 U.S.C. § 342(a)(3)] in that your products consist in whole or in part of any filthy, putrid, or decomposed substance, or if it is otherwise unfit for food, and within the meaning of section 402(a)(4) of the Act [21 U.S.C. § 342(a)(4)] in that they have been prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health.\u003C\u002Fp>\n\n\u003Cp>1. You did not exclude pests from your facility to protect against contamination of food, as required by 21 CFR 117.35(c). Specifically, our investigators observed evidence of rodent activity, including live rodents, dead rodents in various states of decay, rodent excreta pellets (REP), gnaw marks in food and food packaging, and odors indicative of rodent infestation throughout the entire facility including areas where human food is routinely stored. Further, the following observations were noted by the investigators.\u003C\u002Fp>\n\n\u003Cp>a. Dead rodents along the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and in a mechanical trap along the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\nb. Live rodents exiting a box containing chocolate candy and walking across aisle \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\nc. Signs of rodent gnawed food products:\u003Cbr>\n• Gnawed and spilled meal replacement shakes on Aisle \u003Cstrong>(b)(4)\u003C\u002Fstrong> with REP too numerous to count on and under the pallet emitting a foul odor. Flying insects were also observed surrounding the pallet.\u003Cbr>\n• Gnawed chocolate candy in a box containing multiple chocolate products.\u003Cbr>\n• Gnawed cartons of boxed soup on a pallet of multiple food products located in the aisle adjacent to pallet location \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\n• A pallet containing bottled water and a gnawed chocolate bar at pallet location \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\nd. Signs of rodent activity and movement observed throughout the facility include:\u003Cbr>\n• Rodent tracks in dust on a black plastic trash bag in a tote of household items stored along the \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> area adjacent to pallets of soda and bottles of salad dressing.\u003Cbr>\n• Rodent tracks in dust on top of a pallet of sparkling water in plastic bottles at pallet location \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\n• Paw prints on wooden pallet located at pallet location \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\n• Rodent tracks in dust on black plastic totes located at pallet location \u003Cstrong>(b)(4)\u003C\u002Fstrong> directly next to a pallet of salad dressing in plastic bottles.\u003Cbr>\ne. Ubiquitous presence of rodent excreta pellets (REP) throughout the facility and specifically noted in the following locations:\u003Cbr>\n• REPs too numerous to count were observed on and under the pallet of gnawed and spilled meal replacement shakes that were emitting a foul odor.\u003Cbr>\n• REPs on the floor on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> corner of the warehouse in front of the exterior door.\u003Cbr>\n• REPs on the floor at pallet location \u003Cstrong>(b)(4)\u003C\u002Fstrong> adjacent to a box containing cheese puff snacks.\u003Cbr>\n• REPs too numerous to count along \u003Cstrong>(b)(4)\u003C\u002Fstrong> at pallet location \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\n• REPs in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> corner of the warehouse.\u003Cbr>\n• REPs too numerous to count along the \u003Cstrong>(b)(4)\u003C\u002Fstrong> near the \u003Cstrong>(b)(4)\u003C\u002Fstrong> corner of the warehouse behind pallet location \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\n• REP on a plastic wrapped package of bottled sport beverage located at pallet location \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Small flying insects were also observed around this pallet.\u003Cbr>\n• REPs on top of pallets located at \u003Cstrong>(b)(4)\u003C\u002Fstrong> with unknown contents.\u003Cbr>\n• Apparent rodent hair and REPs too numerous to count at pallet location \u003Cstrong>(b)(4)\u003C\u002Fstrong> next to a mechanical trap.\u003Cbr>\nf. In addition to visual observations, FDA documented the following findings:\u003Cbr>\n• FDA collected several samples during the inspection. These samples included human food products (samples 1220261, 1220262, and 1220263) product packaging, and a filth sample (sample 1220260). These samples were submitted to FDA labs for analysis. FDA’s analysis found the presence of gnaw marks in the packaging, flies and fly body parts, and\u002For REPs in these samples. Further, the filth sample included REPs collected from locations throughout the facility.\u003Cbr>\n• FDA conducted a review of your pest control records between February 15, 2022 and June 26, 2023 which documented the increasing observation of rodents within your facility. During this timeframe, your pest control records document a total of 60 mice and 153 rats being captured. The pest control report dated September 27, 2022 documented the greatest number of mice recovered with 21 mice. Pest control reports dated April 24, 2023 and May 15, 2025 documented the greatest number of rats being captured with a total of 12 for each.\u003C\u002Fp>\n\n\u003Cp>2. You did not maintain your plant in a clean and sanitary condition and in repair adequate to prevent food from becoming adulterated, as required by 21 CFR 117.35(a). Specifically, insanitary conditions were observed around your facility demonstrating that sanitation and housekeeping operations were inadequate. These insanitary conditions are providing food sources and pest harborage areas for rodents and other pests. The following insanitary conditions were observed:\u003C\u002Fp>\n\n\u003Cp>a. Spilled and putrid food product, including gnawed meal replacement shakes, leaking pallets of soda, putrid gnawed oat milk soup (Sample 1220263)\u003Cbr>\nb. Opened food and food wrappers in boxes of product. Open chocolate bar observed in a pallet with bottled water located at pallet location \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\nc. Three holes in drywall, each approximately 4 inches by 5 inches, were observed in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> near the incoming product holding area.\u003Cbr>\nd. A large cardboard tote with loose cat food, a towel, and used plastic wrap labeled “Don’t Touch” was observed in pallet location \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm stated that there was a cat that had kittens in the facility recently. It was later explained that an employee found kittens in the facility about 8 weeks prior.\u003Cbr>\ne. Rodent excreta pellets universally throughout the facility\u003C\u002Fp>\n\n\u003Cp>In your responses dated August 10, 2023, and September 11, 2023, you state that you have increased contracted pest control service visits at your facility and provided a copy of your Integrated Pest Management Service Program. You report that there was only one dead mouse catch in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> food area in the six weeks post-fumigation. You also state that you have retrained personnel on inspection and rejection standards and increased external inspection and maintenance activities for the facility. We will verify the effectiveness of your corrective actions during our next inspection.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Adulterated Human Drugs\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>During our June 22 to July 19, 2023 inspection of your facility, investigators from the FDA determined that your firm holds and distributes OTC drug products that are adulterated within the meaning of section 501(a)(2)(B) of the Act [21 U.S.C.351(a)(2)(B)] in that the building used in the holding of drug products was not maintained in a clean and sanitary condition as required by 21 CFR 211.56(a) and was infested by rodents, insects, and other vermin. The drug products held at your facility were also adulterated under 501(a)(2)(A) of the Act [21 U.S.C. 351(a)(2)(A)] in that the drug products were prepared, packed, or held under insanitary conditions whereby they may have been contaminated with filth or rendered injurious to health.\u003C\u002Fp>\n\n\u003Cp>During the inspection, our investigator observed filthy conditions in your facility. We observed significant rodent activity throughout the facility. We observed dead rodents in various areas inside your facility, rodent urine and feces around packages containing drug products, and pungent odors in various areas inside your facility. As you are aware, rodents are disease vectors and goods contaminated with rodent feces and\u002For urine may cause \u003Cem>Salmonella\u003C\u002Fem> and other infectious diseases. Infants, children, pregnant women, the elderly, and immunocompromised persons are at greatest risk for infection and are more likely to have severe symptoms. Consumers can become infected by handling contaminated drugs, including packaging, and then transferring the bacteria from their hands to their mouth. Additionally, \u003Cem>Salmonella\u003C\u002Fem> on hands or clothes can spread the bacteria to other people, objects, and surfaces.\u003C\u002Fp>\n\n\u003Cp>Products stored at your facility, including adulterated drug products, were shipped to your customers after being held in the above-mentioned conditions. You were aware of a rodent infestation at your facility since at least May 2022, and you continued to ship products, including drug products, to customers up until July 14, 2023, when fumigation of the facility occurred.\u003C\u002Fp>\n\n\u003Cp>In your responses dated August 10, 2023, and September 11, 2023, you state that you have increased contracted pest control service visits at your facility and provided a copy of your Integrated Pest Management Service Program. You also state that you have retrained personnel on inspection and rejection standards and increased external inspection and maintenance activities for the facility. In addition, you note that as part of your process, you destroy any OTC drug products with a compromised consumer package. We will verify the effectiveness of your corrective actions during our next inspection.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Adulterated Devices\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>Devices have been prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or whereby they may have been rendered injurious to health, in violation of 501(a)(2)(A) of the Food, Drug and Cosmetic Act.\u003C\u002Fp>\n\n\u003Cp>Specifically, the devices held at your facility were exposed to significant rodent infestation. Investigators documented signs of rodent gnawing, live rodents, and apparent rodent like urine and scratches on the pallet of adult diapers and tampons. The conditions described above for foods and drugs reflect the general objectionable conditions of the warehouse under which you also held devices regulated by FDA. Additionally, all products in the facility were exposed to a fumigation process from July 14-17, 2023. Although your responses indicated that the devices exposed to the fumigation were destroyed, the responses did not include actions to be taken for FDA regulated products when exposed to future fumigations.\u003C\u002Fp>\n\n\u003Cp>Your responses dated August 10, 2023, and September 11, 2023, are not adequate. The responses focus on activities conducted at the facility on W. Bradin Road and includes information on why your facility should be considered a Food Storage Facility (ambient temperature). In addition, the supporting documentation, such as the FDA Current Good Manufacturing Practices (Sanitation) procedure, INM.RCD4.01 dated 3\u002F6\u002F2021, addresses sanitation and requirements for food products but does not address specific activities and requirements for medical devices.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. Your firm should investigate and determine the causes of any violations and take prompt actions to correct any violations and bring the products into compliance. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>In addition, FDA offers the following comment:\u003C\u002Fp>\n\n\u003Cp>• We observed boxes of products stored on pallets in a manner that makes inspection and cleaning more difficult. Pallets were stored less than 12 inches from each other in the aisles of pallet racks, which hinders the ability to inspect for pest activity and clean between pallets.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to Chad J. Whitwell, Compliance Officer, U.S. Food and Drug Administration at the following email: Chad.Whitwell@fda.hhs.gov (preferred) or you may also mail a hard copy addressed to Chad J. Whitwell, Compliance Officer, U.S. Food and Drug Administration at 1201 Main St, Suite 7200, Dallas, TX 75202. If you have questions regarding any issues in this letter, please contact Mr. Whitwell at 214-253-5328 or by email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Edmundo Garcia, Jr.\u003Cbr>\nProgram Division Director HAF West 3\u003C\u002Fp>\n\n\u003Cp>Cc:\u003C\u002Fp>\n\n\u003Cp>Mr. Donald C. Spivey, Sr. Manager Warehouse II\u003Cbr>\nInmar Supply Chain Solutions, LLC\u003Cbr>\n1131 W. Bardin Rd. Ste. 131\u003Cbr>\nArlington, TX 76017\u003C\u002Fp>\n\n\u003Cp>Fred Jorgenson, EVP &amp; Chief Legal Officer\u003Cbr>\nInmar Supply Chain Solutions, LLC\u003Cbr>\n1 W. 4th St., Suite 500\u003Cbr>\nWinston-Salem, NC 27101\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(5),&nbsp;(b)(6),&nbsp;(b)(7)(C)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS Overnight\n\nProduct:\n\nDrugs\nFood & Beverages\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nSpencer Baird\n\nRecipient Title\n\nChief Executive Officer\n\nInmar Supply Chain Solutions, LLC\n\n1 W. 4th St., Suite 500\n\nWinston-Salem, NC 27101\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West III\n\nUnited States\n\nWARNING LETTER\n\nJanuary 30, 2024\n\nCMS# 666158\n\nDear Spencer Baird:\n\nThe United States Food and Drug Administration (FDA) inspected your facility, Inmar Supply Chain Solutions, LLC, located at 1131 W Bardin Rd. Ste 131, Arlington, TX 76017 from June 22, 2023 through July 19, 2023. Your facility holds and distributes various human foods; cosmetics; over-the-counter drugs (OTC drugs); and devices. Based on the inspectional findings, we have identified serious violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations.\n\nUnder section 301(a) of the Act [21 U.S.C. § 331(a), the introduction or delivery for introduction into interstate commerce of any food, drug, device, or cosmetic that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the Act [21 U.S.C. § 331(k)] to do any act with respect to a food, drug, device, or cosmetic, if such act is done while the products are held for sale after shipment in interstate commerce and results in the products being adulterated. You can find the Act and FDA regulations through links on the FDA’s home page at http:\u002F\u002Fwww.fda.gov.\n\nWe acknowledge your firm initiated a voluntary recall of certain products regulated by the FDA that were stored and shipped to interstate customers from January 1, 2023 through July 19, 2023 due to the presence of rodents and rodent activity at your firm. At the close of the inspection, you were issued a Form FDA 483, Inspectional Observations, dated July 19, 2023. FDA received your written responses to those observations on August 10, 2023 and September 11, 2023. We have reviewed your responses and we discuss your significant violations and your corrective actions below.\n\nAdulterated Human Foods\n\nThe inspection of your facility revealed serious violations of FDA’s regulations for Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Foods under Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). These violations cause your human food and dietary supplement products to be adulterated within the meaning of section 402(a)(3) of the Act [21 U.S.C. § 342(a)(3)] in that your products consist in whole or in part of any filthy, putrid, or decomposed substance, or if it is otherwise unfit for food, and within the meaning of section 402(a)(4) of the Act [21 U.S.C. § 342(a)(4)] in that they have been prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health.\n\n1. You did not exclude pests from your facility to protect against contamination of food, as required by 21 CFR 117.35(c). Specifically, our investigators observed evidence of rodent activity, including live rodents, dead rodents in various states of decay, rodent excreta pellets (REP), gnaw marks in food and food packaging, and odors indicative of rodent infestation throughout the entire facility including areas where human food is routinely stored. Further, the following observations were noted by the investigators.\n\na. Dead rodents along the (b)(4) and in a mechanical trap along the (b)(4).\n\nb. Live rodents exiting a box containing chocolate candy and walking across aisle (b)(4).\n\nc. Signs of rodent gnawed food products:\n\n• Gnawed and spilled meal replacement shakes on Aisle (b)(4) with REP too numerous to count on and under the pallet emitting a foul odor. Flying insects were also observed surrounding the pallet.\n\n• Gnawed chocolate candy in a box containing multiple chocolate products.\n\n• Gnawed cartons of boxed soup on a pallet of multiple food products located in the aisle adjacent to pallet location (b)(4).\n\n• A pallet containing bottled water and a gnawed chocolate bar at pallet location (b)(4).\n\nd. Signs of rodent activity and movement observed throughout the facility include:\n\n• Rodent tracks in dust on a black plastic trash bag in a tote of household items stored along the (b)(4) in the (b)(4) area adjacent to pallets of soda and bottles of salad dressing.\n\n• Rodent tracks in dust on top of a pallet of sparkling water in plastic bottles at pallet location (b)(4).\n\n• Paw prints on wooden pallet located at pallet location (b)(4).\n\n• Rodent tracks in dust on black plastic totes located at pallet location (b)(4) directly next to a pallet of salad dressing in plastic bottles.\n\ne. Ubiquitous presence of rodent excreta pellets (REP) throughout the facility and specifically noted in the following locations:\n\n• REPs too numerous to count were observed on and under the pallet of gnawed and spilled meal replacement shakes that were emitting a foul odor.\n\n• REPs on the floor on the (b)(4) corner of the warehouse in front of the exterior door.\n\n• REPs on the floor at pallet location (b)(4) adjacent to a box containing cheese puff snacks.\n\n• REPs too numerous to count along (b)(4) at pallet location (b)(4).\n\n• REPs in the (b)(4) corner of the warehouse.\n\n• REPs too numerous to count along the (b)(4) near the (b)(4) corner of the warehouse behind pallet location (b)(4).\n\n• REP on a plastic wrapped package of bottled sport beverage located at pallet location (b)(4). Small flying insects were also observed around this pallet.\n\n• REPs on top of pallets located at (b)(4) with unknown contents.\n\n• Apparent rodent hair and REPs too numerous to count at pallet location (b)(4) next to a mechanical trap.\n\nf. In addition to visual observations, FDA documented the following findings:\n\n• FDA collected several samples during the inspection. These samples included human food products (samples 1220261, 1220262, and 1220263) product packaging, and a filth sample (sample 1220260). These samples were submitted to FDA labs for analysis. FDA’s analysis found the presence of gnaw marks in the packaging, flies and fly body parts, and\u002For REPs in these samples. Further, the filth sample included REPs collected from locations throughout the facility.\n\n• FDA conducted a review of your pest control records between February 15, 2022 and June 26, 2023 which documented the increasing observation of rodents within your facility. During this timeframe, your pest control records document a total of 60 mice and 153 rats being captured. The pest control report dated September 27, 2022 documented the greatest number of mice recovered with 21 mice. Pest control reports dated April 24, 2023 and May 15, 2025 documented the greatest number of rats being captured with a total of 12 for each.\n\n2. You did not maintain your plant in a clean and sanitary condition and in repair adequate to prevent food from becoming adulterated, as required by 21 CFR 117.35(a). Specifically, insanitary conditions were observed around your facility demonstrating that sanitation and housekeeping operations were inadequate. These insanitary conditions are providing food sources and pest harborage areas for rodents and other pests. The following insanitary conditions were observed:\n\na. Spilled and putrid food product, including gnawed meal replacement shakes, leaking pallets of soda, putrid gnawed oat milk soup (Sample 1220263)\n\nb. Opened food and food wrappers in boxes of product. Open chocolate bar observed in a pallet with bottled water located at pallet location (b)(4)\n\nc. Three holes in drywall, each approximately 4 inches by 5 inches, were observed in the (b)(4) near the incoming product holding area.\n\nd. A large cardboard tote with loose cat food, a towel, and used plastic wrap labeled “Don’t Touch” was observed in pallet location (b)(4). Your firm stated that there was a cat that had kittens in the facility recently. It was later explained that an employee found kittens in the facility about 8 weeks prior.\n\ne. Rodent excreta pellets universally throughout the facility\n\nIn your responses dated August 10, 2023, and September 11, 2023, you state that you have increased contracted pest control service visits at your facility and provided a copy of your Integrated Pest Management Service Program. You report that there was only one dead mouse catch in the (b)(4) food area in the six weeks post-fumigation. You also state that you have retrained personnel on inspection and rejection standards and increased external inspection and maintenance activities for the facility. We will verify the effectiveness of your corrective actions during our next inspection.\n\nAdulterated Human Drugs\n\nDuring our June 22 to July 19, 2023 inspection of your facility, investigators from the FDA determined that your firm holds and distributes OTC drug products that are adulterated within the meaning of section 501(a)(2)(B) of the Act [21 U.S.C.351(a)(2)(B)] in that the building used in the holding of drug products was not maintained in a clean and sanitary condition as required by 21 CFR 211.56(a) and was infested by rodents, insects, and other vermin. The drug products held at your facility were also adulterated under 501(a)(2)(A) of the Act [21 U.S.C. 351(a)(2)(A)] in that the drug products were prepared, packed, or held under insanitary conditions whereby they may have been contaminated with filth or rendered injurious to health.\n\nDuring the inspection, our investigator observed filthy conditions in your facility. We observed significant rodent activity throughout the facility. We observed dead rodents in various areas inside your facility, rodent urine and feces around packages containing drug products, and pungent odors in various areas inside your facility. As you are aware, rodents are disease vectors and goods contaminated with rodent feces and\u002For urine may cause Salmonella and other infectious diseases. Infants, children, pregnant women, the elderly, and immunocompromised persons are at greatest risk for infection and are more likely to have severe symptoms. Consumers can become infected by handling contaminated drugs, including packaging, and then transferring the bacteria from their hands to their mouth. Additionally, Salmonella on hands or clothes can spread the bacteria to other people, objects, and surfaces.\n\nProducts stored at your facility, including adulterated drug products, were shipped to your customers after being held in the above-mentioned conditions. You were aware of a rodent infestation at your facility since at least May 2022, and you continued to ship products, including drug products, to customers up until July 14, 2023, when fumigation of the facility occurred.\n\nIn your responses dated August 10, 2023, and September 11, 2023, you state that you have increased contracted pest control service visits at your facility and provided a copy of your Integrated Pest Management Service Program. You also state that you have retrained personnel on inspection and rejection standards and increased external inspection and maintenance activities for the facility. In addition, you note that as part of your process, you destroy any OTC drug products with a compromised consumer package. We will verify the effectiveness of your corrective actions during our next inspection.\n\nAdulterated Devices\n\nDevices have been prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or whereby they may have been rendered injurious to health, in violation of 501(a)(2)(A) of the Food, Drug and Cosmetic Act.\n\nSpecifically, the devices held at your facility were exposed to significant rodent infestation. Investigators documented signs of rodent gnawing, live rodents, and apparent rodent like urine and scratches on the pallet of adult diapers and tampons. The conditions described above for foods and drugs reflect the general objectionable conditions of the warehouse under which you also held devices regulated by FDA. Additionally, all products in the facility were exposed to a fumigation process from July 14-17, 2023. Although your responses indicated that the devices exposed to the fumigation were destroyed, the responses did not include actions to be taken for FDA regulated products when exposed to future fumigations.\n\nYour responses dated August 10, 2023, and September 11, 2023, are not adequate. The responses focus on activities conducted at the facility on W. Bradin Road and includes information on why your facility should be considered a Food Storage Facility (ambient temperature). In addition, the supporting documentation, such as the FDA Current Good Manufacturing Practices (Sanitation) procedure, INM.RCD4.01 dated 3\u002F6\u002F2021, addresses sanitation and requirements for food products but does not address specific activities and requirements for medical devices.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. Your firm should investigate and determine the causes of any violations and take prompt actions to correct any violations and bring the products into compliance. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nIn addition, FDA offers the following comment:\n\n• We observed boxes of products stored on pallets in a manner that makes inspection and cleaning more difficult. Pallets were stored less than 12 inches from each other in the aisles of pallet racks, which hinders the ability to inspect for pest activity and clean between pallets.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to Chad J. Whitwell, Compliance Officer, U.S. Food and Drug Administration at the following email: Chad.Whitwell@fda.hhs.gov (preferred) or you may also mail a hard copy addressed to Chad J. Whitwell, Compliance Officer, U.S. Food and Drug Administration at 1201 Main St, Suite 7200, Dallas, TX 75202. If you have questions regarding any issues in this letter, please contact Mr. Whitwell at 214-253-5328 or by email.\n\nSincerely,\n\n\u002FS\u002F\n\nEdmundo Garcia, Jr.\n\nProgram Division Director HAF West 3\n\nCc:\n\nMr. Donald C. Spivey, Sr. Manager Warehouse II\n\nInmar Supply Chain Solutions, LLC\n\n1131 W. Bardin Rd. Ste. 131\n\nArlington, TX 76017\n\nFred Jorgenson, EVP & Chief Legal Officer\n\nInmar Supply Chain Solutions, LLC\n\n1 W. 4th St., Suite 500\n\nWinston-Salem, NC 27101\n\n(b)(5), (b)(6), (b)(7)(C)","Inmar Supply Chain Solutions, LLC","inmar-supply-chain-solutions-llc-666158-01302024","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finmar-supply-chain-solutions-llc-666158-01302024","2026-10-26T08:08:58.950925+00:00","2024-02-06","666158","DrugsFood & BeveragesMedical Devices","2024-11-04","Spencer Baird","2026-08-20T00:19:14.1+00:00","UPS Overnight","2024-01-30",{"id":202,"raw":203,"subject":207,"body_html":208,"body_text":209,"firm_name":210,"letter_id":211,"created_at":65,"fei_number":19,"letter_url":212,"updated_at":213,"action_type":22,"case_status":23,"posted_date":68,"marcs_cms_no":214,"product_type":26,"closeout_date":19,"issuing_office":206,"recipient_name":215,"body_fetched_at":216,"delivery_method":217,"recipient_title":19,"reference_number":19,"action_taken_date":218,"medical_device_id":19,"response_letter_date":19},3123,[56,204,205,206,207,13,13,13],"\u003Ctime datetime=\"2021-09-29T04:00:00Z\">09\u002F29\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftrue-chemical-solutions-llc-616672-09292021\">True Chemical Solutions, LLC\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Failure to Permit Access to or Copying of Records","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Travis Pitcock\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>True Chemical Solutions, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6215 W. County Road 112\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Midland\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>79706\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-21-60\u003C\u002Fp>\n\n\u003Cp>September 29, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Pitcock:\u003C\u002Fp>\n\n\u003Cp>Your firm is registered with the United States Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products; specifically, products listed include HAPPY HANDS Hand Sanitizer Topical Gel with Moisturizing Solution. On November 10, 2020, the FDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 374(a)(4), to the contact e-mail address provided in your registration file. This request went unanswered, as did numerous telephone calls from the Agency regarding this matter, so the Agency sent a follow-up written request for such records and other information by certified return-receipt mail on May 4, 2021. Delivery was confirmed by your signature, but you failed to respond to these attempted communications or otherwise provide the requested records or other information. Pursuant to section 704(a)(4), FDA’s request and follow-up communication included a sufficient and clear description of the records sought.\u003C\u002Fp>\n\n\u003Cp>It is a prohibited act under section 301(e) of the FD&amp;C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a).\u003C\u002Fp>\n\n\u003Cp>Since declaration of the COVID-19 public health emergency,\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> a number of hand sanitizer products have been recalled due to quality issues ranging from substitution with other drug substances to subpotency.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> The Agency has reached out to registered OTC drug firms with hand sanitizers included in their product listing to assess the overall quality of the drugs registered as manufactured by these firms. Because your OTC drug firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs registered as manufactured at your facility.\u003C\u002Fp>\n\n\u003Cp>We note that, while your firm is registered with the FDA as a manufacturer of OTC drug products, your website indicates your firm is also involved in pipeline operations and fracturing, also known as fracking. Fracking operations typically involve multiple chemicals that could be harmful to patients if they were to contaminate drugs, such as your hand sanitizers.\u003C\u002Fp>\n\n\u003Cp>Respond to this letter within 48 hours to confirm or update your registration and\u002For drug listing status and indicate whether you will respond to the request for records and other information. If you are no longer manufacturing drugs, delist all the drugs previously listed with FDA, using the last lot expiration date as the marketing end date of the product, and deregister your facility accordingly.\u003C\u002Fp>\n\n\u003Cp>The Agency may conduct an inspection to verify information provided and\u002For to evaluate the compliance of your manufacturing operations.\u003C\u002Fp>\n\n\u003Cp>Continued non-response regarding questions of the quality assurance of the drugs manufactured at your facility may lead to inclusion on the Agency’s list of hand sanitizers consumers should not use, at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>You may provide additional information for our consideration as we continue to assess your activities and practices.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Identify your response with FEI 3016866715 and ATTN: Marisa Heayn.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nFrancis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research, FDA\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The HHS Declaration of a Public Health Emergency is available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002F2019-nCoV.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002F2019-nCoV.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Travis Pitcock\n\nRecipient Title\n\nChief Executive Officer\n\nTrue Chemical Solutions, LLC\n\n6215 W. County Road 112\n\nMidland, TX 79706\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-21-60\n\nSeptember 29, 2021\n\nDear Mr. Pitcock:\n\nYour firm is registered with the United States Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products; specifically, products listed include HAPPY HANDS Hand Sanitizer Topical Gel with Moisturizing Solution. On November 10, 2020, the FDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 374(a)(4), to the contact e-mail address provided in your registration file. This request went unanswered, as did numerous telephone calls from the Agency regarding this matter, so the Agency sent a follow-up written request for such records and other information by certified return-receipt mail on May 4, 2021. Delivery was confirmed by your signature, but you failed to respond to these attempted communications or otherwise provide the requested records or other information. Pursuant to section 704(a)(4), FDA’s request and follow-up communication included a sufficient and clear description of the records sought.\n\nIt is a prohibited act under section 301(e) of the FD&C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a).\n\nSince declaration of the COVID-19 public health emergency,1 a number of hand sanitizer products have been recalled due to quality issues ranging from substitution with other drug substances to subpotency.2 The Agency has reached out to registered OTC drug firms with hand sanitizers included in their product listing to assess the overall quality of the drugs registered as manufactured by these firms. Because your OTC drug firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs registered as manufactured at your facility.\n\nWe note that, while your firm is registered with the FDA as a manufacturer of OTC drug products, your website indicates your firm is also involved in pipeline operations and fracturing, also known as fracking. Fracking operations typically involve multiple chemicals that could be harmful to patients if they were to contaminate drugs, such as your hand sanitizers.\n\nRespond to this letter within 48 hours to confirm or update your registration and\u002For drug listing status and indicate whether you will respond to the request for records and other information. If you are no longer manufacturing drugs, delist all the drugs previously listed with FDA, using the last lot expiration date as the marketing end date of the product, and deregister your facility accordingly.\n\nThe Agency may conduct an inspection to verify information provided and\u002For to evaluate the compliance of your manufacturing operations.\n\nContinued non-response regarding questions of the quality assurance of the drugs manufactured at your facility may lead to inclusion on the Agency’s list of hand sanitizers consumers should not use, at: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use.\n\nYou may provide additional information for our consideration as we continue to assess your activities and practices.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\n\nIdentify your response with FEI 3016866715 and ATTN: Marisa Heayn.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research, FDA\n\n__________________________\n\n1 The HHS Declaration of a Public Health Emergency is available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002F2019-nCoV.aspx.\n\n2 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance.","True Chemical Solutions, LLC","true-chemical-solutions-llc-616672-09292021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftrue-chemical-solutions-llc-616672-09292021","2026-10-26T08:10:15.483298+00:00","616672","Mr. Travis Pitcock","2026-08-20T02:35:09.615+00:00","VIA UPS","2021-09-29",{"id":220,"raw":221,"subject":226,"body_html":227,"body_text":228,"firm_name":229,"letter_id":230,"created_at":231,"fei_number":19,"letter_url":232,"updated_at":233,"action_type":22,"case_status":23,"posted_date":234,"marcs_cms_no":235,"product_type":26,"closeout_date":19,"issuing_office":79,"recipient_name":19,"body_fetched_at":236,"delivery_method":93,"recipient_title":19,"reference_number":19,"action_taken_date":237,"medical_device_id":19,"response_letter_date":19},300,[222,223,224,79,225,13,13,13],"\u003Ctime datetime=\"2026-03-03T05:00:00Z\">03\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-02-20T05:00:00Z\">02\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkare-solutions-llc-dba-zappy-717991-02202026\">Kare Solutions, LLC dba Zappy \u003C\u002Fa>","False &amp; Misleading Claims\u002FMisbranded (Telehealth)","False & Misleading Claims\u002FMisbranded (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Kare Solutions, LLC dba Zappy \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7660H Fay Ave, Suite 504\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>La Jolla\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92037\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:customer@zappyhealth.com\"> customer@zappyhealth.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>February 20, 2026\u003C\u002Fp>\u003Cp>Zappy:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fzappyhealth.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide, tirzepatide, and liraglutide drug products.\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As described below, your website’s false or misleading claims concerning compounded semaglutide, tirzepatide, and liraglutide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The compounded semaglutide, tirzepatide, and liraglutide products displayed on your website identify “Zappy” on the pictured label, suggesting Zappy is the compounder of those drugs when in fact it is not.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, the representations on your website that Zappy is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>Additionally, the following claims concerning compounded semaglutide, tirzepatide, and liraglutide products appear on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“Semaglutide (Active Pharmaceutical Ingredient in Wegovy®)See Wegovy FDA Information” [sic]\u003C\u002Fli>\u003Cli>“Liraglutide (Active Pharmaceutical Ingredient in Saxenda®)See Saxenda FDA Information” [sic]\u003C\u002Fli>\u003Cli>“Tirzepatide (Active Pharmaceutical Ingredient in Zepbound®)See Zepbound FDA Information” [sic]\u003C\u002Fli>\u003Cli>“a proven medication”\u003C\u002Fli>\u003Cli>“Clinically studied and shown to deliver powerful results when combined with healthy habits.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The representations and claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of violations.\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded semaglutide, tirzepatide, and liraglutide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&amp;C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the Act, including the new drug approval requirements.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Such steps may include:\u003C\u002Fp>\u003Cp>1) Identifying the entities that produce the compounded products offered on your website;\u003C\u002Fp>\u003Cp>2) Providing a representative sample of labeling for such products; and\u003C\u002Fp>\u003Cp>3) Addressing the basis for other website claims that could be construed as false or misleading or demonstrating that such claims have been modified or removed in light of FDCA §§ 502(a) and 502(bb)) [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. In your written response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded products that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Matthew J. Lash\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide, tirzepatide, and liraglutide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See also 21 CFR § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); FDCA §503(b) [21 § U.S.C. 353(b)], FDCA §503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 CFR § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FDCA [21 USC § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1…”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FDCA [21 USC § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 USC § 353(b)(2)].\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nKare Solutions, LLC dba Zappy\n\n7660H Fay Ave, Suite 504\n\nLa Jolla, CA 92037\n\nUnited States\n\ncustomer@zappyhealth.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFebruary 20, 2026\nZappy:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fzappyhealth.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide, tirzepatide, and liraglutide drug products.1 As described below, your website’s false or misleading claims concerning compounded semaglutide, tirzepatide, and liraglutide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe compounded semaglutide, tirzepatide, and liraglutide products displayed on your website identify “Zappy” on the pictured label, suggesting Zappy is the compounder of those drugs when in fact it is not.2 Accordingly, the representations on your website that Zappy is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nAdditionally, the following claims concerning compounded semaglutide, tirzepatide, and liraglutide products appear on your website:\n“Semaglutide (Active Pharmaceutical Ingredient in Wegovy®)See Wegovy FDA Information” [sic]\n“Liraglutide (Active Pharmaceutical Ingredient in Saxenda®)See Saxenda FDA Information” [sic]\n“Tirzepatide (Active Pharmaceutical Ingredient in Zepbound®)See Zepbound FDA Information” [sic]\n“a proven medication”\n“Clinically studied and shown to deliver powerful results when combined with healthy habits.”\nCompounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The representations and claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of violations.\nFor the reasons discussed above, your compounded semaglutide, tirzepatide, and liraglutide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the Act, including the new drug approval requirements.\nYou should take immediate action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Such steps may include:\n1) Identifying the entities that produce the compounded products offered on your website;\n2) Providing a representative sample of labeling for such products; and\n3) Addressing the basis for other website claims that could be construed as false or misleading or demonstrating that such claims have been modified or removed in light of FDCA §§ 502(a) and 502(bb)) [21 U.S.C. §§ 352(a) and (bb)].\nThis letter notifies you of our concerns and provides you an opportunity to address them. In your written response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded products that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n______________________\n1 The semaglutide, tirzepatide, and liraglutide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n2 See also 21 CFR § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); FDCA §503(b) [21 § U.S.C. 353(b)], FDCA §503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 CFR § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FDCA [21 USC § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1…”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FDCA [21 USC § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 USC § 353(b)(2)].","Kare Solutions, LLC dba Zappy","kare-solutions-llc-dba-zappy-717991-02202026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkare-solutions-llc-dba-zappy-717991-02202026","2026-10-26T08:09:07.758418+00:00","2026-03-03","717991","2026-08-19T04:54:41.769+00:00","2026-02-20",{"id":239,"raw":240,"subject":244,"body_html":245,"body_text":246,"firm_name":247,"letter_id":248,"created_at":190,"fei_number":19,"letter_url":249,"updated_at":250,"action_type":22,"case_status":23,"posted_date":251,"marcs_cms_no":252,"product_type":26,"closeout_date":19,"issuing_office":206,"recipient_name":253,"body_fetched_at":254,"delivery_method":137,"recipient_title":19,"reference_number":19,"action_taken_date":255,"medical_device_id":19,"response_letter_date":19},1869,[241,242,243,206,244,13,13,13],"\u003Ctime datetime=\"2023-09-12T13:00:00Z\">09\u002F12\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-11T04:00:00Z\">09\u002F11\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdr-vitamins-llc-dba-dr-vitamin-solutions-663127-09112023\">DR Vitamins, LLC dba DR Vitamin Solutions\u003C\u002Fa>","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jonathan Formby\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>DR Vitamins, LLC dba DR Vitamin Solutions\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7804 Harwood Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>North Richland Hills\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76180-5901\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@drvitaminsolutions.com\"> info@drvitaminsolutions.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 11, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: 663127\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Jonathan Formby:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address www.drvitaminsolutions.com in July 2023. We have also reviewed your social media websites at https:\u002F\u002Ftwitter.com\u002FDRVitamins and www.facebook.com\u002FDRVitamins; these websites direct consumers to your website www.drvitaminsolutions.com to purchase your products. The FDA has observed that your website offers “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” for sale in the United States.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Additionally, we reviewed your product listings on your Amazon storefront at https:\u002F\u002Fwww.amazon.com\u002Fstores\u002FDRVitaminSolutions\u002Fpage\u002F07F25A08-22FE-4E3D-8C74-5ACF57D4F83F where you have multiple listings of “Vision Clarity Eye Drops.” Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>Your “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” products are especially concerning from a public health perspective. Ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.\u003C\u002Fp>\n\n\u003Cp>In addition, the drugs “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” are not properly listed with FDA causing them to be misbranded drugs under section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o). Introduction or delivery for introduction of such misbranded drug(s) into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on a review of your websites, your “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” products are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples of claims from your website www.drvitaminsolutions.com, your social media websites, https:\u002F\u002Ftwitter.com\u002FDRVitamins and www.facebook.com\u002FDRVitamins, and Amazon storefront that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>On your product webpage for “Vision Clarity Eye Drops”:\u003Cbr>\n• \"Say Goodbye To Dry Eyes and Eye Irritations With Vision Clarity Eye Drops!”\u003Cbr>\n• “[C]ontain heavily researched lubricants to help combat dry eye and other irritations.”\u003Cbr>\n• Under “Dosage &amp; Use”: “For use as a lubricant to prevent further irritation or to relieve dryness of the eye.”\u003Cbr>\n• Customer review: “I used to use Bright Eyes III, but this brand seems to feel better when I put the drops in. I continue to see improvement with my cataracts!”\u003Cbr>\n• Customer review: “Great product it really works, I can tell the difference. I recommend it, Beats having an unnecessary and expensive cataract surgery. My eyes are starting to clear up, almost no fogginess.”\u003Cbr>\n• Customer review: “Just wanted you to know my fantastic results with your eye drops. I have been using them for almost a month now and the floaters in my eyes have disappeared. I feel my cataracts are much improved but I will know at my next vision appointment.”\u003Cbr>\n• Customer review: “My mother wanted me to order Vision Clarity drops for her cataracts. Since I am placing my second order for an additional 6 boxes, I must tell you she is very happy. When I look at her eyes now it is amazing. She says she can see better than she has in years.”\u003C\u002Fp>\n\n\u003Cp>On your product webpage for “Life Extension Brite Eyes III”:\u003Cbr>\n• “The Brite Eyes III formula also contains the antioxidant N-acetyl-carnosine . . . Some experts think that carnosine has potential to support antioxidant activity which resists the presence of cataracts on the lens of the eye.”\u003Cbr>\n• Under “Dosage &amp; Use”: “For those with cataracts, glaucoma and other eye ailments, it is recommended to take 1 drop 4 times a day at various intervals morning, noon, evening and before bed.”\u003C\u002Fp>\n\n\u003Cp>On your product webpage for “Can-C Eye Drops”:\u003Cbr>\n• “By providing compounds like N-Acetyl-Carnosine (NAC), these Can-C Eye Drops are made to serve as your ultimate eye shield. As such, they may help to protect the eyes from damage in the form of free radicals, UV rays, and thereby, even cataracts.”\u003C\u002Fp>\n\n\u003Cp>On your product webpage for “Longevity Science Visual Ocuity”:\u003Cbr>\n• “[E]xpertly crafted to aid in the relief of dry, itchy eyes and other afflictions which might cause discomfort and limited vision.”\u003C\u002Fp>\n\n\u003Cp>On your webpage https:\u002F\u002Fwww.drvitaminsolutions.com\u002Fblog\u002Freview-n-acetyl-carnosine-nac-eye-drops-2019\u002F:\u003Cbr>\n• “While Carnosine itself is a familiar amino acid compound with well-documented antioxidant properties, N-Acetyl-Carnosine (NAC) is a unique form of Carnosine with a very distinct intended usage. Over the past decade and a half, NAC eye drops\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> have become an increasingly popular product for resisting and reversing cataracts in both pets and humans.”\u003C\u002Fp>\n\n\u003Cp>On your webpage https:\u002F\u002Fwww.drvitaminsolutions.com\u002Fblog\u002Fbenefits-n-acetyl-carnosine-drops-nac-eyes-especially-cataracts\u002F:\u003Cbr>\n• “N-Acetyl-Carnosine (NAC) drops can help. Especially with cataracts.”\u003Cbr>\n• “There has been quite a bit of research with NAC, N-Acetyl-Carnosine drops especially for cataracts. Results from one study’s conclusion were very encouraging. ‘Topical NAC shows potential for the treatment and prevention of cataracts.’”\u003Cbr>\n• “References:\u003Cbr>\n&nbsp; &nbsp; o gov. Efficacy of N-acetyl-carnosine in treatment of cataracts.\u003Cbr>\n&nbsp; &nbsp; o Dr. David Williams. Carnosine for Cataracts.”\u003C\u002Fp>\n\n\u003Cp>On your webpage https:\u002F\u002Fwww.drvitaminsolutions.com\u002Fblog\u002Fnac-carnosine-eye-drops-and-eye-health\u002F:\u003Cbr>\n• “Eye drops with N-Acetyl-Carnosine (NAC) can be helpful for eye health. There was a 2-year study was done where one group got the NAC drops and one group did not. The group that had used the drops had improvement while the other group got worse. ‘Tolerability of NAC eye drops was good in almost all patients, with no reports of ocular or systemic adverse effects. Topical NAC shows potential for the treatment and prevention of cataracts.’”\u003Cbr>\n• “These drops have been used for several eye health issues, but the most common use is for cataracts. NAC uses natural ingredients and the body’s main antioxidant glutathione to chip away at the damaged cells of the cataracts. The damaged cells are cleared away and healthy cells can be protected from further damage.”\u003C\u002Fp>\n\n\u003Cp>On your social media websites at https:\u002F\u002Ftwitter.com\u002FDRVitamins and www.facebook.com\u002FDRVitamins:\u003Cbr>\n• February 9, 2019 Twitter post: An image of the “Vision Clarity Eye Drops” with the text, “Carnosine, a cataracts worst nightmare.”\u003Cbr>\n• July 11, 2019 Facebook video post: “Today, I would like to talk to you about our Vision Clarity Eye Drops. These are very popular and the key ingredient in them is N-Acetylcarnosine and they also have a lubricant. People use them for various health issues with their eyes, but the most popular by far is cataracts. We do not make any medical claims nor guarantees on any specific health issue, but we are very thankful that for over 10 years, people have been able to avoid having cataract surgery because they’ve used these drops. We suggest using 1 drop in each eye 4 times a day. It typically takes people on average of about 3 months to see a noticeable difference. And the best results usually take several months.”\u003Cbr>\n• July 14, 2023 Facebook post: “Eye Health Bundle Pack . . . includes Can-C Eye Drops . . . ‘I have used these eye drops for many years. I have the the [sic] beginning of cataracts that have not progressed and my near sightedness has not gotten worse in over two years. I also find the drops are soothing to my eyes. I highly recommend this product.’”\u003C\u002Fp>\n\n\u003Cp>On your Amazon product webpage for “Vision Clarity Eye Drops” at https:\u002F\u002Fwww.amazon.com\u002FCarnosine-Lubricants-Hypromellose-Antioxidant-Lubricating\u002Fdp\u002FB008J6QR8Q, you have an image that resembles an over-the-counter (OTC) drug facts label, and it displays Glycerin 1.0% and N-Acetylcarnosine (NAC) 1.0% as active ingredients. Furthermore, next to the OTC drug facts label, you include the claim, “clinically studied ingredients[:] cataracts[,] dry eyes[, and] floaters.”\u003C\u002Fp>\n\n\u003Cp>Your “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Subject to exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for your “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” products.\u003C\u002Fp>\n\n\u003Cp>“Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” are marketed as ophthalmic demulcent (lubricant) drug products and are subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application – commonly referred to as “OTC monograph drugs” – may be legally marketed if they meet applicable requirements. In particular, ophthalmic demulcent (lubricant) drug products are deemed to be GRASE and not a “new drug” if, among other things, they conform to the conditions of use set forth in the Over-the-Counter Monograph M018: Ophthalmic Drug Products for Over-the-Counter Human Use (hereinafter Monograph M018).\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> However, your “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” do not conform to the conditions of use specified in Monograph M018 because these products are formulated with the active ingredient N-Acetyl-Carnosine (NAC), and labeled with indications to treat or prevent cataracts, neither of which are permitted under the final administrative order. Therefore, these products do not meet the requirements under section 505G.\u003C\u002Fp>\n\n\u003Cp>We note that you list the NAC ingredient as an inactive ingredient or excipient on the label of your “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” products. However, your firm makes many therapeutic claims for NAC that cause it to be considered an active ingredient.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> For example, your website includes a blog post entitled, “The Benefits of N-Acetyl-Carnosine (NAC) for Your Eyes, Especially for Cataracts.” Many other examples of therapeutic claims related to NAC can be found in the various claims cited in this letter above which make it clear that NAC is intended to furnish pharmacological activity or other direct effect, including in the treatment of cataracts, and is thus an active ingredient. As previously stated, NAC is not a permitted active ingredient in Monograph M018 and treating or preventing cataracts is not a permitted indication in Monograph M018.\u003C\u002Fp>\n\n\u003Cp>FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling. Moreover, there is no evident basis under the FD&amp;C Act under which these products would be legally marketed without an approved application. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Registration and Drug Listing Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Under section 510(j)(1) of the FD&amp;C Act, 21 U.S.C. 360(j)(1), and 21 CFR 207.41, all drugs manufactured, prepared, propagated, compounded, or processed for U.S. commercial distribution must be listed with FDA. The drug products “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” are not properly listed with FDA.5 Therefore, these drug products are misbranded under section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o). The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Jill Furman\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>_______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Your firm markets these ophthalmic products as containing N-acetylcarnosine (NAC).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> You include a direct hyperlink to your “Vision Clarity Eye Drops” product webpage.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Section 505G(a)(1) of the FD&amp;C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs\", notably conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 CFR 330 prior to enactment of the CARES Act. In the case of OTC ophthalmic drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M018: Ophthalmic Drug Products for Over-the-Counter Human Use. (See Order ID OTC000023, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F.)\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> See e.g., 21 CFR 314.3(b) and 21 CFR 210.3(b)(7), which define an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man.”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Your drug listing for “Vision Clarity Eye Drops” (NDC 71108-001-05) is inactive as of January 31, 2020. To date, FDA has not received an updated submission for the drug product “Vision Clarity Eye Drops” (NDC 71108-001-05).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJonathan Formby\n\nRecipient Title\n\nPresident\n\nDR Vitamins, LLC dba DR Vitamin Solutions\n\n7804 Harwood Rd\n\nNorth Richland Hills, TX 76180-5901\n\nUnited States\n\ninfo@drvitaminsolutions.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nSeptember 11, 2023\n\nRE: 663127\n\nDear Jonathan Formby:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address www.drvitaminsolutions.com in July 2023. We have also reviewed your social media websites at https:\u002F\u002Ftwitter.com\u002FDRVitamins and www.facebook.com\u002FDRVitamins; these websites direct consumers to your website www.drvitaminsolutions.com to purchase your products. The FDA has observed that your website offers “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” for sale in the United States.1 Additionally, we reviewed your product listings on your Amazon storefront at https:\u002F\u002Fwww.amazon.com\u002Fstores\u002FDRVitaminSolutions\u002Fpage\u002F07F25A08-22FE-4E3D-8C74-5ACF57D4F83F where you have multiple listings of “Vision Clarity Eye Drops.” Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nYour “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” products are especially concerning from a public health perspective. Ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.\n\nIn addition, the drugs “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” are not properly listed with FDA causing them to be misbranded drugs under section 502(o) of the FD&C Act, 21 U.S.C. 352(o). Introduction or delivery for introduction of such misbranded drug(s) into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nUnapproved New Drug Violations\n\nBased on a review of your websites, your “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples of claims from your website www.drvitaminsolutions.com, your social media websites, https:\u002F\u002Ftwitter.com\u002FDRVitamins and www.facebook.com\u002FDRVitamins, and Amazon storefront that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\n\nOn your product webpage for “Vision Clarity Eye Drops”:\n\n• \"Say Goodbye To Dry Eyes and Eye Irritations With Vision Clarity Eye Drops!”\n\n• “[C]ontain heavily researched lubricants to help combat dry eye and other irritations.”\n\n• Under “Dosage & Use”: “For use as a lubricant to prevent further irritation or to relieve dryness of the eye.”\n\n• Customer review: “I used to use Bright Eyes III, but this brand seems to feel better when I put the drops in. I continue to see improvement with my cataracts!”\n\n• Customer review: “Great product it really works, I can tell the difference. I recommend it, Beats having an unnecessary and expensive cataract surgery. My eyes are starting to clear up, almost no fogginess.”\n\n• Customer review: “Just wanted you to know my fantastic results with your eye drops. I have been using them for almost a month now and the floaters in my eyes have disappeared. I feel my cataracts are much improved but I will know at my next vision appointment.”\n\n• Customer review: “My mother wanted me to order Vision Clarity drops for her cataracts. Since I am placing my second order for an additional 6 boxes, I must tell you she is very happy. When I look at her eyes now it is amazing. She says she can see better than she has in years.”\n\nOn your product webpage for “Life Extension Brite Eyes III”:\n\n• “The Brite Eyes III formula also contains the antioxidant N-acetyl-carnosine . . . Some experts think that carnosine has potential to support antioxidant activity which resists the presence of cataracts on the lens of the eye.”\n\n• Under “Dosage & Use”: “For those with cataracts, glaucoma and other eye ailments, it is recommended to take 1 drop 4 times a day at various intervals morning, noon, evening and before bed.”\n\nOn your product webpage for “Can-C Eye Drops”:\n\n• “By providing compounds like N-Acetyl-Carnosine (NAC), these Can-C Eye Drops are made to serve as your ultimate eye shield. As such, they may help to protect the eyes from damage in the form of free radicals, UV rays, and thereby, even cataracts.”\n\nOn your product webpage for “Longevity Science Visual Ocuity”:\n\n• “[E]xpertly crafted to aid in the relief of dry, itchy eyes and other afflictions which might cause discomfort and limited vision.”\n\nOn your webpage https:\u002F\u002Fwww.drvitaminsolutions.com\u002Fblog\u002Freview-n-acetyl-carnosine-nac-eye-drops-2019\u002F:\n\n• “While Carnosine itself is a familiar amino acid compound with well-documented antioxidant properties, N-Acetyl-Carnosine (NAC) is a unique form of Carnosine with a very distinct intended usage. Over the past decade and a half, NAC eye drops2 have become an increasingly popular product for resisting and reversing cataracts in both pets and humans.”\n\nOn your webpage https:\u002F\u002Fwww.drvitaminsolutions.com\u002Fblog\u002Fbenefits-n-acetyl-carnosine-drops-nac-eyes-especially-cataracts\u002F:\n\n• “N-Acetyl-Carnosine (NAC) drops can help. Especially with cataracts.”\n\n• “There has been quite a bit of research with NAC, N-Acetyl-Carnosine drops especially for cataracts. Results from one study’s conclusion were very encouraging. ‘Topical NAC shows potential for the treatment and prevention of cataracts.’”\n\n• “References:\n\no gov. Efficacy of N-acetyl-carnosine in treatment of cataracts.\n\no Dr. David Williams. Carnosine for Cataracts.”\n\nOn your webpage https:\u002F\u002Fwww.drvitaminsolutions.com\u002Fblog\u002Fnac-carnosine-eye-drops-and-eye-health\u002F:\n\n• “Eye drops with N-Acetyl-Carnosine (NAC) can be helpful for eye health. There was a 2-year study was done where one group got the NAC drops and one group did not. The group that had used the drops had improvement while the other group got worse. ‘Tolerability of NAC eye drops was good in almost all patients, with no reports of ocular or systemic adverse effects. Topical NAC shows potential for the treatment and prevention of cataracts.’”\n\n• “These drops have been used for several eye health issues, but the most common use is for cataracts. NAC uses natural ingredients and the body’s main antioxidant glutathione to chip away at the damaged cells of the cataracts. The damaged cells are cleared away and healthy cells can be protected from further damage.”\n\nOn your social media websites at https:\u002F\u002Ftwitter.com\u002FDRVitamins and www.facebook.com\u002FDRVitamins:\n\n• February 9, 2019 Twitter post: An image of the “Vision Clarity Eye Drops” with the text, “Carnosine, a cataracts worst nightmare.”\n\n• July 11, 2019 Facebook video post: “Today, I would like to talk to you about our Vision Clarity Eye Drops. These are very popular and the key ingredient in them is N-Acetylcarnosine and they also have a lubricant. People use them for various health issues with their eyes, but the most popular by far is cataracts. We do not make any medical claims nor guarantees on any specific health issue, but we are very thankful that for over 10 years, people have been able to avoid having cataract surgery because they’ve used these drops. We suggest using 1 drop in each eye 4 times a day. It typically takes people on average of about 3 months to see a noticeable difference. And the best results usually take several months.”\n\n• July 14, 2023 Facebook post: “Eye Health Bundle Pack . . . includes Can-C Eye Drops . . . ‘I have used these eye drops for many years. I have the the [sic] beginning of cataracts that have not progressed and my near sightedness has not gotten worse in over two years. I also find the drops are soothing to my eyes. I highly recommend this product.’”\n\nOn your Amazon product webpage for “Vision Clarity Eye Drops” at https:\u002F\u002Fwww.amazon.com\u002FCarnosine-Lubricants-Hypromellose-Antioxidant-Lubricating\u002Fdp\u002FB008J6QR8Q, you have an image that resembles an over-the-counter (OTC) drug facts label, and it displays Glycerin 1.0% and N-Acetylcarnosine (NAC) 1.0% as active ingredients. Furthermore, next to the OTC drug facts label, you include the claim, “clinically studied ingredients[:] cataracts[,] dry eyes[, and] floaters.”\n\nYour “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for your “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” products.\n\n“Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” are marketed as ophthalmic demulcent (lubricant) drug products and are subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application – commonly referred to as “OTC monograph drugs” – may be legally marketed if they meet applicable requirements. In particular, ophthalmic demulcent (lubricant) drug products are deemed to be GRASE and not a “new drug” if, among other things, they conform to the conditions of use set forth in the Over-the-Counter Monograph M018: Ophthalmic Drug Products for Over-the-Counter Human Use (hereinafter Monograph M018).3 However, your “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” do not conform to the conditions of use specified in Monograph M018 because these products are formulated with the active ingredient N-Acetyl-Carnosine (NAC), and labeled with indications to treat or prevent cataracts, neither of which are permitted under the final administrative order. Therefore, these products do not meet the requirements under section 505G.\n\nWe note that you list the NAC ingredient as an inactive ingredient or excipient on the label of your “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” products. However, your firm makes many therapeutic claims for NAC that cause it to be considered an active ingredient.4 For example, your website includes a blog post entitled, “The Benefits of N-Acetyl-Carnosine (NAC) for Your Eyes, Especially for Cataracts.” Many other examples of therapeutic claims related to NAC can be found in the various claims cited in this letter above which make it clear that NAC is intended to furnish pharmacological activity or other direct effect, including in the treatment of cataracts, and is thus an active ingredient. As previously stated, NAC is not a permitted active ingredient in Monograph M018 and treating or preventing cataracts is not a permitted indication in Monograph M018.\n\nFDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling. Moreover, there is no evident basis under the FD&C Act under which these products would be legally marketed without an approved application. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nRegistration and Drug Listing Violations\n\nUnder section 510(j)(1) of the FD&C Act, 21 U.S.C. 360(j)(1), and 21 CFR 207.41, all drugs manufactured, prepared, propagated, compounded, or processed for U.S. commercial distribution must be listed with FDA. The drug products “Vision Clarity Eye Drops,” “Life Extension Brite Eyes III,” “Can-C Eye Drops,” and “Longevity Science Visual Ocuity” are not properly listed with FDA.5 Therefore, these drug products are misbranded under section 502(o) of the FD&C Act, 21 U.S.C. 352(o). The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nJill Furman\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n_______________________\n\n1 Your firm markets these ophthalmic products as containing N-acetylcarnosine (NAC).\n\n2 You include a direct hyperlink to your “Vision Clarity Eye Drops” product webpage.\n\n3 Section 505G(a)(1) of the FD&C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs\", notably conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 CFR 330 prior to enactment of the CARES Act. In the case of OTC ophthalmic drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M018: Ophthalmic Drug Products for Over-the-Counter Human Use. (See Order ID OTC000023, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F.)\n\n4 See e.g., 21 CFR 314.3(b) and 21 CFR 210.3(b)(7), which define an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man.”\n\n5 Your drug listing for “Vision Clarity Eye Drops” (NDC 71108-001-05) is inactive as of January 31, 2020. To date, FDA has not received an updated submission for the drug product “Vision Clarity Eye Drops” (NDC 71108-001-05).","DR Vitamins, LLC dba DR Vitamin Solutions","dr-vitamins-llc-dba-dr-vitamin-solutions-663127-09112023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdr-vitamins-llc-dba-dr-vitamin-solutions-663127-09112023","2026-10-26T08:08:27.096198+00:00","2023-09-12","663127","Jonathan Formby","2026-08-20T00:41:55.52+00:00","2023-09-11",{"id":257,"raw":258,"subject":38,"body_html":262,"body_text":263,"firm_name":264,"letter_id":265,"created_at":266,"fei_number":19,"letter_url":267,"updated_at":268,"action_type":22,"case_status":23,"posted_date":269,"marcs_cms_no":270,"product_type":47,"closeout_date":19,"issuing_office":37,"recipient_name":271,"body_fetched_at":272,"delivery_method":50,"recipient_title":19,"reference_number":19,"action_taken_date":273,"medical_device_id":19,"response_letter_date":19},2871,[259,260,261,37,38,13,13,13],"\u003Ctime datetime=\"2022-02-15T14:20:00Z\">02\u002F15\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-02-04T05:00:00Z\">02\u002F04\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvapor-solutions-and-labs-llc-626095-02042022\">Vapor Solutions and Labs, LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Brian Stanek and Moe Abujamous\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Vapor Solutions and Labs, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>319 Business Ln., Ste. 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ashland\u003C\u002Fspan>, \u003Cspan>VA\u003C\u002Fspan> \u003Cspan>23005-2322\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Brian@buffalodistro.com\"> Brian@buffalodistro.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@buffalodistro.com\"> info@buffalodistro.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sales@buffalodistro.com\"> sales@buffalodistro.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>February 4, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Brian Stanek and Moe Abujamous,\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.vaporsolutionslabs.com determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquid products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fwww.vaporsolutionslabs.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: By the Pound – Strawberry, Sqeez Limeade, Country Clouds Chocolate Puddin’ Pie, and Sqeez Berryade.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 120 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA) assigned STN PM0003492 on September 8, 2020. However, FDA issued negative actions for PMTA STN PM0003492 in the form of a Marketing Denial Order determinations on September 8, 2021 which covers 19,613 products and in the form of Refuse to Accept letter on June 30, 2021 which covers 1,904 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by PMTA STN PM0003492 that resulted in a negative action including Refuse to Accept and Marketing Denial Order determination, are adulterated and misbranded.\u003C\u002Fp>\n\n\u003Cp>All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Refuse to Accept determination, Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2201731, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>True Vape USA\u003Cbr>\nAttn: Brian Stanek and Moe Abujamous\u003Cbr>\n4444 Sarellen Rd.\u003Cbr>\nHenrico, VA 23231\u003Cbr>\ninfo@truevapeusa.com\u003C\u002Fp>\n\n\u003Cp>Virginia Small Business Law, PLLC\u003Cbr>\n15 E Franklin St.\u003Cbr>\nRichmond, VA 23219-2143\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com\u003C\u002Fp>\n\n\u003Cp>Fastly\u003Cbr>\nabuse@fastly.com\u003C\u002Fp>\n\n\u003Cp>Shopify\u003Cbr>\nabuse@shopify.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nBrian Stanek and Moe Abujamous\n\nVapor Solutions and Labs, LLC\n\n319 Business Ln., Ste. 100\n\nAshland, VA 23005-2322\n\nUnited States\n\nBrian@buffalodistro.com\n\ninfo@buffalodistro.com\n\nsales@buffalodistro.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nFebruary 4, 2022\n\nWARNING LETTER\n\nDear Brian Stanek and Moe Abujamous,\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.vaporsolutionslabs.com determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquid products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fwww.vaporsolutionslabs.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: By the Pound – Strawberry, Sqeez Limeade, Country Clouds Chocolate Puddin’ Pie, and Sqeez Berryade.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 120 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA) assigned STN PM0003492 on September 8, 2020. However, FDA issued negative actions for PMTA STN PM0003492 in the form of a Marketing Denial Order determinations on September 8, 2021 which covers 19,613 products and in the form of Refuse to Accept letter on June 30, 2021 which covers 1,904 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by PMTA STN PM0003492 that resulted in a negative action including Refuse to Accept and Marketing Denial Order determination, are adulterated and misbranded.\n\nAll new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Refuse to Accept determination, Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2201731, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nTrue Vape USA\n\nAttn: Brian Stanek and Moe Abujamous\n\n4444 Sarellen Rd.\n\nHenrico, VA 23231\n\ninfo@truevapeusa.com\n\nVirginia Small Business Law, PLLC\n\n15 E Franklin St.\n\nRichmond, VA 23219-2143\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nFastly\n\nabuse@fastly.com\n\nShopify\n\nabuse@shopify.com","Vapor Solutions and Labs, LLC","vapor-solutions-and-labs-llc-626095-02042022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvapor-solutions-and-labs-llc-626095-02042022","2026-10-26T08:10:25.205061+00:00","2022-02-15","626095","Brian Stanek and Moe Abujamous","2026-08-20T02:11:39.024+00:00","2022-02-04",{"id":275,"raw":276,"subject":281,"body_html":282,"body_text":283,"firm_name":284,"letter_id":285,"created_at":266,"fei_number":19,"letter_url":286,"updated_at":287,"action_type":22,"case_status":23,"posted_date":288,"marcs_cms_no":289,"product_type":26,"closeout_date":19,"issuing_office":280,"recipient_name":290,"body_fetched_at":291,"delivery_method":217,"recipient_title":19,"reference_number":19,"action_taken_date":292,"medical_device_id":19,"response_letter_date":19},2895,[277,278,279,280,281,13,13,13],"\u003Ctime datetime=\"2022-02-01T14:20:00Z\">02\u002F01\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-10-22T04:00:00Z\">10\u002F22\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fapplied-health-solutions-inc-616778-10222021\">Applied Health Solutions, Inc.\u003C\u002Fa>","Office of Human and Animal Food Operations - Division IV West","New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>William Evans\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Applied Health Solutions, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>11231 N 84th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Scottsdale\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85260\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations - Division IV West\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 22, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\n\u003Cstrong>Ref: CMS Case # 616778\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Evans:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fstore.appliedhealth.com in July-August 2021 and has determined that you take orders there for the Applied Health Solutions brand products B Complex, Daily Detox, CellRenewPRO, CellRenewSTS, and PowerZyme Prime, and the NutriBiotic brand products Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate. We also reviewed your website at the Internet address https:\u002F\u002Fappliedhealth.com, which directs consumers to your website https:\u002F\u002Fstore.appliedhealth.com to purchase your products. The claims on your websites establish these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Examples of the website claims that establish the intended use of the products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>B Complex product:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>On the “Prevent MRSA Infection” blog post (https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F), which hyperlinks to the product webpage for B Complex:\u003C\u002Fp>\n\n\u003Cp>• “Prevent MRSA Infection . . . Annihilate infections before they start -Strengthen Your Immunity[.] Anything that can be done to boost your immune system will benefit you when you come in contact with this bacteria. . . . make sure you are getting plenty of immune boosting vitamins. . . . B-complex . . .”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Daily Detox product:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>On the Daily Detox product webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fcollections\u002Fdetox-cleansing-support\u002Fproducts\u002Fdaily-detox-toxin-binding-agents):\u003C\u002Fp>\n\n\u003Cp>• “Broccoli Extract – BroccoSinolate [an ingredient in Daily Detox] . . . rich in . . . glucosinolates . . . Glucosinolates . . . help lower cancer risks and protect against cardiovascular disease. Another benefit . . . is the ability to help fight bacterial, viral, and fungal infections.”\u003C\u002Fp>\n\n\u003Cp>On the “Prevent MRSA Infection” blog post (https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F), which hyperlinks to the product webpage for Daily Detox:\u003C\u002Fp>\n\n\u003Cp>• “Regular use of Daily Detox offers powerful antioxidant protection against seasonal colds and flu.”\u003C\u002Fp>\n\n\u003Cp>• “NATURAL TREATMENT: Good riddance “SuperBug”! These nutrients contain anti-microbial and anti-bacterial properties: Applied Health’s Daily Detox . . .”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>PowerZyme Prime product:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>On the PowerZyme Prime ingredients webpage (https:\u002F\u002Fappliedhealth.com\u002Fpowerzyme-digestive-enzymes\u002Fpowerzyme-ingredients\u002F):\u003C\u002Fp>\n\n\u003Cp>• “Lysozyme [an ingredient in PowerZyme Prime] . . . Documented in human studies to inhibit the growth of Candida albicans.”\u003C\u002Fp>\n\n\u003Cp>• “Serratia peptidase [an ingredient in PowerZyme Prime] . . . exhibits well documented fibrinolytic (prevention of blood clots), anti-inflammatory, and anti-edematous (prevents swelling of tissues from water entrapment – edema) activities and lessens the viscosity of exudates (a fluid of protein and cellular elements that escapes blood vessels due to inflammation and settles in nearby tissues).”\u003C\u002Fp>\n\n\u003Cp>On the “Chronic Candida Syndrome” blog post (https:\u002F\u002Fappliedhealth.com\u002Fchronic-candida-syndrome\u002F):\u003C\u002Fp>\n\n\u003Cp>• “What causes Candidiasis? . . . Other contributing factors to Candida imbalance are . . . Lack of digestive enzymes . . .” [the phrase “digestive enzymes” hyperlinks to the PowerZyme Prime product webpage]\u003C\u002Fp>\n\n\u003Cp>On the “Chronic Candida Syndrome Part 2” blog post (https:\u002F\u002Fappliedhealth.com\u002Fchronic-candida-syndrome-part-2\u002F):\u003Cbr>\n\u003Cbr>\n• “Incidence of Candidiasis is rapidly increasing. Several reasons for this are: . . . Lack of proper digestive enzymes in our diet. . . . As always, we prefer to recommend more holistic methods for our readers. However, remember that it is important to rotate even natural therapies, because resistant strains of Candida mutate easily. . . . Nutrients and antioxidants that support the immune system are also important, such as: Digestive Enzymes . . .” [the PowerZyme Prime product is also referred to as “Digestive Enzymes” on the PowerZyme Prime product webpage]\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Grapefruit Seed Extract CapsulesPlus product:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>On the Grapefruit Seed Extract CapsulesPlus product webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fproducts\u002Fnutribiotic-grapefruit-seed-extract-with-echinacea-and-artemisia-annua):\u003C\u002Fp>\n\n\u003Cp>• “It is effective against pathogens because it belongs to a family of compounds known as quaternary compounds.”\u003C\u002Fp>\n\n\u003Cp>• “Additional information to consider on Grapefruit Seed Extract [an ingredient in Grapefruit Seed Extract CapsulesPlus] is available at: Grapefruit Seed Extract for Cold\u002FFlu Season:\u003Cbr>\nhttps:\u002F\u002Fappliedhealth.com\u002Fgrapefruit-seed-extract-rx-for-cold-and-flu-season\u002F . . . Prevent MRSA Infection: https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F . . .”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Grapefruit Seed Extract Liquid Concentrate product:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>On the Grapefruit Seed Extract Liquid Concentrate product webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fproducts\u002Fnutribiotic-grapefruit-seed-extract-liquid):\u003C\u002Fp>\n\n\u003Cp>• “Additional information to consider on Grapefruit Seed Extract [an ingredient in Grapefruit Seed Extract Liquid Concentrate]: Grapefruit Seed Extract for Cold\u002FFlu Season: https:\u002F\u002Fappliedhealth.com\u002Fgrapefruit-seed-extract-rx-for-cold-and-flu-season\u002F . . . Prevent MRSA Infection: https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F . . .”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Grapefruit Seed Extract Liquid Concentrate and Grapefruit Seed Extract CapsulesPlus products:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>On the “Prevent MRSA Infection” blog post (https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F):\u003C\u002Fp>\n\n\u003Cp>• “NATURAL TREATMENT: Good riddance “SuperBug”! These nutrients contain anti-microbial and anti-bacterial properties . . . Grapefruit Seed Extract [an ingredient in Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate]”\u003C\u002Fp>\n\n\u003Cp>On the “Benefits of Grapefruit seed Extract” webpage (https:\u002F\u002Fappliedhealth.com\u002Fbenefits-of-grapefruit-seed-extract\u002F), which hyperlinks to the Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate product webpages:\u003C\u002Fp>\n\n\u003Cp>• “Grapefruit Seed Extract (GSE) [an ingredient in Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate] . . . Used as a . . . antimicrobial product, it is known to be highly effective for fighting infection . . . Even in studies comparing its effectiveness to chlorine bleach, isopropyl alcohol, and colloidal silver, GSE has been found to be superior as an antimicrobial.”\u003C\u002Fp>\n\n\u003Cp>• “. . . research showing the effectiveness of GSE against AIDS.”\u003C\u002Fp>\n\n\u003Cp>• “All over the world, GSE has been used for killing a wide variety of bacteria (such as: Salmonella, E. coli, Staph and Strep germs), viruses, herpes, parasites, and fungi, including Candida. It is effective against more than 800 bacterial and viral strains, 100 strains of fungus, as well as a large number of single-cell and multi-celled parasites.”\u003C\u002Fp>\n\n\u003Cp>• “. . . the antimicrobial properties of GSE . . .”\u003C\u002Fp>\n\n\u003Cp>• “. . . antifungal properties of GSE have made it an important part of successful anti-Candida programs – a fact that has linked the names Candida and Grapefruit Seed Extract.”\u003C\u002Fp>\n\n\u003Cp>• “‘In the treatment of intestinal protozoan infections . . . [ellipsis in original] drugs are generally so toxic that they cannot be administered for prolonged periods of time, whereas GSE can be administered for weeks or months; prolonged treatment being essential for the cure of chronic protozoan infections . . . [ellipsis in original]’”\u003C\u002Fp>\n\n\u003Cp>• “To aid in the anti-Candida treatment, . . . GSE should be taken between meals. . . .”\u003C\u002Fp>\n\n\u003Cp>• “. . . a variety of other ailments can be helped by GSE, such as: . . .\u003C\u002Fp>\n\n\u003Cp>&nbsp; − AIDS – An increasing number of HIV positive people are able to improve their immune system by using GSE to fight viruses, bacteria, fungi, Candida, or parasites. . . .\u003Cbr>\n&nbsp; − Colds, flus, viruses – Take 10-15 drops, or 1-2 capsules\u002Ftablets, 3 times a day, at the first signs of cold or flu. . . .\u003Cbr>\n&nbsp; − Chronic Fatigue Syndrome – To generally build up immune system, gradually increase GSE amount to the recommended dosage for colds, flus, and viruses. . . .\u003Cbr>\n&nbsp; − Diarrhea – Use 15 to 20 drops in juice every four hours; no more than 60 drops per day. For parasites, higher doses may be necessary. . . .\u003Cbr>\n&nbsp; − Parasites . . .\u003Cbr>\n&nbsp; − Traveler’s Diarrhea (Montezuma’s Revenge) – Use 1-2 drops of GSE in a glass of water each day as a preventative. . . .\u003Cbr>\n&nbsp; − Ulcers . . .”\u003C\u002Fp>\n\n\u003Cp>On the “Grapefruit Seed Extract Rx for Cold and Flu Season” webpage (https:\u002F\u002Fappliedhealth.com\u002Fgrapefruit-seed-extract-rx-for-cold-and-flu-season\u002F), which hyperlinks to the Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate product webpages:\u003C\u002Fp>\n\n\u003Cp>• “Grapefruit Seed Extract [an ingredient in Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate] RX for Cold and Flu Season”\u003C\u002Fp>\n\n\u003Cp>• “A Must-Have For Every Home During Cold and Flu Season”\u003C\u002Fp>\n\n\u003Cp>• “Whether it’s a sore throat, earache, viral infection, intestinal problem, or anything else related to a virus, fungus, or bad bacteria, if you are the main caregiver in your home, Grapefruit Seed Extract is a must-have for your cupboard.”\u003C\u002Fp>\n\n\u003Cp>• “. . . it is ‘Grapefruit’ Seed Extract (abbreviated as GSE or GFSE) that works as a natural antibiotic with anti-viral, anti-bacterial, and anti-fungal properties.”\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Internal Uses”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “Fight Colds, Flus, Viruses”\u003Cbr>\n&nbsp; − “Reach for the GSE at the first symptoms of flu or cold.”\u003Cbr>\n&nbsp; − “Traveler’s Diarrhea – As a preventative when traveling in areas with questionable water, mix 1 or 2 drops GSE in each glass of water, or on your toothbrush to disinfect and help prevent Traveler’s diarrhea.”\u003Cbr>\n&nbsp; − “Diarrhea – If you do experience a case of diarrhea, take 15 to 25 drops GSE every 3 to 4 hours in water or juice – no more than 75 drops per day. Or, 2 capsules\u002Ftablets (no more than 6 per day) every 4 hours.”\u003Cbr>\n&nbsp; − “Parasites . . . Use the same amount of GSE as for diarrhea, with possibly increasing to a maximum of 5 doses per day.”\u003Cbr>\n&nbsp; − “There have been anecdotal reports of GSE helping some serious illnesses, such as Chronic Fatigue Syndrome, AIDS, and even Cancer.”\u003Cbr>\n\u003Cbr>\n• “There are many more uses for GSE. Once you have successfully used it for something simple, like fighting a cold, you may find yourself reaching for it, regularly, whenever you find a need for its anti-viral, anti-fungal, and anti-bacterial properties.”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>CellRenewPRO product:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>On the CellRenewPRO product webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fcollections\u002Fjoint-soft-tissue-support\u002Fproducts\u002Fcellrenew-pro-hydrolyzed-collagen-type-ii):\u003C\u002Fp>\n\n\u003Cp>• “CellRenew PRO provides multi-dimensional nutritional components vital for repairing connective soft tissue (joints, skin, cardiovascular, etc.).”\u003C\u002Fp>\n\n\u003Cp>On the CellRenewPRO supplement facts and monograph webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fpages\u002Fcellrenew-pro-defined):\u003C\u002Fp>\n\n\u003Cp>• “CellRenew Pro is Ultimate Joint Repair”\u003C\u002Fp>\n\n\u003Cp>• “CellRenew PRO provides multi-dimensional nutritional components vital for repairing connective soft tissue (joints, skin, cardiovascular, etc.).”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>CellRenewPRO and CellRenewSTS products:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>On the CellRenewPRO (https:\u002F\u002Fstore.appliedhealth.com\u002Fpages\u002Fcellrenew-pro-defined) and CellRenewSTS (https:\u002F\u002Fstore.appliedhealth.com\u002Fpages\u002Fcellrenew-sts-supplement-facts-and-monograph) supplement facts and monograph webpages:\u003C\u002Fp>\n\n\u003Cp>• “CellRenew contains Hydrolyzed Collagen Type II derived from 100% pure chicken sternal cartilage. As an abundant source of naturally-occurring Hyaluronic Acid and Chondroitin Sulfates, Collagen Type II is easily absorbed to restore joint and cartilage health.”\u003C\u002Fp>\n\n\u003Cp>• “It is an absorbable hydrolyzed collagen type II product . . . that . . . relieves joint discomfort and increases mobility.”\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Research”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “Collagen Type II (CCII) [an ingredient in CellRenewPRO and CellRenewSTS] . . . can suppress pro-inflammatory activity to reduce joint discomfort and restore cartilage health. CCII from chicken sternal cartilage was shown to reduce chronic joint inflammation . . .”\u003Cbr>\n&nbsp; − “A three-month study recruited 60 patients with chronic joint inflammation to take CCII or a placebo. Results indicated CCII alleviated swollen and tender joints in the treatment group. Four patients in the treatment group had a complete remission of chronic joint inflammation.”\u003Cbr>\n&nbsp; − “Similarly, a pilot-study recruited female subjects with joint pain to take Hydrolyzed Collagen Type II for 42 days. Subjects reported a significant improvement in joint mobility and decrease in joint pain and stiffness.”\u003Cbr>\n&nbsp; − “CCII is evidenced to be effective among adolescents with chronic joint inflammation. A pilot-study administered CCII to 10 adolescent patients with chronic joint inflammation for 12 weeks. Eight patients experienced a reduction in swollen and tender joints. A similar pilot-study recruited nine adolescents with chronic joint inflammation to take an oral Collagen Type II, finding the supplement . . . reduced joint inflammation.”\u003Cbr>\n&nbsp; − “Chondroitin Sulfate (Component of Collagen Type II) [an ingredient in CellRenewPRO and CellRenewSTS] Naturally found in sternal chicken Collagen Type II, chondroitin sulfate has anti-inflammatory activity that reduces joint swelling, maintains synovial fluid levels, and spacing between the joints. Further, chondroitin sulfate reduces the proliferation of proteins to reduce joint inflammation.”\u003Cbr>\n&nbsp; − “A one-year study recruited 42 patients with knee pain to take chondroitin sulfate or a placebo. Subjects taking chondroitin sulfate had greater joint mobility and less pain, when compared to the placebo group.”\u003Cbr>\n&nbsp; − “A three-month study recruited 110 patients with knee pain to take chondroitin sulfate or a placebo finding supplementation improved knee function, reduced pain, and maintained joint space in the knee.”\u003Cbr>\n&nbsp; − “Researchers suggested chondroitin sulfate and glucosamine could repair and regenerate cartilage . . .”\u003Cbr>\n&nbsp; − “Hyaluronic Acid (Component of Collagen Type II) [an ingredient in CellRenewPRO and CellRenewSTS] . . . Studies have suggested hyaluronic acid has anti-inflammatory activity that suppresses pro-inflammatory and pain mechanisms in the body.”\u003Cbr>\n&nbsp; − “Researchers found that HA inhibited inflammatory cytokine activity in mice with inflamed joints. A similar study reviewed the effect of HA on acute and chronic inflammation in rats, finding HA suppressed inflammatory reactions . . .”\u003C\u002Fp>\n\n\u003Cp>On the homepage for the https:\u002F\u002Fappliedhealth.com website:\u003C\u002Fp>\n\n\u003Cp>• “How do you help knee pain? . . . CellRenew PRO is Extreme Knee Protection”\u003C\u002Fp>\n\n\u003Cp>• “CellRenew Additional Links . . . CellRenew Collagen Type II and Knee Pain . . . Is Collagen Type II A Cure For Arthritis And Heart Disease . . .”\u003Cbr>\n\u003Cbr>\n• In the response to the question “What is CellRenew?”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “Unlike other protocols for arthritis symptoms, whether prescription or natural, CellRenew is guaranteed for results.”\u003Cbr>\n&nbsp; − “It contains naturally occurring Hyaluronic Acid and Chondroitin Sulfate. The results of a human clinical trial using this material showed significant improvements in the reduction of joint swelling, tenderness, and pain, as well as successful increases in mobility.”\u003C\u002Fp>\n\n\u003Cp>• In the response to the question “Who is a good candidate to take CellRenew?”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “Although studies have shown that many different conditions respond to Collagen Type II, the conditions that have shown the greatest response are rheumatoid arthritis and osteoarthritis. If you have grown weary of traditional protocols that only cover-up symptoms and neglect to address the root cause, then you are an excellent candidate to begin a program of Collagen Type II.”\u003Cbr>\n&nbsp; − “CellRenew is also used as a preventative measure for athletes who . . . are looking for a way to maintain healthy joints prior to the onset of osteoarthritis.”\u003C\u002Fp>\n\n\u003Cp>• In response to the question “What will it do for me?”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “Collagen Type II (CTII) [an ingredient in CellRenewPRO and CellRenewSTS] has been suggested to offer significant benefits for some types of arthritis. . . . Rheumatoid arthritis (RA) is the most well known of the autoimmune types of arthritis. In the case of RA, the collagen in the joints is attacked.”\u003Cbr>\n&nbsp; − “Depending on the particular type of arthritis you experience, CTII goes to work in different ways. If you suffer from RA, CTII acts as an oral tolerization agent, instructing the body to stop the immune response to the collagen in the joints. . . . For those suffering from osteoarthritis, CTII provides the critical building blocks that restore a healthy state to the cartilage in the joints.”\u003Cbr>\n&nbsp; − “CellRenew is made from chicken sternal cartilage that contains the highest level of naturally occurring anti-inflammatory proteoglycans (Hyaluronic Acid and Chondroitin Sulfate A) of any other material tested, including shark cartilage. It is important to note that the combination of the proteoglycans and the Collagen Type II proteins . . . provide the building blocks required to rebuild lost cartilage to restore the joint to a normal state.”\u003C\u002Fp>\n\n\u003Cp>• In response to the question “What do the studies show?”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “The results of a recent double-blind, placebo-controlled, clinical trial has proved the benefits of Collagen Type II for treating the symptoms of pain and immobility associated with arthritis. . . . report an 89.9% positive response rate, within 45 days, for the participants who consumed at least 2000 mg of Collagen Type II per day.”\u003Cbr>\n&nbsp; − “[R]eported having successfully treated more than 50 patients, starting in 1974, with osteoarthritis, rheumatoid arthritis, psoriasis, and many other ailments. . . .”\u003Cbr>\n&nbsp; − “Of the different types of cartilage tested, the one with the highest level of Collagen Type II, anti-inflammatory proteoglycans (the healing properties) was chicken sternal cartilage. CellRenew is 100% chicken sternal cartilage.”\u003C\u002Fp>\n\n\u003Cp>• In response to the question “What else is it good for?”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “Besides the better-known associations with osteoarthritis and rheumatoid arthritis, it has also been suggested that Collagen Type II might benefit heart disease, psoriasis, progressive myopia, and some other autoimmune diseases.”\u003C\u002Fp>\n\n\u003Cp>• In response to the question “How long before I improve?”:&nbsp;&nbsp;\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “Although some people have noticed an improvement with their symptoms after only a week or two of starting a CellRenew program, many take between 4 and 6 weeks. . . . some forms of arthritis symptoms tend to respond faster – on average – than other forms. For instance, we do know that rheumatoid arthritis sufferers have a tendency to respond faster . . .”\u003C\u002Fp>\n\n\u003Cp>Under the heading “CellRenew Customer Stories” on the homepage for the https:\u002F\u002Fappliedhealth.com website:\u003C\u002Fp>\n\n\u003Cp>• “‘I have been taking CellRenew since May of 2003. . . . This product has kept my arthritis at bay. . . .’”\u003C\u002Fp>\n\n\u003Cp>• “‘[T]hank you for the dramatic results I have experienced in the first three weeks of taking CellRenew. For the past twenty years, I have been living with severe lower back pain. I was diagnosed with a degenerative disc disorder in the L2, L3, and L4 vertebrae. . . . CellRenew has improved my quality of life one thousand percent.’”\u003C\u002Fp>\n\n\u003Cp>• “‘Fourteen months ago – diagnosed with scoliosis, osteoarthritis of the spine and degenerative disc disease – my active life was gone . . . I was in excruciating pain most of the time. . . . On the xray [sic], my spine looked like a rock pile. . . . Enter CellRenew, and within one month, the improvement was incredible. That was four months ago. . . . I have my life back. I know that CellRenew works!’”\u003C\u002Fp>\n\n\u003Cp>• “‘I wanted to tell you all about how thrilled I am with CellRenew. I have been taking CellRenew for just over a year now. I have not had a single ache or pain in at least 10 months. I have experienced no side effects, except for one good side effect. I have changed my eyeglass prescription, twice! Both times were for the better! My eyesight is improving. . . .’”\u003C\u002Fp>\n\n\u003Cp>Under the heading “In the beginning…” on the homepage for the https:\u002F\u002Fappliedhealth.com website:\u003C\u002Fp>\n\n\u003Cp>• “Bill Evans, President, Applied Health . . . my lifestyle was finally catching up to me . . . due to rapidly progressing arthritis. . . . Instead of a future filled with the pursuit of my favorite activities, and dreams of conquering the Bucket List, I only saw the prospect of surgeries, painkillers, and physical therapy. I decided there had to be a better way than knee replacement and a cocktail of medications. A year later, in 1997, we started Applied Health and introduced our first Collagen-based, joint support product using hydrolyzed collagen type II . . . We called it CellRenew, and over 20 years later, we still have devoted users . . . [ellipsis in original] myself among them.”\u003C\u002Fp>\n\n\u003Cp>On the “CellRenew Hydrolyzed Collagen Type II Technical Outline” webpage (https:\u002F\u002Fappliedhealth.com\u002Fcellrenew-collagen-type-ii\u002Fcellrenew-technical-outline\u002F):\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Key Product Highlights\u002FBullets”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “CellRenew is so effective that the raw material has been awarded two United States Patents . . . for the treatment of connective tissue disorder, osteoarthritis, degenerative joint disease, joint defects, vascular disease, and cartilage injuries . . .”\u003Cbr>\n&nbsp; − “May help support proper inflammatory function due to its chondroitin sulfate content . . .”\u003Cbr>\n&nbsp; − “May possibly support proper wound healing due to its potent hyaluronic acid content . . .”\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Studies and Mechanisms of action”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “CellRenew and its components can have a powerful impact on joints and conditions associated with abnormal joint function. One study [footnote omitted] published in 2000 entitled ‘Role of collagen hydrolysate in bone and joint disease’, reviews how collagen can be a powerful tool in helping with osteoarthritis and even osteoporosis. . . . Mechanism of action: The components of CellRenew . . . lower the chance for deterioration.”\u003Cbr>\n&nbsp; − “‘[H]yaluronan preparations have been shown to decrease pain and increase function in patients with osteoarthritis of the knee.’ Mechanism of action: Hyaluronic Acid seems to work through several mechanisms of action including restoration of more normal synovial fluid with improved viscoelasticity, effects on cartilage biosynthesis and degradation, anti-inflammatory effects, and direct analgesic effects.”\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Patent Claims”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “2. A method for treating an individual with a connective tissue disorder . . .”\u003Cbr>\n&nbsp; − “3. The method of claim 2, wherein said connective tissue disorder is selected from the group consisting of degenerative joint diseases, joint defects, osteoarthritis, polychondritis, vascular disease, cartilage injuries, progressive myopia and Menier’s [sic] disease.”\u003C\u002Fp>\n\n\u003Cp>On the “Effects of Collagen Type II For Subjective Pain Relief” webpage (https:\u002F\u002Fappliedhealth.com\u002Fcellrenew-collagen-type-ii\u002Fhydrolyzed-collagen-clinical-trial\u002F), which contains a hyperlink to the online storefront where the CellRenewPRO and CellRenewSTS products can be purchased:\u003C\u002Fp>\n\n\u003Cp>• The following quote appears after a summary of a study on the effects of Collagen Type II (an ingredient in CellRenewPRO and CellRenewSTS) on the course of pain syndromes, including rheumatoid arthritic pain, osteoarthritis joint pain, post surgical joint pain, post traumatic pain, fibrositis, gouty arthritis, lumbosacral pain with\u002Fwithout radicular pain, and cervical spine pain with\u002Fwithout radicular pain: “‘The results were overwhelmingly positive for pain relief and the side benefits were remarkable! This product has changed my life significantly.’”\u003C\u002Fp>\n\n\u003Cp>On the “Is Collagen Type II A Cure For Arthritis And Heart Disease?” webpage (https:\u002F\u002Fappliedhealth.com\u002Fcellrenew-collagen-type-ii\u002Fcollagen-type-ii-cure-arthritis-heart-disease\u002F), which hyperlinks to the online storefront where the CellRenewPRO and CellRenewSTS products can be purchased:\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Collagen Type II [an ingredient in CellRenewPRO and CellRenewSTS] and Arthritis”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “. . . 50 million Americans suffer from some form of arthritis, either rheumatoid or osteoarthritis, as well as a variety of other arthritic conditions. . . . Could it be that one nutritional medicine called collagen type II can ameliorate both disorders in an effective way?”\u003Cbr>\n&nbsp; − “It may turn out that the natural components of cartilage hold the greatest promise of ameliorating both arthritis and heart disease.”\u003Cbr>\n&nbsp; − “If collagen type II is derived from chicken sternal cartilage, from chicks six to eight weeks old, it contains the greatest number of anti-inflammatory and joint supporting proteoglycans. These proteoglycans include glucosamine sulfate which has over 30 years of double-blind, placebo-controlled studies indicating that it actually helps to rebuild the cartilage in arthritis joints.”\u003Cbr>\n&nbsp; − “[I]t contains a high concentration of chondroitin sulfate A, which is a powerful anti-inflammatory . . .”\u003Cbr>\n&nbsp; − “[C]ollagen type II also contains a powerful, newly discovered antioxidant proteoglycan called cartilage matrix glycoprotein (CMGP), which can help reduce the oxidative damage to the joint.”\u003Cbr>\n&nbsp; − “When people suffer from arthritis, there is a selective destruction of collagen type II in the joint cartilage itself. Scientists know that this particular component of cartilage is being attacked by white blood cells and somehow this activates the immune system in the rheumatoid arthritic patient to develop antibodies to collagen type II. This then sets up an immune response to all of the cartilage that is degenerating in the body. Thus, both wrists hurt, both knees hurt, the hips, the back, etc.”\u003Cbr>\n&nbsp; − “The question now becomes how does collagen type II turn off the immune system in the rheumatoid arthritic. The answer is that collagen type II’s effectiveness is accomplished through ‘oral tolerance.’”\u003Cbr>\n&nbsp; − “. . . investigate the side effects of chicken sternal collagen type II being fed to arthritic rats. . . . By the second or third months the rats no longer displayed any symptoms of arthritis. There was a profound amelioration of the disease.”\u003Cbr>\n&nbsp; − “. . . studied ten people with severe rheumatoid arthritis. They eliminated the standard therapies such as NSAIDS and methotrexate and fed the patients pure collagen type II derived from chicken sternal cartilage. At the end of the second month, six of the ten patients showed substantial improvement and one showed a complete regression of the disease that lasted 26 months with no side effects.”\u003Cbr>\n&nbsp; − “. . . conducted a phase II trial on 59 patients with, again, severe active rheumatoid arthritis. . . . What is interesting is that those who were off all drugs and taking collagen type II showed very significant stabilization and improvement, while those on placebos continued to deteriorate. In fact, four collagen type II patients showed a complete resolution of the disease . . .”\u003Cbr>\n&nbsp; − “We see that oral ingestion of collagen type II may well prove to be the most effective natural means of arthritis management regardless of the form of the disease.”\u003Cbr>\n&nbsp; − “. . . this is precisely why it works in osteoarthritis . . . collagen type II has such a high concentration of glucosamine and chondroitin . . .”\u003Cbr>\n&nbsp; − “In lieu [sic] of the fact that there are no side effects with collagen type II, this would seem to be the product of choice when suffering from any form of arthritic condition.”\u003Cbr>\n&nbsp; − “. . . collagen II components are truly chondro-protective agents because they . . . reprogram destructive chondrocytes and cytokines, reducing inflammation . . . protect the surface of the cartilage from oxidative damage . . . act as a powerful anti-inflammatory and pain modulator.”\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Collagen Type II [an ingredient in CellRenewPRO and CellRenewSTS] and Heart Disease”:\u003Cbr>\n\u003Cbr>\n&nbsp; − “Medicines such as aspirin and NSAIDS, as well as natural therapeutics such as fish liver oil or antiarthritic herbs, cannot compete with the overall biochemical power of collagen type II.”\u003Cbr>\n&nbsp; − “. . . collagen type II is 14.2 percent chondroitin sulfate A. . . . Chondroitin sulfate A (CSA) has a powerful antithrombogenic or anticoagulant affect, which, in essence, prevents blood clots and has been shown to reduce the incidence of stroke.”\u003Cbr>\n&nbsp; − “. . . CSA literally reduced the cholesterol and other lipids in the blood and actually ‘cleared’ cholesterol from the lining of arteries, including the aorta.”\u003Cbr>\n&nbsp; − “This indicates a 600 percent reduction in the incidence of fatal heart attacks simply by taking oral CSA on a daily basis . . .”\u003Cbr>\n&nbsp; − “Collagen type II has also found some support in the research for the amelioration of autoimmune disease caused by breast implant poisoning, as well as amelioration of Menier’s [sic] disease and progressive myopia.”\u003C\u002Fp>\n\n\u003Cp>On the “The Village of Long Life” webpage (https:\u002F\u002Fappliedhealth.com\u002Fcellrenew-collagen-type-ii\u002Fhyaluronic-acid-abc-news\u002F), which hyperlinks to the online storefront where the CellRenewPRO and CellRenewSTS products can be purchased:\u003C\u002Fp>\n\n\u003Cp>• “. . . hyaluronic acid [a component of the Hydrolyzed Collagen II ingredient in the CellRenewPRO and CellRenewSTS products] has been used for years in eye surgery as a shock absorber to protect the retina, and has been proven effective in lubricating arthritic joints.”\u003C\u002Fp>\n\n\u003Cp>• “But HA has been shown to have wound-healing and tissue-reconstruction applications . . .”\u003C\u002Fp>\n\n\u003Cp>On the “Collagen Type II for Arthritis Pain Relief” blog post (https:\u002F\u002Fappliedhealth.com\u002Fcollagen-type-ii-for-arthritis-pain-relief\u002F):\u003C\u002Fp>\n\n\u003Cp>• “Collagen Type II [an ingredient in the CellRenewPRO and CellRenewSTS products] for Arthritis Pain Relief”\u003C\u002Fp>\n\n\u003Cp>• “Does Collagen Type II relieve osteoarthritis? Research says, yes.”\u003C\u002Fp>\n\n\u003Cp>• “Collagen type II (CTII) is an effective source for alleviating joint stiffness and increasing mobility. Several studies have found CTII reduces joint pain in rheumatoid arthritis, but a new study . . . found that it is also an effective treatment for osteoarthritis.”\u003C\u002Fp>\n\n\u003Cp>• “Researchers recruited 52 subjects with osteoarthritis in the knees to take CTII or a glucosamine\u002Fchondroitin combination for 90 days. . . . Overall, CTII reduced joint pain by 40%.”\u003C\u002Fp>\n\n\u003Cp>• “How does collagen type II alleviate joint pain? CTII is the primary form of collagen naturally found in joint cartilage. The body needs CTII to rebuild connective tissue. Supplementing with a superior form of collagen can help reduce inflammation and the breakdown of collagen in the body. For the best absorption, choose a hydrolyzed collagen type II to restore joint health.”\u003C\u002Fp>\n\n\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your Applied Health Solutions brand products B Complex, Daily Detox, CellRenewPRO, CellRenewSTS, and the NutriBiotic brand products Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, the B Complex, Daily Detox, CellRenewPRO, CellRenewSTS, Grapefruit Seed Extract CapsulesPlus, and Grapefruit Seed Extract Liquid Concentrate products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to the following address: 6th Ave and Kipling St, DFC Bldg. 20, PO Box 25087, Denver, Colorado, 80225-0087, to the attention of Compliance Officer Carrie Jolly or by email to carrie.jolly@fda.hhs.gov. If you need additional information or have questions concerning any products distributed through your website, please contact CO Jolly at carrie.jolly@fda.hhs.gov or (303) 236-9656.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>E. Mark Harris\u003Cbr>\nDenver District Director &amp; Program Division Director\u003Cbr>\nOffice of Human and Animal Food Operations −\u003Cbr>\nDivision IV West\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nWilliam Evans\n\nRecipient Title\n\nPresident\n\nApplied Health Solutions, Inc.\n\n11231 N 84th Street\n\nScottsdale, AZ 85260\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations - Division IV West\n\nUnited States\n\nOctober 22, 2021\n\nWARNING LETTER\n\nRef: CMS Case # 616778\n\nDear Mr. Evans:\n\nThis is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fstore.appliedhealth.com in July-August 2021 and has determined that you take orders there for the Applied Health Solutions brand products B Complex, Daily Detox, CellRenewPRO, CellRenewSTS, and PowerZyme Prime, and the NutriBiotic brand products Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate. We also reviewed your website at the Internet address https:\u002F\u002Fappliedhealth.com, which directs consumers to your website https:\u002F\u002Fstore.appliedhealth.com to purchase your products. The claims on your websites establish these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of the website claims that establish the intended use of the products as drugs include, but may not be limited to, the following:\n\nB Complex product:\n\nOn the “Prevent MRSA Infection” blog post (https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F), which hyperlinks to the product webpage for B Complex:\n\n• “Prevent MRSA Infection . . . Annihilate infections before they start -Strengthen Your Immunity[.] Anything that can be done to boost your immune system will benefit you when you come in contact with this bacteria. . . . make sure you are getting plenty of immune boosting vitamins. . . . B-complex . . .”\n\nDaily Detox product:\n\nOn the Daily Detox product webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fcollections\u002Fdetox-cleansing-support\u002Fproducts\u002Fdaily-detox-toxin-binding-agents):\n\n• “Broccoli Extract – BroccoSinolate [an ingredient in Daily Detox] . . . rich in . . . glucosinolates . . . Glucosinolates . . . help lower cancer risks and protect against cardiovascular disease. Another benefit . . . is the ability to help fight bacterial, viral, and fungal infections.”\n\nOn the “Prevent MRSA Infection” blog post (https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F), which hyperlinks to the product webpage for Daily Detox:\n\n• “Regular use of Daily Detox offers powerful antioxidant protection against seasonal colds and flu.”\n\n• “NATURAL TREATMENT: Good riddance “SuperBug”! These nutrients contain anti-microbial and anti-bacterial properties: Applied Health’s Daily Detox . . .”\n\nPowerZyme Prime product:\n\nOn the PowerZyme Prime ingredients webpage (https:\u002F\u002Fappliedhealth.com\u002Fpowerzyme-digestive-enzymes\u002Fpowerzyme-ingredients\u002F):\n\n• “Lysozyme [an ingredient in PowerZyme Prime] . . . Documented in human studies to inhibit the growth of Candida albicans.”\n\n• “Serratia peptidase [an ingredient in PowerZyme Prime] . . . exhibits well documented fibrinolytic (prevention of blood clots), anti-inflammatory, and anti-edematous (prevents swelling of tissues from water entrapment – edema) activities and lessens the viscosity of exudates (a fluid of protein and cellular elements that escapes blood vessels due to inflammation and settles in nearby tissues).”\n\nOn the “Chronic Candida Syndrome” blog post (https:\u002F\u002Fappliedhealth.com\u002Fchronic-candida-syndrome\u002F):\n\n• “What causes Candidiasis? . . . Other contributing factors to Candida imbalance are . . . Lack of digestive enzymes . . .” [the phrase “digestive enzymes” hyperlinks to the PowerZyme Prime product webpage]\n\nOn the “Chronic Candida Syndrome Part 2” blog post (https:\u002F\u002Fappliedhealth.com\u002Fchronic-candida-syndrome-part-2\u002F):\n\n• “Incidence of Candidiasis is rapidly increasing. Several reasons for this are: . . . Lack of proper digestive enzymes in our diet. . . . As always, we prefer to recommend more holistic methods for our readers. However, remember that it is important to rotate even natural therapies, because resistant strains of Candida mutate easily. . . . Nutrients and antioxidants that support the immune system are also important, such as: Digestive Enzymes . . .” [the PowerZyme Prime product is also referred to as “Digestive Enzymes” on the PowerZyme Prime product webpage]\n\nGrapefruit Seed Extract CapsulesPlus product:\n\nOn the Grapefruit Seed Extract CapsulesPlus product webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fproducts\u002Fnutribiotic-grapefruit-seed-extract-with-echinacea-and-artemisia-annua):\n\n• “It is effective against pathogens because it belongs to a family of compounds known as quaternary compounds.”\n\n• “Additional information to consider on Grapefruit Seed Extract [an ingredient in Grapefruit Seed Extract CapsulesPlus] is available at: Grapefruit Seed Extract for Cold\u002FFlu Season:\n\nhttps:\u002F\u002Fappliedhealth.com\u002Fgrapefruit-seed-extract-rx-for-cold-and-flu-season\u002F . . . Prevent MRSA Infection: https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F . . .”\n\nGrapefruit Seed Extract Liquid Concentrate product:\n\nOn the Grapefruit Seed Extract Liquid Concentrate product webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fproducts\u002Fnutribiotic-grapefruit-seed-extract-liquid):\n\n• “Additional information to consider on Grapefruit Seed Extract [an ingredient in Grapefruit Seed Extract Liquid Concentrate]: Grapefruit Seed Extract for Cold\u002FFlu Season: https:\u002F\u002Fappliedhealth.com\u002Fgrapefruit-seed-extract-rx-for-cold-and-flu-season\u002F . . . Prevent MRSA Infection: https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F . . .”\n\nGrapefruit Seed Extract Liquid Concentrate and Grapefruit Seed Extract CapsulesPlus products:\n\nOn the “Prevent MRSA Infection” blog post (https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F):\n\n• “NATURAL TREATMENT: Good riddance “SuperBug”! These nutrients contain anti-microbial and anti-bacterial properties . . . Grapefruit Seed Extract [an ingredient in Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate]”\n\nOn the “Benefits of Grapefruit seed Extract” webpage (https:\u002F\u002Fappliedhealth.com\u002Fbenefits-of-grapefruit-seed-extract\u002F), which hyperlinks to the Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate product webpages:\n\n• “Grapefruit Seed Extract (GSE) [an ingredient in Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate] . . . Used as a . . . antimicrobial product, it is known to be highly effective for fighting infection . . . Even in studies comparing its effectiveness to chlorine bleach, isopropyl alcohol, and colloidal silver, GSE has been found to be superior as an antimicrobial.”\n\n• “. . . research showing the effectiveness of GSE against AIDS.”\n\n• “All over the world, GSE has been used for killing a wide variety of bacteria (such as: Salmonella, E. coli, Staph and Strep germs), viruses, herpes, parasites, and fungi, including Candida. It is effective against more than 800 bacterial and viral strains, 100 strains of fungus, as well as a large number of single-cell and multi-celled parasites.”\n\n• “. . . the antimicrobial properties of GSE . . .”\n\n• “. . . antifungal properties of GSE have made it an important part of successful anti-Candida programs – a fact that has linked the names Candida and Grapefruit Seed Extract.”\n\n• “‘In the treatment of intestinal protozoan infections . . . [ellipsis in original] drugs are generally so toxic that they cannot be administered for prolonged periods of time, whereas GSE can be administered for weeks or months; prolonged treatment being essential for the cure of chronic protozoan infections . . . [ellipsis in original]’”\n\n• “To aid in the anti-Candida treatment, . . . GSE should be taken between meals. . . .”\n\n• “. . . a variety of other ailments can be helped by GSE, such as: . . .\n\n− AIDS – An increasing number of HIV positive people are able to improve their immune system by using GSE to fight viruses, bacteria, fungi, Candida, or parasites. . . .\n\n− Colds, flus, viruses – Take 10-15 drops, or 1-2 capsules\u002Ftablets, 3 times a day, at the first signs of cold or flu. . . .\n\n− Chronic Fatigue Syndrome – To generally build up immune system, gradually increase GSE amount to the recommended dosage for colds, flus, and viruses. . . .\n\n− Diarrhea – Use 15 to 20 drops in juice every four hours; no more than 60 drops per day. For parasites, higher doses may be necessary. . . .\n\n− Parasites . . .\n\n− Traveler’s Diarrhea (Montezuma’s Revenge) – Use 1-2 drops of GSE in a glass of water each day as a preventative. . . .\n\n− Ulcers . . .”\n\nOn the “Grapefruit Seed Extract Rx for Cold and Flu Season” webpage (https:\u002F\u002Fappliedhealth.com\u002Fgrapefruit-seed-extract-rx-for-cold-and-flu-season\u002F), which hyperlinks to the Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate product webpages:\n\n• “Grapefruit Seed Extract [an ingredient in Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate] RX for Cold and Flu Season”\n\n• “A Must-Have For Every Home During Cold and Flu Season”\n\n• “Whether it’s a sore throat, earache, viral infection, intestinal problem, or anything else related to a virus, fungus, or bad bacteria, if you are the main caregiver in your home, Grapefruit Seed Extract is a must-have for your cupboard.”\n\n• “. . . it is ‘Grapefruit’ Seed Extract (abbreviated as GSE or GFSE) that works as a natural antibiotic with anti-viral, anti-bacterial, and anti-fungal properties.”\n\n• Under the heading “Internal Uses”:\n\n− “Fight Colds, Flus, Viruses”\n\n− “Reach for the GSE at the first symptoms of flu or cold.”\n\n− “Traveler’s Diarrhea – As a preventative when traveling in areas with questionable water, mix 1 or 2 drops GSE in each glass of water, or on your toothbrush to disinfect and help prevent Traveler’s diarrhea.”\n\n− “Diarrhea – If you do experience a case of diarrhea, take 15 to 25 drops GSE every 3 to 4 hours in water or juice – no more than 75 drops per day. Or, 2 capsules\u002Ftablets (no more than 6 per day) every 4 hours.”\n\n− “Parasites . . . Use the same amount of GSE as for diarrhea, with possibly increasing to a maximum of 5 doses per day.”\n\n− “There have been anecdotal reports of GSE helping some serious illnesses, such as Chronic Fatigue Syndrome, AIDS, and even Cancer.”\n\n• “There are many more uses for GSE. Once you have successfully used it for something simple, like fighting a cold, you may find yourself reaching for it, regularly, whenever you find a need for its anti-viral, anti-fungal, and anti-bacterial properties.”\n\nCellRenewPRO product:\n\nOn the CellRenewPRO product webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fcollections\u002Fjoint-soft-tissue-support\u002Fproducts\u002Fcellrenew-pro-hydrolyzed-collagen-type-ii):\n\n• “CellRenew PRO provides multi-dimensional nutritional components vital for repairing connective soft tissue (joints, skin, cardiovascular, etc.).”\n\nOn the CellRenewPRO supplement facts and monograph webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fpages\u002Fcellrenew-pro-defined):\n\n• “CellRenew Pro is Ultimate Joint Repair”\n\n• “CellRenew PRO provides multi-dimensional nutritional components vital for repairing connective soft tissue (joints, skin, cardiovascular, etc.).”\n\nCellRenewPRO and CellRenewSTS products:\n\nOn the CellRenewPRO (https:\u002F\u002Fstore.appliedhealth.com\u002Fpages\u002Fcellrenew-pro-defined) and CellRenewSTS (https:\u002F\u002Fstore.appliedhealth.com\u002Fpages\u002Fcellrenew-sts-supplement-facts-and-monograph) supplement facts and monograph webpages:\n\n• “CellRenew contains Hydrolyzed Collagen Type II derived from 100% pure chicken sternal cartilage. As an abundant source of naturally-occurring Hyaluronic Acid and Chondroitin Sulfates, Collagen Type II is easily absorbed to restore joint and cartilage health.”\n\n• “It is an absorbable hydrolyzed collagen type II product . . . that . . . relieves joint discomfort and increases mobility.”\n\n• Under the heading “Research”:\n\n− “Collagen Type II (CCII) [an ingredient in CellRenewPRO and CellRenewSTS] . . . can suppress pro-inflammatory activity to reduce joint discomfort and restore cartilage health. CCII from chicken sternal cartilage was shown to reduce chronic joint inflammation . . .”\n\n− “A three-month study recruited 60 patients with chronic joint inflammation to take CCII or a placebo. Results indicated CCII alleviated swollen and tender joints in the treatment group. Four patients in the treatment group had a complete remission of chronic joint inflammation.”\n\n− “Similarly, a pilot-study recruited female subjects with joint pain to take Hydrolyzed Collagen Type II for 42 days. Subjects reported a significant improvement in joint mobility and decrease in joint pain and stiffness.”\n\n− “CCII is evidenced to be effective among adolescents with chronic joint inflammation. A pilot-study administered CCII to 10 adolescent patients with chronic joint inflammation for 12 weeks. Eight patients experienced a reduction in swollen and tender joints. A similar pilot-study recruited nine adolescents with chronic joint inflammation to take an oral Collagen Type II, finding the supplement . . . reduced joint inflammation.”\n\n− “Chondroitin Sulfate (Component of Collagen Type II) [an ingredient in CellRenewPRO and CellRenewSTS] Naturally found in sternal chicken Collagen Type II, chondroitin sulfate has anti-inflammatory activity that reduces joint swelling, maintains synovial fluid levels, and spacing between the joints. Further, chondroitin sulfate reduces the proliferation of proteins to reduce joint inflammation.”\n\n− “A one-year study recruited 42 patients with knee pain to take chondroitin sulfate or a placebo. Subjects taking chondroitin sulfate had greater joint mobility and less pain, when compared to the placebo group.”\n\n− “A three-month study recruited 110 patients with knee pain to take chondroitin sulfate or a placebo finding supplementation improved knee function, reduced pain, and maintained joint space in the knee.”\n\n− “Researchers suggested chondroitin sulfate and glucosamine could repair and regenerate cartilage . . .”\n\n− “Hyaluronic Acid (Component of Collagen Type II) [an ingredient in CellRenewPRO and CellRenewSTS] . . . Studies have suggested hyaluronic acid has anti-inflammatory activity that suppresses pro-inflammatory and pain mechanisms in the body.”\n\n− “Researchers found that HA inhibited inflammatory cytokine activity in mice with inflamed joints. A similar study reviewed the effect of HA on acute and chronic inflammation in rats, finding HA suppressed inflammatory reactions . . .”\n\nOn the homepage for the https:\u002F\u002Fappliedhealth.com website:\n\n• “How do you help knee pain? . . . CellRenew PRO is Extreme Knee Protection”\n\n• “CellRenew Additional Links . . . CellRenew Collagen Type II and Knee Pain . . . Is Collagen Type II A Cure For Arthritis And Heart Disease . . .”\n\n• In the response to the question “What is CellRenew?”:\n\n− “Unlike other protocols for arthritis symptoms, whether prescription or natural, CellRenew is guaranteed for results.”\n\n− “It contains naturally occurring Hyaluronic Acid and Chondroitin Sulfate. The results of a human clinical trial using this material showed significant improvements in the reduction of joint swelling, tenderness, and pain, as well as successful increases in mobility.”\n\n• In the response to the question “Who is a good candidate to take CellRenew?”:\n\n− “Although studies have shown that many different conditions respond to Collagen Type II, the conditions that have shown the greatest response are rheumatoid arthritis and osteoarthritis. If you have grown weary of traditional protocols that only cover-up symptoms and neglect to address the root cause, then you are an excellent candidate to begin a program of Collagen Type II.”\n\n− “CellRenew is also used as a preventative measure for athletes who . . . are looking for a way to maintain healthy joints prior to the onset of osteoarthritis.”\n\n• In response to the question “What will it do for me?”:\n\n− “Collagen Type II (CTII) [an ingredient in CellRenewPRO and CellRenewSTS] has been suggested to offer significant benefits for some types of arthritis. . . . Rheumatoid arthritis (RA) is the most well known of the autoimmune types of arthritis. In the case of RA, the collagen in the joints is attacked.”\n\n− “Depending on the particular type of arthritis you experience, CTII goes to work in different ways. If you suffer from RA, CTII acts as an oral tolerization agent, instructing the body to stop the immune response to the collagen in the joints. . . . For those suffering from osteoarthritis, CTII provides the critical building blocks that restore a healthy state to the cartilage in the joints.”\n\n− “CellRenew is made from chicken sternal cartilage that contains the highest level of naturally occurring anti-inflammatory proteoglycans (Hyaluronic Acid and Chondroitin Sulfate A) of any other material tested, including shark cartilage. It is important to note that the combination of the proteoglycans and the Collagen Type II proteins . . . provide the building blocks required to rebuild lost cartilage to restore the joint to a normal state.”\n\n• In response to the question “What do the studies show?”:\n\n− “The results of a recent double-blind, placebo-controlled, clinical trial has proved the benefits of Collagen Type II for treating the symptoms of pain and immobility associated with arthritis. . . . report an 89.9% positive response rate, within 45 days, for the participants who consumed at least 2000 mg of Collagen Type II per day.”\n\n− “[R]eported having successfully treated more than 50 patients, starting in 1974, with osteoarthritis, rheumatoid arthritis, psoriasis, and many other ailments. . . .”\n\n− “Of the different types of cartilage tested, the one with the highest level of Collagen Type II, anti-inflammatory proteoglycans (the healing properties) was chicken sternal cartilage. CellRenew is 100% chicken sternal cartilage.”\n\n• In response to the question “What else is it good for?”:\n\n− “Besides the better-known associations with osteoarthritis and rheumatoid arthritis, it has also been suggested that Collagen Type II might benefit heart disease, psoriasis, progressive myopia, and some other autoimmune diseases.”\n\n• In response to the question “How long before I improve?”:\n\n− “Although some people have noticed an improvement with their symptoms after only a week or two of starting a CellRenew program, many take between 4 and 6 weeks. . . . some forms of arthritis symptoms tend to respond faster – on average – than other forms. For instance, we do know that rheumatoid arthritis sufferers have a tendency to respond faster . . .”\n\nUnder the heading “CellRenew Customer Stories” on the homepage for the https:\u002F\u002Fappliedhealth.com website:\n\n• “‘I have been taking CellRenew since May of 2003. . . . This product has kept my arthritis at bay. . . .’”\n\n• “‘[T]hank you for the dramatic results I have experienced in the first three weeks of taking CellRenew. For the past twenty years, I have been living with severe lower back pain. I was diagnosed with a degenerative disc disorder in the L2, L3, and L4 vertebrae. . . . CellRenew has improved my quality of life one thousand percent.’”\n\n• “‘Fourteen months ago – diagnosed with scoliosis, osteoarthritis of the spine and degenerative disc disease – my active life was gone . . . I was in excruciating pain most of the time. . . . On the xray [sic], my spine looked like a rock pile. . . . Enter CellRenew, and within one month, the improvement was incredible. That was four months ago. . . . I have my life back. I know that CellRenew works!’”\n\n• “‘I wanted to tell you all about how thrilled I am with CellRenew. I have been taking CellRenew for just over a year now. I have not had a single ache or pain in at least 10 months. I have experienced no side effects, except for one good side effect. I have changed my eyeglass prescription, twice! Both times were for the better! My eyesight is improving. . . .’”\n\nUnder the heading “In the beginning…” on the homepage for the https:\u002F\u002Fappliedhealth.com website:\n\n• “Bill Evans, President, Applied Health . . . my lifestyle was finally catching up to me . . . due to rapidly progressing arthritis. . . . Instead of a future filled with the pursuit of my favorite activities, and dreams of conquering the Bucket List, I only saw the prospect of surgeries, painkillers, and physical therapy. I decided there had to be a better way than knee replacement and a cocktail of medications. A year later, in 1997, we started Applied Health and introduced our first Collagen-based, joint support product using hydrolyzed collagen type II . . . We called it CellRenew, and over 20 years later, we still have devoted users . . . [ellipsis in original] myself among them.”\n\nOn the “CellRenew Hydrolyzed Collagen Type II Technical Outline” webpage (https:\u002F\u002Fappliedhealth.com\u002Fcellrenew-collagen-type-ii\u002Fcellrenew-technical-outline\u002F):\n\n• Under the heading “Key Product Highlights\u002FBullets”:\n\n− “CellRenew is so effective that the raw material has been awarded two United States Patents . . . for the treatment of connective tissue disorder, osteoarthritis, degenerative joint disease, joint defects, vascular disease, and cartilage injuries . . .”\n\n− “May help support proper inflammatory function due to its chondroitin sulfate content . . .”\n\n− “May possibly support proper wound healing due to its potent hyaluronic acid content . . .”\n\n• Under the heading “Studies and Mechanisms of action”:\n\n− “CellRenew and its components can have a powerful impact on joints and conditions associated with abnormal joint function. One study [footnote omitted] published in 2000 entitled ‘Role of collagen hydrolysate in bone and joint disease’, reviews how collagen can be a powerful tool in helping with osteoarthritis and even osteoporosis. . . . Mechanism of action: The components of CellRenew . . . lower the chance for deterioration.”\n\n− “‘[H]yaluronan preparations have been shown to decrease pain and increase function in patients with osteoarthritis of the knee.’ Mechanism of action: Hyaluronic Acid seems to work through several mechanisms of action including restoration of more normal synovial fluid with improved viscoelasticity, effects on cartilage biosynthesis and degradation, anti-inflammatory effects, and direct analgesic effects.”\n\n• Under the heading “Patent Claims”:\n\n− “2. A method for treating an individual with a connective tissue disorder . . .”\n\n− “3. The method of claim 2, wherein said connective tissue disorder is selected from the group consisting of degenerative joint diseases, joint defects, osteoarthritis, polychondritis, vascular disease, cartilage injuries, progressive myopia and Menier’s [sic] disease.”\n\nOn the “Effects of Collagen Type II For Subjective Pain Relief” webpage (https:\u002F\u002Fappliedhealth.com\u002Fcellrenew-collagen-type-ii\u002Fhydrolyzed-collagen-clinical-trial\u002F), which contains a hyperlink to the online storefront where the CellRenewPRO and CellRenewSTS products can be purchased:\n\n• The following quote appears after a summary of a study on the effects of Collagen Type II (an ingredient in CellRenewPRO and CellRenewSTS) on the course of pain syndromes, including rheumatoid arthritic pain, osteoarthritis joint pain, post surgical joint pain, post traumatic pain, fibrositis, gouty arthritis, lumbosacral pain with\u002Fwithout radicular pain, and cervical spine pain with\u002Fwithout radicular pain: “‘The results were overwhelmingly positive for pain relief and the side benefits were remarkable! This product has changed my life significantly.’”\n\nOn the “Is Collagen Type II A Cure For Arthritis And Heart Disease?” webpage (https:\u002F\u002Fappliedhealth.com\u002Fcellrenew-collagen-type-ii\u002Fcollagen-type-ii-cure-arthritis-heart-disease\u002F), which hyperlinks to the online storefront where the CellRenewPRO and CellRenewSTS products can be purchased:\n\n• Under the heading “Collagen Type II [an ingredient in CellRenewPRO and CellRenewSTS] and Arthritis”:\n\n− “. . . 50 million Americans suffer from some form of arthritis, either rheumatoid or osteoarthritis, as well as a variety of other arthritic conditions. . . . Could it be that one nutritional medicine called collagen type II can ameliorate both disorders in an effective way?”\n\n− “It may turn out that the natural components of cartilage hold the greatest promise of ameliorating both arthritis and heart disease.”\n\n− “If collagen type II is derived from chicken sternal cartilage, from chicks six to eight weeks old, it contains the greatest number of anti-inflammatory and joint supporting proteoglycans. These proteoglycans include glucosamine sulfate which has over 30 years of double-blind, placebo-controlled studies indicating that it actually helps to rebuild the cartilage in arthritis joints.”\n\n− “[I]t contains a high concentration of chondroitin sulfate A, which is a powerful anti-inflammatory . . .”\n\n− “[C]ollagen type II also contains a powerful, newly discovered antioxidant proteoglycan called cartilage matrix glycoprotein (CMGP), which can help reduce the oxidative damage to the joint.”\n\n− “When people suffer from arthritis, there is a selective destruction of collagen type II in the joint cartilage itself. Scientists know that this particular component of cartilage is being attacked by white blood cells and somehow this activates the immune system in the rheumatoid arthritic patient to develop antibodies to collagen type II. This then sets up an immune response to all of the cartilage that is degenerating in the body. Thus, both wrists hurt, both knees hurt, the hips, the back, etc.”\n\n− “The question now becomes how does collagen type II turn off the immune system in the rheumatoid arthritic. The answer is that collagen type II’s effectiveness is accomplished through ‘oral tolerance.’”\n\n− “. . . investigate the side effects of chicken sternal collagen type II being fed to arthritic rats. . . . By the second or third months the rats no longer displayed any symptoms of arthritis. There was a profound amelioration of the disease.”\n\n− “. . . studied ten people with severe rheumatoid arthritis. They eliminated the standard therapies such as NSAIDS and methotrexate and fed the patients pure collagen type II derived from chicken sternal cartilage. At the end of the second month, six of the ten patients showed substantial improvement and one showed a complete regression of the disease that lasted 26 months with no side effects.”\n\n− “. . . conducted a phase II trial on 59 patients with, again, severe active rheumatoid arthritis. . . . What is interesting is that those who were off all drugs and taking collagen type II showed very significant stabilization and improvement, while those on placebos continued to deteriorate. In fact, four collagen type II patients showed a complete resolution of the disease . . .”\n\n− “We see that oral ingestion of collagen type II may well prove to be the most effective natural means of arthritis management regardless of the form of the disease.”\n\n− “. . . this is precisely why it works in osteoarthritis . . . collagen type II has such a high concentration of glucosamine and chondroitin . . .”\n\n− “In lieu [sic] of the fact that there are no side effects with collagen type II, this would seem to be the product of choice when suffering from any form of arthritic condition.”\n\n− “. . . collagen II components are truly chondro-protective agents because they . . . reprogram destructive chondrocytes and cytokines, reducing inflammation . . . protect the surface of the cartilage from oxidative damage . . . act as a powerful anti-inflammatory and pain modulator.”\n\n• Under the heading “Collagen Type II [an ingredient in CellRenewPRO and CellRenewSTS] and Heart Disease”:\n\n− “Medicines such as aspirin and NSAIDS, as well as natural therapeutics such as fish liver oil or antiarthritic herbs, cannot compete with the overall biochemical power of collagen type II.”\n\n− “. . . collagen type II is 14.2 percent chondroitin sulfate A. . . . Chondroitin sulfate A (CSA) has a powerful antithrombogenic or anticoagulant affect, which, in essence, prevents blood clots and has been shown to reduce the incidence of stroke.”\n\n− “. . . CSA literally reduced the cholesterol and other lipids in the blood and actually ‘cleared’ cholesterol from the lining of arteries, including the aorta.”\n\n− “This indicates a 600 percent reduction in the incidence of fatal heart attacks simply by taking oral CSA on a daily basis . . .”\n\n− “Collagen type II has also found some support in the research for the amelioration of autoimmune disease caused by breast implant poisoning, as well as amelioration of Menier’s [sic] disease and progressive myopia.”\n\nOn the “The Village of Long Life” webpage (https:\u002F\u002Fappliedhealth.com\u002Fcellrenew-collagen-type-ii\u002Fhyaluronic-acid-abc-news\u002F), which hyperlinks to the online storefront where the CellRenewPRO and CellRenewSTS products can be purchased:\n\n• “. . . hyaluronic acid [a component of the Hydrolyzed Collagen II ingredient in the CellRenewPRO and CellRenewSTS products] has been used for years in eye surgery as a shock absorber to protect the retina, and has been proven effective in lubricating arthritic joints.”\n\n• “But HA has been shown to have wound-healing and tissue-reconstruction applications . . .”\n\nOn the “Collagen Type II for Arthritis Pain Relief” blog post (https:\u002F\u002Fappliedhealth.com\u002Fcollagen-type-ii-for-arthritis-pain-relief\u002F):\n\n• “Collagen Type II [an ingredient in the CellRenewPRO and CellRenewSTS products] for Arthritis Pain Relief”\n\n• “Does Collagen Type II relieve osteoarthritis? Research says, yes.”\n\n• “Collagen type II (CTII) is an effective source for alleviating joint stiffness and increasing mobility. Several studies have found CTII reduces joint pain in rheumatoid arthritis, but a new study . . . found that it is also an effective treatment for osteoarthritis.”\n\n• “Researchers recruited 52 subjects with osteoarthritis in the knees to take CTII or a glucosamine\u002Fchondroitin combination for 90 days. . . . Overall, CTII reduced joint pain by 40%.”\n\n• “How does collagen type II alleviate joint pain? CTII is the primary form of collagen naturally found in joint cartilage. The body needs CTII to rebuild connective tissue. Supplementing with a superior form of collagen can help reduce inflammation and the breakdown of collagen in the body. For the best absorption, choose a hydrolyzed collagen type II to restore joint health.”\n\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour Applied Health Solutions brand products B Complex, Daily Detox, CellRenewPRO, CellRenewSTS, and the NutriBiotic brand products Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, the B Complex, Daily Detox, CellRenewPRO, CellRenewSTS, Grapefruit Seed Extract CapsulesPlus, and Grapefruit Seed Extract Liquid Concentrate products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to the following address: 6th Ave and Kipling St, DFC Bldg. 20, PO Box 25087, Denver, Colorado, 80225-0087, to the attention of Compliance Officer Carrie Jolly or by email to carrie.jolly@fda.hhs.gov. If you need additional information or have questions concerning any products distributed through your website, please contact CO Jolly at carrie.jolly@fda.hhs.gov or (303) 236-9656.\n\nSincerely,\n\n\u002FS\u002F\n\nE. Mark Harris\n\nDenver District Director & Program Division Director\n\nOffice of Human and Animal Food Operations −\n\nDivision IV West","Applied Health Solutions, Inc.","applied-health-solutions-inc-616778-10222021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fapplied-health-solutions-inc-616778-10222021","2026-10-26T08:07:56.864908+00:00","2022-02-01","616778","William Evans","2026-08-20T02:12:48.529+00:00","2021-10-22",{"id":294,"raw":295,"subject":299,"body_html":300,"body_text":301,"firm_name":302,"letter_id":303,"created_at":304,"fei_number":19,"letter_url":305,"updated_at":306,"action_type":22,"case_status":23,"posted_date":307,"marcs_cms_no":308,"product_type":309,"closeout_date":19,"issuing_office":59,"recipient_name":310,"body_fetched_at":311,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":312,"medical_device_id":19,"response_letter_date":19},3595,[296,297,298,59,299,13,13,13],"\u003Ctime datetime=\"2026-08-18T04:00:00Z\">08\u002F18\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-07-24T04:00:00Z\">07\u002F24\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnipro-renal-solutions-usa-corporation-732874-07242026\"> Nipro Renal Solutions USA, Corporation \u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n                          \u003Cbr>UDI\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Tsuyoshi Yamazaki\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd> Nipro Renal Solutions USA, Corporation \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>509 Fishing Creek Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lewisberry\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>17339\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 732874\u003C\u002Fp>\u003Cp>July 16, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Yamazaki:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Lewisberry, PA from February 2, 2026 through March 27, 2026, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures dry and liquid hemodialysis dialysate concentrate solutions. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality Management System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality Management System Regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received responses from Rachael Nelsen, Vice President of Quality Affairs &amp; Regulatory Affairs, dated April 17, 2026 and May 29, 2026, and from Vikram Chandra, Senior Vice President of Quality Affairs &amp; Regulatory Affairs, dated July 14, 2026 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to ensure that product which does not conform to product requirements is identified and controlled to prevent its unintended use or delivery; and failure to document a procedure defining the controls and related responsibilities and authorities for the identification, documentation, segregation, evaluation, and disposition of nonconforming product, as required by ISO 13485:2016, Clause 8.3.1. Specifically,\u003C\u002Fp>\u003Cp>a. Your firm released and distributed finished hemodialysis products with out-of-specification (OOS) endotoxin results on multiple occasions. Specifically, your firm released the following lots of products despite your Laboratory Report Forms (DMR 5404) incorrectly indicated that endotoxin LAL testing had 'Passed,' and the Finished Product Packet (SOP QSM012; Effective Date 04\u002F28\u002F23) contained Quality's signed acceptance of each lot, despite each example exceeding the \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002FmL endotoxin specification:\u003C\u002Fp>\u003Cul>\u003Cli>On May 6, 2025, MedicaLyte Bicarbonate Powder (45X), Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> (expiration 04\u002F30\u002F2027), was released with an endotoxin result of \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002FmL\u003C\u002Fli>\u003Cli>On December 18, 2025, MedicaLyte Bicarbonate Powder (DB+201-25), Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> (expiration 12\u002F05\u002F2027), was released with an endotoxin result of \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002FmL\u003C\u002Fli>\u003Cli>On May 22, 2025, Citric Complete Dry Citric Acid Concentrate, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> (expiration 05\u002F19\u002F2027), was released with an endotoxin result of \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002FmL\u003C\u002Fli>\u003C\u002Ful>\u003Cp>b. Your firm's Investigations procedure (NRSU-SOP-0060, Revision 02, Effective Date December 8, 2025) and the Endotoxin Analysis work instruction (NRSU-WI-0061, Revision 02, Effective Date October 31, 2025, and Revision 01, Effective Date August 25, 2025) define processes for investigating OOS results. Section 7.2 of NRSU-SOP-0060 requires a MasterControl form for each investigation initiated for OOS results and issues found during production. However, an OOS log for January 2025 through February 2026, generated at investigators' request during the inspection, revealed thirteen product-related endotoxin failures and \u003Cstrong>(b)(4)\u003C\u002Fstrong> endotoxin failures for which your firm was unable to provide any documented investigation or nonconformance documentation.\u003C\u002Fp>\u003Cp>We reviewed your firm's responses and conclude that they are not adequate. Your firm provided Health Hazard Assessments (NRSU-RPT-0028 Rev 02 and NRSU-RPT-0045) asserting that retain samples of the above lots yielded compliant endotoxin results, and therefore no field action or customer notification is warranted, attributing the OOS documentation to documentation errors. However, retesting of retain samples is not an appropriate justification for not performing a field action or customer notification when the original test results demonstrated product with endotoxin test results exceeding specification. Furthermore, our Agency has reviewed these results and your firm’s response (including the Health Hazard Assessment and Customer Notification Determination) and has determined that these lots of products with endotoxin levels higher than specification may cause a risk to health, namely \u003Cstrong>(b)(4)\u003C\u002Fstrong> reactions. In your response, please provide what your firm’s planned action(s) are related to these adulterated, released lots of products.&nbsp;\u003C\u002Fp>\u003Cp>Additionally, your firm initiated CAPAs 26004 and 26005, with promised corrective actions including revisions to NRSU-SOP-0060 to establish clear, enforceable, and risk-based criteria for investigation initiation and escalation across all applicable quality events — including laboratory OOS results, \u003Cstrong>(b)(4)\u003C\u002Fstrong> and utility monitoring failures, and nonconforming product. However, these items remain in progress as of your July 14, 2026 response. In response to this letter, provide documentation for any outstanding corrective actions, including verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\u003C\u002Fp>\u003Cp>2. Failure to take action to eliminate the cause of nonconformities in order to prevent recurrence, failure to take any necessary corrective actions without undue delay, and failure to take corrective actions proportionate to the effects of the nonconformities encountered, as required by ISO 13485:2016, Clause 8.5.2.\u003C\u002Fp>\u003Cp>Specifically, your firm's Corrective and Preventive Action (CAPA) procedure (NRSU-SOP-0059, Revision 01, Effective Date 10\u002F08\u002F2024) has not been fully implemented in that corrective actions have not been proportionate to the effects of the nonconformities encountered, have not been taken without undue delay, and have not prevented recurrence of nonconformities. For example:\u003C\u002Fp>\u003Cul>\u003Cli>CAPA-25012 (initiated June 13, 2025, for endotoxin documentation failures) was found to be ineffective when your firm discovered that Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, MedicaLyte Bicarbonate Powder (DB+201-25), was released with an OOS endotoxin result after corrective actions had been implemented, demonstrating recurrence of the nonconformance.\u003C\u002Fli>\u003Cli>CAPA-25014 (initiated August 4, 2025 to address facility and equipment maintenance deficiencies including corrosion, contamination, and poor environmental controls in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> room) was extended on January 19, 2026, to a revised due date of March 30, 2026. Despite this, during a facility tour on February 13, 2026 (\u003Cstrong>(b)(4)\u003C\u002Fstrong> days after CAPA initiation), product residue was observed to be accumulated on and suspended from bottle filling machine nozzles, demonstrating that necessary corrective actions had not been taken without undue delay.\u003C\u002Fli>\u003Cli>CAPA-25005 (initiated May 22, 2025, for failing to follow the Monitoring Production Systems procedure) had a corrective action expected completion date of April 9, 2026 which is approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> days from initiation. Despite this, review of quality packets from September 2025, November 2025, and January 2026 during the inspection found that maintenance, sanitization, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring forms continued to be missing and\u002For incomplete, demonstrating that necessary corrective actions had not been taken without undue delay.\u003C\u002Fli>\u003Cli>CAPA-25010 (initiated June 4, 2025, for failure to follow and perform sampling of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system per NRSU-SOP-0039) corrective actions were completed on January 6, 2026. However, inspection review of January 2026 \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring records revealed that multiple sample port tests and \u003Cstrong>(b)(4)\u003C\u002Fstrong> had not been conducted for colony count and endotoxin monitoring without any documented justification, demonstrating that your firm failed to eliminate the cause of nonconformities to prevent recurrence.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The adequacy of your firm's responses cannot be determined at this time. Your firm stated that CAPAs 25005, 25010, 25014, and 25015 had all been initiated prior to the current FDA inspection. Your firm's response promises revisions to NRSU-SOP-0059, implementation of a CAPA tracking system, and training for applicable personnel, with a target completion date of August 7, 2026. CAPA-25015, which directly addresses your CAPA process itself, remains open. None of the underlying nonconformances addressed by the above CAPAs have been resolved, and all remain ongoing or have reoccurred. In response to this letter provide documentation for any status updates for the outstanding corrective actions, including verification of effectiveness, when completed. If corrective actions are not complete, provide a timeframe for completion.\u003C\u002Fp>\u003Cp>3. Failure to document procedures for design and development, as required by ISO 13485:2016, Clause 7.3.1.\u003C\u002Fp>\u003Cp>Specifically, although your firm maintains procedure NRSU-SOP-0018, Design Control (Revision 00, Effective Date 05\u002F01\u002F2020), and your Quality Manual (NRSU-MAN-0001, Revision 01, Effective Date 04\u002F21\u002F2025) describe design and development requirements including design and development planning, design input, design output, design review, design verification and validation, design transfer, design changes, and design history file your firm was unable to produce any records during the inspection demonstrating that any of your six marketed devices were developed in accordance with Clause 7.3, No design and development files have been maintained for your six products cleared under K223431, K193155, K171750, K012547, K131202, or K901471.\u003C\u002Fp>\u003Cp>The adequacy of your firm's responses cannot be determined at this time. Your firm initiated CAPA-25026 which commits to performing a DHF Gap Assessment and Reconstruction Program, with a gap assessment completion targeted for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and remediation timelines to be established thereafter. However, these items remain in progress as of your July 14, 2026 response. In response to this letter provide documentation for any outstanding corrective actions, including CAPA verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\u003C\u002Fp>\u003Cp>4. Failure to document procedures to control design and development changes, as required by ISO 13485:2016, Clause 7.3.9.\u003C\u002Fp>\u003Cp>Specifically, your firm's design control procedure, NRSU-SOP-0018 (Revision 00, Effective Date 05\u002F01\u002F2020), does not include a design change process, and instead references your change control procedure NRSU-SOP-0019. However, NRSU-SOP-0019 does not include a requirement for evaluation of the effect of the changes on constituent parts and product in process or already delivered, including inputs and outputs of risk management and product realization processes, such as design and development verification and validation activities. The following design changes were implemented without the required design and development change records, risk analyses, or documented impact assessments:\u003C\u002Fp>\u003Cul>\u003Cli>Transition from \u003Cstrong>(b)(4)\u003C\u002Fstrong> packaging for the dry product lines in September 2023\u003C\u002Fli>\u003Cli>Change in the thickness of the primary packaging film from \u003Cstrong>(b)(4)\u003C\u002Fstrong> for both dry product lines in September 2023\u003C\u002Fli>\u003Cli>Change of the endotoxin level specification from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002FmL to \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002FmL for the Liquid Citric Acid Concentrate LC 228 (45x) in March 2025\u003C\u002Fli>\u003Cli>Change of the endotoxin level specification from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002FmL to \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002FmL for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Liquid Acidic Concentrate products in March 2025\u003C\u002Fli>\u003Cli>Change of the endotoxin level specification from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002FmL to \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002FmL for the Liquid Acidic Concentrate AC 213 (45x) in April 2025\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The adequacy of your firm's responses cannot be determined at this time. Your firm initiated CAPA-25026, which promises retrospective design change impact assessments, initiation of change records, revision to NRSU-SOP-0018 (targeted completion July 31, 2026), and revision to NRSU-SOP-0019 (targeted completion October 31, 2026). In response to this letter provide documentation for any outstanding corrective actions, including CAPA verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\u003C\u002Fp>\u003Cp>5. Failure to document the requirements for infrastructure needed to achieve conformity to product requirements, prevent product mix-up, and ensure orderly handling of product, as required by ISO 13485:2016, Clause 6.3.\u003C\u002Fp>\u003Cp>Specifically, your firm has failed to perform maintenance on buildings, workspaces, associated utilities as well as process equipment as required by Clause 6.3(a) and (b). Your procedures NRSU-SOP-0037 'Monitoring Production Systems' (Revision 00, Effective Date 04\u002F13\u002F2020) and NRSU-WI-0040 'Operation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> System' (Revision 00, Effective Date 03\u002F30\u002F2020) govern operation and maintenance of production systems, including the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system and bottle filling equipment. During a facility walkthrough on February 13, 2026, our investigator observed multiple pipes leaking in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system. Your firm was unable to provide any documentation related to these leaks, including repairs made, corrective actions taken, or an assessment of the impact of these leaks and repairs on \u003Cstrong>(b)(4)\u003C\u002Fstrong> functionality and continued conformity to requirements.\u003C\u002Fp>\u003Cp>Additionally, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> (serial number \u003Cstrong>(b)(4)\u003C\u002Fstrong>) is the only instrument used for endotoxin testing including \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring and final product acceptance. Your firm was unable to provide records demonstrating that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> had been changed or that preventive maintenance had ever been performed for this instrument, despite Section 7 of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Operator Manual (Revision A, 2025) requiring \u003Cstrong>(b)(4)\u003C\u002Fstrong> replacement and recommended \u003Cstrong>(b)(4)\u003C\u002Fstrong> service intervals.\u003C\u002Fp>\u003Cp>We reviewed your firm's responses and conclude that they are not adequate. Your firm initiated CAPA-25027, which promises implementation of a validated \u003Cstrong>(b)(4)\u003C\u002Fstrong> through multiple phases with a target completion date of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and an assessment to identify infrastructure with overdue or incomplete maintenance, calibration, or validation activities by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your firm's responses do not specifically address any corrections or corrective actions planned for the numerous pipe leaks observed, including repairs planned or made or an assessment of the impact on product quality. In addition, provide any documentation for the outstanding corrective actions, including verification of effectiveness. If corrective actions will not be complete, provide a timeframe for completion.\u003C\u002Fp>\u003Cp>6. Failure to perform calibration or verification of measuring equipment in accordance with documented procedures, as required by ISO 13485:2016, Clause 7.6.\u003C\u002Fp>\u003Cp>Specifically, your firm's calibration work instruction NRSU-WI-0012 'Calibrations' (Revision 00, Effective Date 04\u002F10\u002F2020) has not been implemented. For example, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> (serial number \u003Cstrong>(b)(4)\u003C\u002Fstrong>) is the sole instrument used for endotoxin testing for both \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring and final product release across all product lines. Despite being in use since December 18, 2023, this instrument has never been calibrated, and a calibration schedule has never been established. Furthermore, your firm's work instruction NRSU-WI-0061 (Revision 03, Effective Date 12\u002F03\u002F2025) required \u003Cstrong>(b)(4)\u003C\u002Fstrong> calibration reports; however, no reports were provided.\u003C\u002Fp>\u003Cp>We reviewed your firm's responses and conclude that they are not adequate. While we acknowledge your firm initiated CAPA-25027, which promises implementation of a validated \u003Cstrong>(b)(4)\u003C\u002Fstrong> with planned completion by \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and an infrastructure\u002Fmaintenance assessment by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm has not provided a plan to assess the validity of previous test results obtained using the uncalibrated \u003Cstrong>(b)(4)\u003C\u002Fstrong>, nor any proposed action for product previously released based on those results. In response to this letter provide any planned evaluation and assessment related to results obtained from this uncalibrated instrument as well as documentation for any other outstanding corrective actions, including verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\u003C\u002Fp>\u003Cp>7. Failure to document procedures for validation of processes for production and service provisions, as required by ISO 13485:2016, Clause 7.5.6.\u003C\u002Fp>\u003Cp>Specifically, your firm does not have a documented procedure for validation of processes for production equipment. Your work instruction NRSU-WI-0029 'Validated Systems and Equipment Change' (Revision 00, Effective Date 07\u002F12\u002F2021), was provided as the sole document governing validation. This work instruction does not include all the requirements found within sections a) through g) of Clause 7.5.6.\u003C\u002Fp>\u003Cp>Additionally, your firm was unable to provide documentation that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> (serial number \u003Cstrong>(b)(4)\u003C\u002Fstrong>), which is used for endotoxin monitoring of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and final product release was validated as the only document provided was a combined Installation, Operational, and Performance Qualification (IOPQ) test results from December 15 and 18, 2023. This document only provides testing results for products with an endotoxin specification of \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002FmL. The following endotoxin testing applications performed routinely by your firm were not included in this IOPQ document and have not been adequately validated:\u003C\u002Fp>\u003Cul>\u003Cli>Endotoxin testing of all liquid product lines (Liquid Acidic Concentrate, Liquid Citric Acid Concentrate, and Liquid Sodium Bicarbonate Hemodialysis Solution)\u003C\u002Fli>\u003Cli>The retesting procedure for endotoxin results found to be out-of-specification.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. Your firm initiated CAPA-25002 prior to the current inspection and completed additional performance qualification (PQ) activities for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> instrument, which were provided in your July 14, 2026 response. However, this additional PQ (NRSU-VAL-0153 Addendum 1) was limited to your Liquid Acetic Acid products. In response to this letter provide any PQ activities for your other product lines as well as documentation for any other outstanding corrective actions, including verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\u003C\u002Fp>\u003Cp>8. Failure to document one or more processes for risk management in product realization, as required by ISO 13485:2016, Clause 7.1.\u003C\u002Fp>\u003Cp>Specifically, your firm has not established a systematic, documented, risk-based approach to identifying, evaluating, and controlling risks associated with product realization processes. For example, your firm does not have policies, procedures, or practices for overall risk management, design risk analysis, or process risk analysis with requirements for continual evaluation and updates. Your firm maintains risk analysis reports for each of its products; however, these reports have not been updated since their initial creation. For example, the risk analysis for MedicaLyte Liquid Bicarbonate (NRSU-RPT-0004, Effective Date 11\u002F13\u002F2020) states that all risks are either negligible or acceptable. Despite an ongoing Class I Recall (Z-1730-2025 \u002F RES 96646) of MedicaLyte Liquid Bicarbonate Concentrate initiated April 11, 2025, due to microbial and fungal contamination, the risk analysis for this product has not been updated since November 13, 2020. Your firm's design control procedure NRSU-SOP-0018 (Revision 00, Effective Date 05\u002F01\u002F2020) requires updates to risk management documentation when known and potential hazards are identified.\u003C\u002Fp>\u003Cp>The adequacy of your firm's responses cannot be determined at this time. Your firm initiated CAPA-25006 prior to the current inspection with plans to develop a risk management SOP, review and revise existing product and process risk analysis reports once the new SOP is implemented, and train affected staff, with a target completion date of October 31, 2026. In response to this letter provide documentation for any outstanding corrective actions, including verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\u003C\u002Fp>\u003Cp>9. Failure to monitor supplier performance in meeting requirements for purchased product, as required by ISO 13485:2016, Clause 7.4.1.\u003C\u002Fp>\u003Cp>Specifically, your firm's supplier management procedure (NRSU-SOP-0022, Revision 04, Effective Date December 2, 2025) documents your process for classification and evaluation of suppliers. However, your firm was unable to provide any records demonstrating that suppliers and services had ever been classified or evaluated in accordance with this procedure.\u003C\u002Fp>\u003Cp>The adequacy of your firm's responses cannot be determined at this time. Your firm initiated CAPA-25024 prior to the current FDA inspection and has taken immediate corrections by reviewing and updating the approved supplier list (ASL) and increasing supplier oversight until evaluations and\u002For audits are completed. Corrective actions planned include revision of the supplier management SOP, strengthening supplier audit controls, improvements to the SCAR process, and implementation of quality agreements for all Level I (\u003Cstrong>(b)(4)\u003C\u002Fstrong> risk) suppliers, with a target completion date of November 20, 2026. However, several of these items remain in progress as of your July 14, 2026 response. In response to this letter provide documentation for any outstanding corrective actions, including verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unique Device Identification Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>The inspection revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a), which was promulgated under authority of section 519 of the Act, among other provisions, requires, with exceptions not relevant here, that the label of every medical device bears a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the Nipro Dry complete dry acid concentrate for hemodialysis devices do not bear such a UDI. For example, the labels for these devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, there is no UDI presented in easily readable plain-text (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses automatic identification and data capture (AIDC) technology (see 21 CFR 801.40(a)(2)).\u003C\u002Fp>\u003Cp>In addition, the Nipro Dry complete dry acid concentrate for hemodialysis is misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting the devices. In particular, 21 CFR 830.300(a) and 830.320(b), both of which were promulgated under section 519 of the Act, among other provisions, require, with exceptions not relevant here, that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. Your firm is a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting these devices.\u003C\u002Fp>\u003Cp>The failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B). Based on review of the Global Unique Device Identification Database (GUDID) on June 11, 2026, there are no entries for Nipro Dry complete dry acid concentrate for hemodialysis.\u003C\u002Fp>\u003Cp>A follow up inspection will be required to ensure that corrections and\u002For corrective actions are adequate.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality Management System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Establishment Assessment Team 1 Assistant Director Gina Brackett at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 732874” when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan at sean.moynihan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>CAPT Cesar A. Perez, PhD, USPHS\u003Cbr>Acting Deputy Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>Cc: Vikram Chandra, Sr. VP QA\u002FRA - Nipro Americas Group Companies, Inc., Vikram.Chandra@nipromed.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nUDI\n\nRecipient:\n\nRecipient Name\n\nTsuyoshi Yamazaki\n\nRecipient Title\n\nPresident\n\nNipro Renal Solutions USA, Corporation\n\n509 Fishing Creek Road\n\nLewisberry, PA 17339\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\nCMS # 732874\nJuly 16, 2026\nDear Mr. Yamazaki:\nDuring an inspection of your firm located in Lewisberry, PA from February 2, 2026 through March 27, 2026, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures dry and liquid hemodialysis dialysate concentrate solutions. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality Management System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality Management System Regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received responses from Rachael Nelsen, Vice President of Quality Affairs & Regulatory Affairs, dated April 17, 2026 and May 29, 2026, and from Vikram Chandra, Senior Vice President of Quality Affairs & Regulatory Affairs, dated July 14, 2026 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to ensure that product which does not conform to product requirements is identified and controlled to prevent its unintended use or delivery; and failure to document a procedure defining the controls and related responsibilities and authorities for the identification, documentation, segregation, evaluation, and disposition of nonconforming product, as required by ISO 13485:2016, Clause 8.3.1. Specifically,\na. Your firm released and distributed finished hemodialysis products with out-of-specification (OOS) endotoxin results on multiple occasions. Specifically, your firm released the following lots of products despite your Laboratory Report Forms (DMR 5404) incorrectly indicated that endotoxin LAL testing had 'Passed,' and the Finished Product Packet (SOP QSM012; Effective Date 04\u002F28\u002F23) contained Quality's signed acceptance of each lot, despite each example exceeding the (b)(4)\u002FmL endotoxin specification:\nOn May 6, 2025, MedicaLyte Bicarbonate Powder (45X), Lot (b)(4) (expiration 04\u002F30\u002F2027), was released with an endotoxin result of (b)(4)\u002FmL\nOn December 18, 2025, MedicaLyte Bicarbonate Powder (DB+201-25), Lot (b)(4) (expiration 12\u002F05\u002F2027), was released with an endotoxin result of (b)(4)\u002FmL\nOn May 22, 2025, Citric Complete Dry Citric Acid Concentrate, Lot (b)(4) (expiration 05\u002F19\u002F2027), was released with an endotoxin result of (b)(4)\u002FmL\nb. Your firm's Investigations procedure (NRSU-SOP-0060, Revision 02, Effective Date December 8, 2025) and the Endotoxin Analysis work instruction (NRSU-WI-0061, Revision 02, Effective Date October 31, 2025, and Revision 01, Effective Date August 25, 2025) define processes for investigating OOS results. Section 7.2 of NRSU-SOP-0060 requires a MasterControl form for each investigation initiated for OOS results and issues found during production. However, an OOS log for January 2025 through February 2026, generated at investigators' request during the inspection, revealed thirteen product-related endotoxin failures and (b)(4) endotoxin failures for which your firm was unable to provide any documented investigation or nonconformance documentation.\nWe reviewed your firm's responses and conclude that they are not adequate. Your firm provided Health Hazard Assessments (NRSU-RPT-0028 Rev 02 and NRSU-RPT-0045) asserting that retain samples of the above lots yielded compliant endotoxin results, and therefore no field action or customer notification is warranted, attributing the OOS documentation to documentation errors. However, retesting of retain samples is not an appropriate justification for not performing a field action or customer notification when the original test results demonstrated product with endotoxin test results exceeding specification. Furthermore, our Agency has reviewed these results and your firm’s response (including the Health Hazard Assessment and Customer Notification Determination) and has determined that these lots of products with endotoxin levels higher than specification may cause a risk to health, namely (b)(4) reactions. In your response, please provide what your firm’s planned action(s) are related to these adulterated, released lots of products.\nAdditionally, your firm initiated CAPAs 26004 and 26005, with promised corrective actions including revisions to NRSU-SOP-0060 to establish clear, enforceable, and risk-based criteria for investigation initiation and escalation across all applicable quality events — including laboratory OOS results, (b)(4) and utility monitoring failures, and nonconforming product. However, these items remain in progress as of your July 14, 2026 response. In response to this letter, provide documentation for any outstanding corrective actions, including verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\n2. Failure to take action to eliminate the cause of nonconformities in order to prevent recurrence, failure to take any necessary corrective actions without undue delay, and failure to take corrective actions proportionate to the effects of the nonconformities encountered, as required by ISO 13485:2016, Clause 8.5.2.\nSpecifically, your firm's Corrective and Preventive Action (CAPA) procedure (NRSU-SOP-0059, Revision 01, Effective Date 10\u002F08\u002F2024) has not been fully implemented in that corrective actions have not been proportionate to the effects of the nonconformities encountered, have not been taken without undue delay, and have not prevented recurrence of nonconformities. For example:\nCAPA-25012 (initiated June 13, 2025, for endotoxin documentation failures) was found to be ineffective when your firm discovered that Lot (b)(4), MedicaLyte Bicarbonate Powder (DB+201-25), was released with an OOS endotoxin result after corrective actions had been implemented, demonstrating recurrence of the nonconformance.\nCAPA-25014 (initiated August 4, 2025 to address facility and equipment maintenance deficiencies including corrosion, contamination, and poor environmental controls in the (b)(4) room) was extended on January 19, 2026, to a revised due date of March 30, 2026. Despite this, during a facility tour on February 13, 2026 ((b)(4) days after CAPA initiation), product residue was observed to be accumulated on and suspended from bottle filling machine nozzles, demonstrating that necessary corrective actions had not been taken without undue delay.\nCAPA-25005 (initiated May 22, 2025, for failing to follow the Monitoring Production Systems procedure) had a corrective action expected completion date of April 9, 2026 which is approximately (b)(4) days from initiation. Despite this, review of quality packets from September 2025, November 2025, and January 2026 during the inspection found that maintenance, sanitization, and (b)(4) monitoring forms continued to be missing and\u002For incomplete, demonstrating that necessary corrective actions had not been taken without undue delay.\nCAPA-25010 (initiated June 4, 2025, for failure to follow and perform sampling of the (b)(4) system per NRSU-SOP-0039) corrective actions were completed on January 6, 2026. However, inspection review of January 2026 (b)(4) monitoring records revealed that multiple sample port tests and (b)(4) had not been conducted for colony count and endotoxin monitoring without any documented justification, demonstrating that your firm failed to eliminate the cause of nonconformities to prevent recurrence.\nThe adequacy of your firm's responses cannot be determined at this time. Your firm stated that CAPAs 25005, 25010, 25014, and 25015 had all been initiated prior to the current FDA inspection. Your firm's response promises revisions to NRSU-SOP-0059, implementation of a CAPA tracking system, and training for applicable personnel, with a target completion date of August 7, 2026. CAPA-25015, which directly addresses your CAPA process itself, remains open. None of the underlying nonconformances addressed by the above CAPAs have been resolved, and all remain ongoing or have reoccurred. In response to this letter provide documentation for any status updates for the outstanding corrective actions, including verification of effectiveness, when completed. If corrective actions are not complete, provide a timeframe for completion.\n3. Failure to document procedures for design and development, as required by ISO 13485:2016, Clause 7.3.1.\nSpecifically, although your firm maintains procedure NRSU-SOP-0018, Design Control (Revision 00, Effective Date 05\u002F01\u002F2020), and your Quality Manual (NRSU-MAN-0001, Revision 01, Effective Date 04\u002F21\u002F2025) describe design and development requirements including design and development planning, design input, design output, design review, design verification and validation, design transfer, design changes, and design history file your firm was unable to produce any records during the inspection demonstrating that any of your six marketed devices were developed in accordance with Clause 7.3, No design and development files have been maintained for your six products cleared under K223431, K193155, K171750, K012547, K131202, or K901471.\nThe adequacy of your firm's responses cannot be determined at this time. Your firm initiated CAPA-25026 which commits to performing a DHF Gap Assessment and Reconstruction Program, with a gap assessment completion targeted for (b)(4), and remediation timelines to be established thereafter. However, these items remain in progress as of your July 14, 2026 response. In response to this letter provide documentation for any outstanding corrective actions, including CAPA verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\n4. Failure to document procedures to control design and development changes, as required by ISO 13485:2016, Clause 7.3.9.\nSpecifically, your firm's design control procedure, NRSU-SOP-0018 (Revision 00, Effective Date 05\u002F01\u002F2020), does not include a design change process, and instead references your change control procedure NRSU-SOP-0019. However, NRSU-SOP-0019 does not include a requirement for evaluation of the effect of the changes on constituent parts and product in process or already delivered, including inputs and outputs of risk management and product realization processes, such as design and development verification and validation activities. The following design changes were implemented without the required design and development change records, risk analyses, or documented impact assessments:\nTransition from (b)(4) packaging for the dry product lines in September 2023\nChange in the thickness of the primary packaging film from (b)(4) for both dry product lines in September 2023\nChange of the endotoxin level specification from (b)(4)\u002FmL to (b)(4)\u002FmL for the Liquid Citric Acid Concentrate LC 228 (45x) in March 2025\nChange of the endotoxin level specification from (b)(4)\u002FmL to (b)(4)\u002FmL for (b)(4) Liquid Acidic Concentrate products in March 2025\nChange of the endotoxin level specification from (b)(4)\u002FmL to (b)(4)\u002FmL for the Liquid Acidic Concentrate AC 213 (45x) in April 2025\nThe adequacy of your firm's responses cannot be determined at this time. Your firm initiated CAPA-25026, which promises retrospective design change impact assessments, initiation of change records, revision to NRSU-SOP-0018 (targeted completion July 31, 2026), and revision to NRSU-SOP-0019 (targeted completion October 31, 2026). In response to this letter provide documentation for any outstanding corrective actions, including CAPA verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\n5. Failure to document the requirements for infrastructure needed to achieve conformity to product requirements, prevent product mix-up, and ensure orderly handling of product, as required by ISO 13485:2016, Clause 6.3.\nSpecifically, your firm has failed to perform maintenance on buildings, workspaces, associated utilities as well as process equipment as required by Clause 6.3(a) and (b). Your procedures NRSU-SOP-0037 'Monitoring Production Systems' (Revision 00, Effective Date 04\u002F13\u002F2020) and NRSU-WI-0040 'Operation of the (b)(4) System' (Revision 00, Effective Date 03\u002F30\u002F2020) govern operation and maintenance of production systems, including the (b)(4) system and bottle filling equipment. During a facility walkthrough on February 13, 2026, our investigator observed multiple pipes leaking in the (b)(4) system. Your firm was unable to provide any documentation related to these leaks, including repairs made, corrective actions taken, or an assessment of the impact of these leaks and repairs on (b)(4) functionality and continued conformity to requirements.\nAdditionally, the (b)(4) (serial number (b)(4)) is the only instrument used for endotoxin testing including (b)(4) monitoring and final product acceptance. Your firm was unable to provide records demonstrating that the (b)(4) had been changed or that preventive maintenance had ever been performed for this instrument, despite Section 7 of the (b)(4) Operator Manual (Revision A, 2025) requiring (b)(4) replacement and recommended (b)(4) service intervals.\nWe reviewed your firm's responses and conclude that they are not adequate. Your firm initiated CAPA-25027, which promises implementation of a validated (b)(4) through multiple phases with a target completion date of (b)(4), and an assessment to identify infrastructure with overdue or incomplete maintenance, calibration, or validation activities by (b)(4). However, your firm's responses do not specifically address any corrections or corrective actions planned for the numerous pipe leaks observed, including repairs planned or made or an assessment of the impact on product quality. In addition, provide any documentation for the outstanding corrective actions, including verification of effectiveness. If corrective actions will not be complete, provide a timeframe for completion.\n6. Failure to perform calibration or verification of measuring equipment in accordance with documented procedures, as required by ISO 13485:2016, Clause 7.6.\nSpecifically, your firm's calibration work instruction NRSU-WI-0012 'Calibrations' (Revision 00, Effective Date 04\u002F10\u002F2020) has not been implemented. For example, the (b)(4) (serial number (b)(4)) is the sole instrument used for endotoxin testing for both (b)(4) monitoring and final product release across all product lines. Despite being in use since December 18, 2023, this instrument has never been calibrated, and a calibration schedule has never been established. Furthermore, your firm's work instruction NRSU-WI-0061 (Revision 03, Effective Date 12\u002F03\u002F2025) required (b)(4) calibration reports; however, no reports were provided.\nWe reviewed your firm's responses and conclude that they are not adequate. While we acknowledge your firm initiated CAPA-25027, which promises implementation of a validated (b)(4) with planned completion by (b)(4), and an infrastructure\u002Fmaintenance assessment by (b)(4). Your firm has not provided a plan to assess the validity of previous test results obtained using the uncalibrated (b)(4), nor any proposed action for product previously released based on those results. In response to this letter provide any planned evaluation and assessment related to results obtained from this uncalibrated instrument as well as documentation for any other outstanding corrective actions, including verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\n7. Failure to document procedures for validation of processes for production and service provisions, as required by ISO 13485:2016, Clause 7.5.6.\nSpecifically, your firm does not have a documented procedure for validation of processes for production equipment. Your work instruction NRSU-WI-0029 'Validated Systems and Equipment Change' (Revision 00, Effective Date 07\u002F12\u002F2021), was provided as the sole document governing validation. This work instruction does not include all the requirements found within sections a) through g) of Clause 7.5.6.\nAdditionally, your firm was unable to provide documentation that your (b)(4) (serial number (b)(4)), which is used for endotoxin monitoring of (b)(4) and final product release was validated as the only document provided was a combined Installation, Operational, and Performance Qualification (IOPQ) test results from December 15 and 18, 2023. This document only provides testing results for products with an endotoxin specification of (b)(4)\u002FmL. The following endotoxin testing applications performed routinely by your firm were not included in this IOPQ document and have not been adequately validated:\nEndotoxin testing of all liquid product lines (Liquid Acidic Concentrate, Liquid Citric Acid Concentrate, and Liquid Sodium Bicarbonate Hemodialysis Solution)\nThe retesting procedure for endotoxin results found to be out-of-specification.\nWe reviewed your firm’s responses and conclude that they are not adequate. Your firm initiated CAPA-25002 prior to the current inspection and completed additional performance qualification (PQ) activities for the (b)(4) instrument, which were provided in your July 14, 2026 response. However, this additional PQ (NRSU-VAL-0153 Addendum 1) was limited to your Liquid Acetic Acid products. In response to this letter provide any PQ activities for your other product lines as well as documentation for any other outstanding corrective actions, including verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\n8. Failure to document one or more processes for risk management in product realization, as required by ISO 13485:2016, Clause 7.1.\nSpecifically, your firm has not established a systematic, documented, risk-based approach to identifying, evaluating, and controlling risks associated with product realization processes. For example, your firm does not have policies, procedures, or practices for overall risk management, design risk analysis, or process risk analysis with requirements for continual evaluation and updates. Your firm maintains risk analysis reports for each of its products; however, these reports have not been updated since their initial creation. For example, the risk analysis for MedicaLyte Liquid Bicarbonate (NRSU-RPT-0004, Effective Date 11\u002F13\u002F2020) states that all risks are either negligible or acceptable. Despite an ongoing Class I Recall (Z-1730-2025 \u002F RES 96646) of MedicaLyte Liquid Bicarbonate Concentrate initiated April 11, 2025, due to microbial and fungal contamination, the risk analysis for this product has not been updated since November 13, 2020. Your firm's design control procedure NRSU-SOP-0018 (Revision 00, Effective Date 05\u002F01\u002F2020) requires updates to risk management documentation when known and potential hazards are identified.\nThe adequacy of your firm's responses cannot be determined at this time. Your firm initiated CAPA-25006 prior to the current inspection with plans to develop a risk management SOP, review and revise existing product and process risk analysis reports once the new SOP is implemented, and train affected staff, with a target completion date of October 31, 2026. In response to this letter provide documentation for any outstanding corrective actions, including verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\n9. Failure to monitor supplier performance in meeting requirements for purchased product, as required by ISO 13485:2016, Clause 7.4.1.\nSpecifically, your firm's supplier management procedure (NRSU-SOP-0022, Revision 04, Effective Date December 2, 2025) documents your process for classification and evaluation of suppliers. However, your firm was unable to provide any records demonstrating that suppliers and services had ever been classified or evaluated in accordance with this procedure.\nThe adequacy of your firm's responses cannot be determined at this time. Your firm initiated CAPA-25024 prior to the current FDA inspection and has taken immediate corrections by reviewing and updating the approved supplier list (ASL) and increasing supplier oversight until evaluations and\u002For audits are completed. Corrective actions planned include revision of the supplier management SOP, strengthening supplier audit controls, improvements to the SCAR process, and implementation of quality agreements for all Level I ((b)(4) risk) suppliers, with a target completion date of November 20, 2026. However, several of these items remain in progress as of your July 14, 2026 response. In response to this letter provide documentation for any outstanding corrective actions, including verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\nUnique Device Identification Violations\nThe inspection revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a), which was promulgated under authority of section 519 of the Act, among other provisions, requires, with exceptions not relevant here, that the label of every medical device bears a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the Nipro Dry complete dry acid concentrate for hemodialysis devices do not bear such a UDI. For example, the labels for these devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, there is no UDI presented in easily readable plain-text (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses automatic identification and data capture (AIDC) technology (see 21 CFR 801.40(a)(2)).\nIn addition, the Nipro Dry complete dry acid concentrate for hemodialysis is misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting the devices. In particular, 21 CFR 830.300(a) and 830.320(b), both of which were promulgated under section 519 of the Act, among other provisions, require, with exceptions not relevant here, that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. Your firm is a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting these devices.\nThe failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B). Based on review of the Global Unique Device Identification Database (GUDID) on June 11, 2026, there are no entries for Nipro Dry complete dry acid concentrate for hemodialysis.\nA follow up inspection will be required to ensure that corrections and\u002For corrective actions are adequate.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality Management System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Establishment Assessment Team 1 Assistant Director Gina Brackett at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 732874” when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan at sean.moynihan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nCAPT Cesar A. Perez, PhD, USPHS\nActing Deputy Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCc: Vikram Chandra, Sr. VP QA\u002FRA - Nipro Americas Group Companies, Inc., Vikram.Chandra@nipromed.com","Nipro Renal Solutions USA, Corporation","nipro-renal-solutions-usa-corporation-732874-07242026","2026-08-19T04:06:48.349905+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnipro-renal-solutions-usa-corporation-732874-07242026","2026-10-26T08:09:34.119232+00:00","2026-08-18","732874","Medical Devices UDI","Tsuyoshi Yamazaki","2026-08-19T04:26:47.114+00:00","2026-07-24",{"id":314,"raw":315,"subject":12,"body_html":318,"body_text":319,"firm_name":320,"letter_id":321,"created_at":231,"fei_number":19,"letter_url":322,"updated_at":323,"action_type":22,"case_status":23,"posted_date":324,"marcs_cms_no":325,"product_type":26,"closeout_date":19,"issuing_office":79,"recipient_name":326,"body_fetched_at":327,"delivery_method":217,"recipient_title":19,"reference_number":328,"action_taken_date":234,"medical_device_id":19,"response_letter_date":19},274,[316,222,317,79,12,13,13,13],"\u003Ctime datetime=\"2026-03-10T04:00:00Z\">03\u002F10\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsimtra-biopharma-solutions-720436-03032026\">Simtra BioPharma Solutions\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-49\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Franco Negron\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Simtra BioPharma Solutions\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Building C, Suite 270, 2nd Floor\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>400 Interpace Parkway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Parsippany\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07054\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:frnegron@simtra.com\"> frnegron@simtra.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-49\u003C\u002Fp>\u003Cp>March 3, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Negron:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) conducted an unannounced inspection of your drug manufacturing facility, Simtra Deutschland GmbH, formerly Baxter Oncology GmbH, FEI 3002806419, at Kantstr. 2, 33790 Halle\u002FWestphalia, Germany, from September 18 to 26, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your October 20, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.42(c)(10)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Significant deficiencies were identified with aseptic processing controls in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and restricted access barrier system (RABS) processing lines used to aseptically manufacture sterile drug products for the U.S. market.\u003C\u002Fp>\u003Cp>\u003Cem>Cleaning and Disinfection\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You used \u003Cstrong>(b)(4)\u003C\u002Fstrong> extensively to rinse critical, interior surfaces and aseptic processing equipment in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and RABS lines after production. This \u003Cstrong>(b)(4)\u003C\u002Fstrong> was fed from \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning use points inside your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and RABS through excessively long (up to approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>) deadlegs from your \u003Cstrong>(b)(4)\u003C\u002Fstrong> loop. Deadlegs in \u003Cstrong>(b)(4)\u003C\u002Fstrong> systems are known to cause stagnation of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and excessive microbial growth.\u003C\u002Fp>\u003Cp>Between June 2023 and September 2025, routine testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning use points in your ISO 5 \u003Cstrong>(b)(4)\u003C\u002Fstrong> and RABS resulted in at least 47 microbial recoveries, including 14 that exceeded your action limit. Your routine monitoring samples repeatedly recovered gram-negative, biofilm-forming, \u003Cstrong>(b)(4)\u003C\u002Fstrong> organisms including \u003Cem>Sphingomonas, Methylobacterium, Bradyrhizobium\u003C\u002Fem>, and \u003Cem>Ralstonia\u003C\u002Fem> species. Investigations for at least two incidents associated with microbial recoveries identified the design of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning use point piping as the most likely root cause. However, your corrective action and preventive action (CAPA) plans have failed to comprehensively address the identified deficiencies in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system design.\u003C\u002Fp>\u003Cp>Furthermore, post-production environmental monitoring (EM) samples taken within your ISO 5 \u003Cstrong>(b)(4)\u003C\u002Fstrong> and RABS between June 2023 and September 2025 have resulted in repeated recoveries of gram-negative \u003Cstrong>(b)(4)\u003C\u002Fstrong> organisms including \u003Cem>Sphingomonas, Methylobacterium\u003C\u002Fem>, and \u003Cem>Cupriavidus\u003C\u002Fem> species.\u003C\u002Fp>\u003Cp>This sampling identified a worrisome adverse trend in your RABS in late 2023 in which \u003Cstrong>(b)(4)\u003C\u002Fstrong> gaskets and \u003Cstrong>(b)(4)\u003C\u002Fstrong> were found to be contaminated with gram negative microbes. Significantly, too-numerous-to-count (TNTC) levels were present on RABS \u003Cstrong>(b)(4)\u003C\u002Fstrong> gaskets in multiple instances during this period. Your investigations acknowledged that equipment design (including \u003Cstrong>(b)(4)\u003C\u002Fstrong> gaskets) and maintenance, in combination with cleaning (e.g., residual \u003Cstrong>(b)(4)\u003C\u002Fstrong> from cleaning), caused the deviation.\u003C\u002Fp>\u003Cp>You failed to sufficiently address the underlying cause of residual \u003Cstrong>(b)(4)\u003C\u002Fstrong> in a timely manner, instead relying on personnel to \u003Cstrong>(b)(4)\u003C\u002Fstrong> dry any observed moisture.\u003C\u002Fp>\u003Cp>In your response, you commit to corrective actions including \u003Cstrong>(b)(4)\u003C\u002Fstrong> sanitization of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning use point piping and \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in ISO 5 cleaning. Additionally, you explain your process of \u003Cstrong>(b)(4)\u003C\u002Fstrong>-drying your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and RABS with \u003Cstrong>(b)(4)\u003C\u002Fstrong> drying of residual \u003Cstrong>(b)(4)\u003C\u002Fstrong> during visual inspection by operators. You also commit to implementing \u003Cstrong>(b)(4)\u003C\u002Fstrong> disinfection of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and RABS.\u003C\u002Fp>\u003Cp>Your response is inadequate because your corrective actions fail to address the fundamental, self-identified design flaw in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> supply lines” that lead to each of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and RABS processing lines for cleaning. You also fail to holistically address residual \u003Cstrong>(b)(4)\u003C\u002Fstrong> from cleaning your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and RABS units across your site. The residual \u003Cstrong>(b)(4)\u003C\u002Fstrong> issue poses a significant risk to barrier\u002F\u003Cstrong>(b)(4)\u003C\u002Fstrong> system control (e.g., interference with decontamination cycle efficacy) and can potentially lead to drug product contamination.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Integrity Testing\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to adequately maintain equipment to assure aseptic conditions. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity testing program for \u003Cstrong>(b)(4)\u003C\u002Fstrong> was found to be deficient. For example:\u003C\u002Fp>\u003Cul>\u003Cli>Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity testing program for \u003Cstrong>(b)(4)\u003C\u002Fstrong> permitted \u003Cstrong>(b)(4)\u003C\u002Fstrong> to fail acceptance criteria during pressure decay testing \u003Cstrong>(b)(4)\u003C\u002Fstrong> times before requiring replacement. Your translated procedure states, “All \u003Cstrong>(b)(4)\u003C\u002Fstrong> that fail the leak test (pressure drop test) may be retested. If the \u003Cstrong>(b)(4)\u003C\u002Fstrong> fails more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> times, it must be replaced.”\u003C\u002Fli>\u003Cli>When \u003Cstrong>(b)(4)\u003C\u002Fstrong> failed leak testing, retesting was often not performed the same day but at a later date. As a result, you manufactured drug products using \u003Cstrong>(b)(4)\u003C\u002Fstrong> that had failed leak testing without confirming their integrity. For example, \u003Cstrong>(b)(4)\u003C\u002Fstrong> on line \u003Cstrong>(b)(4)\u003C\u002Fstrong> failed to meet acceptance criteria on July 1, 2025, and did not pass testing until July 19, 2025. In the 18-day period between these tests, your production schedule indicated you manufactured at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of drug products.\u003C\u002Fli>\u003Cli>You lacked raw \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing data. During the inspection, you were unable to locate raw \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity testing data from \u003Cstrong>(b)(4)\u003C\u002Fstrong> for line \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>Instead of reviewing raw \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing data, your quality assurance unit relied on forms containing transcribed information.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you commit to enhancing your \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity testing program through procedural updates requiring additional quality oversight, defining actions following test failures including not permitting production to proceed “following an invalid or failed test,” and implementing quality review of visual and \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing results.\u003C\u002Fp>\u003Cp>You indicate that inappropriate acceptance criteria programmed into your \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity testing device caused many of the failures. You also assert, “[T]here has been no impact to any released batches or the overall control of sterility assurance at the site.”\u003C\u002Fp>\u003Cp>Furthermore, your response states that in your operators’ experience, pressure decay failures are generally not indicative of non-integral \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and they instead relied upon visual inspection.\u003C\u002Fp>\u003Cp>Your response calls into question the reliability of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity testing program. Visual inspections, on their own, are insufficient to monitor \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity. Visual \u003Cstrong>(b)(4)\u003C\u002Fstrong> examinations provide far lower detectability than, and cannot be substituted for, \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity testing devices. It is essential that your firm use \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity testing devices that are capable of reliably detecting sub-visible breaches in \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity.\u003C\u002Fp>\u003Cp>You also failed to perform retrospective evaluation of potentially impacted products and processes. In response to the uninvestigated \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity failures, you concluded there was no quality impact to released batches or overall contamination risk at the site. However, you appear to have limited your review only to examples cited during the inspection.\u003C\u002Fp>\u003Cp>Additionally, you failed to assess equipment management across your site to identify other potentially impacted critical equipment that may affect aseptic conditions. You should give continual attention to the integrity of critical equipment. This includes comprehensive maintenance procedures that establish adequate integrity testing and proactive replacement before breakdown.\u003C\u002Fp>\u003Cp>\u003Cem>Protective Equipment Materials\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to implement other adequate equipment control systems to prevent contamination during aseptic processing. Our investigators observed particles shedding from \u003Cstrong>(b)(4)\u003C\u002Fstrong> material in aseptic areas. For example, loose, visible fibers were observed on and dislodging from \u003Cstrong>(b)(4)\u003C\u002Fstrong> covers during \u003Cstrong>(b)(4)\u003C\u002Fstrong> installation within critical aseptic filling areas. Fibers also were observed on tubing in two locations in line \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Subsequently, unused \u003Cstrong>(b)(4)\u003C\u002Fstrong> covers were inspected and observed to have loose fibers indicating the material itself was the source of contamination. You use the material is used to protect \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the end of sterile tubing.\u003C\u002Fp>\u003Cp>Furthermore, this is an ongoing issue. Your customer reported your previous non-pharmaceutical grade \u003Cstrong>(b)(4)\u003C\u002Fstrong> material as a source of particulate contamination. In response, you introduced your current \u003Cstrong>(b)(4)\u003C\u002Fstrong> material across your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and RABS processing lines without evaluating its particle generating characteristics.\u003C\u002Fp>\u003Cp>In your response, you explain the \u003Cstrong>(b)(4)\u003C\u002Fstrong> seams on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> are the apparent source of visible fibers and they appear to be statically charged. You also indicate you are working with your supplier to address this issue while taking interim controls including awareness training, visual checks of equipment at risk of fibers, removal of observed fibers with sterile lint-free wipes, and the exchange of equipment when fibers are observed attached to product contact surfaces.\u003C\u002Fp>\u003Cp>Your response is inadequate. You limited your retrospective batch review to only the two batches observed to be exposed to loose fibers during the inspection. Your response also fails to assess the particles generated by the \u003Cstrong>(b)(4)\u003C\u002Fstrong> material to determine their characteristics (e.g., size). Additionally, your response fails to support the adequacy of visual inspection as an interim control or to review quality indicators for particle related issues (e.g., complaints, deviations). Finally, your response did not address your failure to evaluate particle generation in the replacement material when you implemented a change control for \u003Cstrong>(b)(4)\u003C\u002Fstrong> in response to a particle generation complaint. This is a quality oversight failure.\u003C\u002Fp>\u003Cp>Aseptic processing operations should be designed and executed to minimize exposure of sterile articles to potential contamination hazards in the manufacturing operation. Flaws in the design of cleanrooms and aseptic processing lines or improper execution of aseptic operations can enable entry of contaminants into the critical (ISO 5) processing area and lead to product contamination.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> technology represents a significant advance over traditional operational designs. However, all technologies have failure modes that require ongoing, vigilant monitoring and maintenance to ensure a state of control, including \u003Cstrong>(b)(4)\u003C\u002Fstrong>. A strong quality system is essential to oversee design and construction of aseptic processing lines and supporting utilities, and to ensure ongoing proper operational control to safeguard against contamination hazards throughout the facility lifecycle.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system design, control, and maintenance including, but not limited to:\u003Cbr>o Identification of deadlegs and any other insanitary elements of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system.\u003Cbr>o A comprehensive remediation plan and detailed CAPA timeline for improving design, control, and maintenance of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system. Include re-piping and modifications to eliminate deadlegs, removal of insanitary fittings, assurance of appropriately designed recirculating loops, and completion of all other needed remediations to ensure sanitary systems. Place special emphasis on identifying and eliminating any deadlegs that feed \u003Cstrong>(b)(4)\u003C\u002Fstrong>, RABS, or other sterile production equipment.\u003Cbr>o The validation report for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system after all identified design issues have been fully corrected and any maintenance repairs have been completed. Include the system validation protocol, the complete test results, and the final validation report. Include the summary of all improvements made to system design, as well as the program for ongoing control and maintenance.\u003C\u002Fli>\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of potential contamination from residual moisture after cleaning. For each production line, assess \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning and \u003Cstrong>(b)(4)\u003C\u002Fstrong> drying cycles, identify specific equipment parts which remain within the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and RABS after cleaning, and address the potential for \u003Cstrong>(b)(4)\u003C\u002Fstrong> to remain stagnant within equipment between production operations. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture products intended to be sterile.\u003C\u002Fli>\u003Cli>Based upon the cleaning effectiveness assessment, provide a CAPA detailing improvements to your cleaning and disinfection program including enhancements to cleaning effectiveness, improved ongoing verification of proper cleaning and disinfection execution for all products and equipment, and all other needed remediations.\u003C\u002Fli>\u003Cli>A comprehensive assessment of the design and control of your firm’s manufacturing operations with a detailed and thorough review of all microbiological hazards.\u003C\u002Fli>\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\u003Cli>A comprehensive evaluation of your ongoing \u003Cstrong>(b)(4)\u003C\u002Fstrong> maintenance program.\u003Cbr>o Address elements including, but not limited to, frequency of integrity tests (e.g., at least \u003Cstrong>(b)(4)\u003C\u002Fstrong>), \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing procedure and methodology, and appropriate practices to reduce the occurrence of invalid tests.\u003Cbr>o Conduct an analysis of the various failure scenarios that have occurred during your \u003Cstrong>(b)(4)\u003C\u002Fstrong> leak testing (e.g., device set-up problems, failure to meet initial pressure, employee interference). Also include further clarity on whether supervisors will be notified immediately, prior to initiation of a retest, of any instance of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity test failure.\u003Cbr>o Include a product impact assessment.\u003Cbr>o Provide associated CAPA.\u003C\u002Fli>\u003Cli>A comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities. A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003Cli>A risk assessment addressing the use of shedding material within your critical ISO 5 production areas. Include a detailed summary of how you determined that your interim controls are adequate to prevent the contamination of products. Include details of your investigation such as evaluation of particle generation, particle size distribution, and the likelihood of detection by visual inspection. Discuss your investigation into potentially impacted lots of product including your evaluation of quality indicators such as complaints and deviations. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycles were inadequately validated to ensure that they were capable of consistently decontaminating all interior surfaces of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and multiple RABS lines in preparation for aseptic production.\u003C\u002Fp>\u003Cp>\u003Cem>Biological Indicator Recoveries\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Inadequacies in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> process were demonstrated through a trend of routine recoveries of biological indicator (BI) growth at completion of validation cycles executed in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> since 2022.\u003C\u002Fp>\u003Cp>Notably, your acceptance criteria were inappropriate in that they allowed routine recovery of multiple BI survivors. For example, positive BIs (upwards of 8 recoveries) were identified in nearly all validation cycles (\u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong>) between 2022 and 2025 on your lines \u003Cstrong>(b)(4)\u003C\u002Fstrong> lines. These positive BIs occurred at various locations within each line. However, based upon your inappropriate acceptance criteria, only two of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> validation cycles were found to be unacceptable.\u003C\u002Fp>\u003Cp>Furthermore, you attributed recent validation failures in 2025 to “rogue” phenomenon in a BI lot, but this fails to recognize the multiple positive BIs that occurred with other BI lots in the same year. You also failed to acknowledge your long-term trend of routine BI positives in most of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> validation studies.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate \u003Cstrong>(b)(4)\u003C\u002Fstrong> Validation\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> validation did not demonstrate reliable decontamination cycle capability. For example:\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> were not \u003Cstrong>(b)(4)\u003C\u002Fstrong> during the \u003Cstrong>(b)(4)\u003C\u002Fstrong> validation cycles such that \u003Cstrong>(b)(4)\u003C\u002Fstrong> were present in the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your validation instruction, PPVA VA 48074e\u002F03, appears to permit \u003Cstrong>(b)(4)\u003C\u002Fstrong> to rest on the bottom of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, creating an occluded surface which undermines the ability of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to decontaminate this critical location.\u003C\u002Fli>\u003Cli>You did not document or adequately specify each location of BI placement. You also lacked scientific evidence to support the triplicate BIs being representative of each location.\u003C\u002Fli>\u003Cli>You allowed repetition of validation cycles without proper investigation in each instance of observed BI growth. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> validation cycle was repeated in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> after initially failing to meet its acceptance criteria for positive BIs (\u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you committed to assessing your \u003Cstrong>(b)(4)\u003C\u002Fstrong> for surface exposure and implementing remediations based on your findings where possible, increasing BIs in \u003Cstrong>(b)(4)\u003C\u002Fstrong> with \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> decontamination process validation, updating your procedures to address failed validation cycles, reducing the allowable BI growth, implementing investigational requirements for any BI growth, and optimizing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycle in your \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your response is inadequate. You failed to address multiple years of consistent recoveries of positive BIs across multiple locations within your \u003Cstrong>(b)(4)\u003C\u002Fstrong> during previous validation cycles. Recurrent failures are indicative of poor cycle robustness and require further investigation. Furthermore, your commitment to increase the number of BIs in \u003Cstrong>(b)(4)\u003C\u002Fstrong> does not address setup and configuration adaptations that can ensure consistent exposure of all interior surfaces to \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Incomplete exposure of interior surfaces to \u003Cstrong>(b)(4)\u003C\u002Fstrong> compromises decontamination effectiveness and places the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and RABS environment at risk. Furthermore, as discussed above, the inconsistent removal of residual moisture prior to \u003Cstrong>(b)(4)\u003C\u002Fstrong> treatment of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and RABS could further compromise \u003Cstrong>(b)(4)\u003C\u002Fstrong> decontamination efficacy.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification and ongoing monitoring of variation to ensure a continuing state of control.&nbsp;\u003C\u002Fli>\u003Cli>A comprehensive, independent review of the adequacy of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycles. Place special attention on \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycle stages including \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Provide a timeline for a detailed report on the findings of the independent review and associated CAPA activities (e.g., cycle parameter changes such as an increased decontamination phase duration; optimized airflow; improved surface exposure).\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your decontamination cycles that includes vigilant monitoring to ensure an ongoing state of control. Also, include your program for assuring ongoing state of control throughout your facility and equipment infrastructure.\u003C\u002Fli>\u003Cli>Procedures to ensure residual \u003Cstrong>(b)(4)\u003C\u002Fstrong> is appropriately removed from RABS and \u003Cstrong>(b)(4)\u003C\u002Fstrong> units before execution of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycles.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Request for a Meeting with FDA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>After you submit your response to this warning letter, we recommend you reach out to this office to arrange for a teleconference to discuss your corrective actions and preventive actions in detail. Please direct your request to Patricia Warren at patricia.warren@fda.hhs.gov and cc: CDER-OC-OMQ-Communications@fda.hhs.gov.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Simtra Deutschland GmbH located at Kantstr. 2, 33790 Halle\u002FWestphalia, Germany, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3002806419 and ATTN: Samantha Bradley.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Rémi Helmig\u003Cbr>Site Director\u003Cbr>Simtra Deutschland GmbH\u003Cbr>Kantstr. 2\u003Cbr>33790 Halle\u002FWestphalia\u003Cbr>Germany\u003Cbr>rhelmig@simtra.com\u003C\u002Fp>\u003Cp>_____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-26-49\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nFranco Negron\n\nRecipient Title\n\nChief Executive Officer\n\nSimtra BioPharma Solutions\n\nBuilding C, Suite 270, 2nd Floor\n\n400 Interpace Parkway\n\nParsippany, NJ 07054\n\nUnited States\n\nfrnegron@simtra.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-49\nMarch 3, 2026\nDear Mr. Negron:\nThe United States Food and Drug Administration (FDA) conducted an unannounced inspection of your drug manufacturing facility, Simtra Deutschland GmbH, formerly Baxter Oncology GmbH, FEI 3002806419, at Kantstr. 2, 33790 Halle\u002FWestphalia, Germany, from September 18 to 26, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your October 20, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.42(c)(10)).\nSignificant deficiencies were identified with aseptic processing controls in your (b)(4) and restricted access barrier system (RABS) processing lines used to aseptically manufacture sterile drug products for the U.S. market.\nCleaning and Disinfection\nYou used (b)(4) extensively to rinse critical, interior surfaces and aseptic processing equipment in your (b)(4) and RABS lines after production. This (b)(4) was fed from (b)(4) cleaning use points inside your (b)(4) and RABS through excessively long (up to approximately (b)(4)) deadlegs from your (b)(4) loop. Deadlegs in (b)(4) systems are known to cause stagnation of (b)(4) and excessive microbial growth.\nBetween June 2023 and September 2025, routine testing of (b)(4) cleaning use points in your ISO 5 (b)(4) and RABS resulted in at least 47 microbial recoveries, including 14 that exceeded your action limit. Your routine monitoring samples repeatedly recovered gram-negative, biofilm-forming, (b)(4) organisms including Sphingomonas, Methylobacterium, Bradyrhizobium, and Ralstonia species. Investigations for at least two incidents associated with microbial recoveries identified the design of your (b)(4) cleaning use point piping as the most likely root cause. However, your corrective action and preventive action (CAPA) plans have failed to comprehensively address the identified deficiencies in your (b)(4) system design.\nFurthermore, post-production environmental monitoring (EM) samples taken within your ISO 5 (b)(4) and RABS between June 2023 and September 2025 have resulted in repeated recoveries of gram-negative (b)(4) organisms including Sphingomonas, Methylobacterium, and Cupriavidus species.\nThis sampling identified a worrisome adverse trend in your RABS in late 2023 in which (b)(4) gaskets and (b)(4) were found to be contaminated with gram negative microbes. Significantly, too-numerous-to-count (TNTC) levels were present on RABS (b)(4) gaskets in multiple instances during this period. Your investigations acknowledged that equipment design (including (b)(4) gaskets) and maintenance, in combination with cleaning (e.g., residual (b)(4) from cleaning), caused the deviation.\nYou failed to sufficiently address the underlying cause of residual (b)(4) in a timely manner, instead relying on personnel to (b)(4) dry any observed moisture.\nIn your response, you commit to corrective actions including (b)(4) sanitization of (b)(4) cleaning use point piping and (b)(4) of the (b)(4) used in ISO 5 cleaning. Additionally, you explain your process of (b)(4)-drying your (b)(4) and RABS with (b)(4) drying of residual (b)(4) during visual inspection by operators. You also commit to implementing (b)(4) disinfection of the (b)(4) in your (b)(4) and RABS.\nYour response is inadequate because your corrective actions fail to address the fundamental, self-identified design flaw in your (b)(4) supply lines” that lead to each of your (b)(4) and RABS processing lines for cleaning. You also fail to holistically address residual (b)(4) from cleaning your (b)(4) and RABS units across your site. The residual (b)(4) issue poses a significant risk to barrier\u002F(b)(4) system control (e.g., interference with decontamination cycle efficacy) and can potentially lead to drug product contamination.\n(b)(4) Integrity Testing\nYou failed to adequately maintain equipment to assure aseptic conditions. Your (b)(4) integrity testing program for (b)(4) was found to be deficient. For example:\nYour (b)(4) integrity testing program for (b)(4) permitted (b)(4) to fail acceptance criteria during pressure decay testing (b)(4) times before requiring replacement. Your translated procedure states, “All (b)(4) that fail the leak test (pressure drop test) may be retested. If the (b)(4) fails more than (b)(4) times, it must be replaced.”\nWhen (b)(4) failed leak testing, retesting was often not performed the same day but at a later date. As a result, you manufactured drug products using (b)(4) that had failed leak testing without confirming their integrity. For example, (b)(4) on line (b)(4) failed to meet acceptance criteria on July 1, 2025, and did not pass testing until July 19, 2025. In the 18-day period between these tests, your production schedule indicated you manufactured at least (b)(4) batches of drug products.\nYou lacked raw (b)(4) testing data. During the inspection, you were unable to locate raw (b)(4) integrity testing data from (b)(4) for line (b)(4).\nInstead of reviewing raw (b)(4) testing data, your quality assurance unit relied on forms containing transcribed information.\nIn your response, you commit to enhancing your (b)(4) integrity testing program through procedural updates requiring additional quality oversight, defining actions following test failures including not permitting production to proceed “following an invalid or failed test,” and implementing quality review of visual and (b)(4) testing results.\nYou indicate that inappropriate acceptance criteria programmed into your (b)(4) integrity testing device caused many of the failures. You also assert, “[T]here has been no impact to any released batches or the overall control of sterility assurance at the site.”\nFurthermore, your response states that in your operators’ experience, pressure decay failures are generally not indicative of non-integral (b)(4), and they instead relied upon visual inspection.\nYour response calls into question the reliability of your (b)(4) integrity testing program. Visual inspections, on their own, are insufficient to monitor (b)(4) integrity. Visual (b)(4) examinations provide far lower detectability than, and cannot be substituted for, (b)(4) integrity testing devices. It is essential that your firm use (b)(4) integrity testing devices that are capable of reliably detecting sub-visible breaches in (b)(4) integrity.\nYou also failed to perform retrospective evaluation of potentially impacted products and processes. In response to the uninvestigated (b)(4) integrity failures, you concluded there was no quality impact to released batches or overall contamination risk at the site. However, you appear to have limited your review only to examples cited during the inspection.\nAdditionally, you failed to assess equipment management across your site to identify other potentially impacted critical equipment that may affect aseptic conditions. You should give continual attention to the integrity of critical equipment. This includes comprehensive maintenance procedures that establish adequate integrity testing and proactive replacement before breakdown.\nProtective Equipment Materials\nYou failed to implement other adequate equipment control systems to prevent contamination during aseptic processing. Our investigators observed particles shedding from (b)(4) material in aseptic areas. For example, loose, visible fibers were observed on and dislodging from (b)(4) covers during (b)(4) installation within critical aseptic filling areas. Fibers also were observed on tubing in two locations in line (b)(4). Subsequently, unused (b)(4) covers were inspected and observed to have loose fibers indicating the material itself was the source of contamination. You use the material is used to protect (b)(4) and the end of sterile tubing.\nFurthermore, this is an ongoing issue. Your customer reported your previous non-pharmaceutical grade (b)(4) material as a source of particulate contamination. In response, you introduced your current (b)(4) material across your (b)(4) and RABS processing lines without evaluating its particle generating characteristics.\nIn your response, you explain the (b)(4) seams on the (b)(4) are the apparent source of visible fibers and they appear to be statically charged. You also indicate you are working with your supplier to address this issue while taking interim controls including awareness training, visual checks of equipment at risk of fibers, removal of observed fibers with sterile lint-free wipes, and the exchange of equipment when fibers are observed attached to product contact surfaces.\nYour response is inadequate. You limited your retrospective batch review to only the two batches observed to be exposed to loose fibers during the inspection. Your response also fails to assess the particles generated by the (b)(4) material to determine their characteristics (e.g., size). Additionally, your response fails to support the adequacy of visual inspection as an interim control or to review quality indicators for particle related issues (e.g., complaints, deviations). Finally, your response did not address your failure to evaluate particle generation in the replacement material when you implemented a change control for (b)(4) in response to a particle generation complaint. This is a quality oversight failure.\nAseptic processing operations should be designed and executed to minimize exposure of sterile articles to potential contamination hazards in the manufacturing operation. Flaws in the design of cleanrooms and aseptic processing lines or improper execution of aseptic operations can enable entry of contaminants into the critical (ISO 5) processing area and lead to product contamination.\n(b)(4) technology represents a significant advance over traditional operational designs. However, all technologies have failure modes that require ongoing, vigilant monitoring and maintenance to ensure a state of control, including (b)(4). A strong quality system is essential to oversee design and construction of aseptic processing lines and supporting utilities, and to ensure ongoing proper operational control to safeguard against contamination hazards throughout the facility lifecycle.\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\nIn response to this letter, provide the following:\nA comprehensive assessment of your (b)(4) system design, control, and maintenance including, but not limited to:\no Identification of deadlegs and any other insanitary elements of your (b)(4) system.\no A comprehensive remediation plan and detailed CAPA timeline for improving design, control, and maintenance of your (b)(4) system. Include re-piping and modifications to eliminate deadlegs, removal of insanitary fittings, assurance of appropriately designed recirculating loops, and completion of all other needed remediations to ensure sanitary systems. Place special emphasis on identifying and eliminating any deadlegs that feed (b)(4), RABS, or other sterile production equipment.\no The validation report for the (b)(4) system after all identified design issues have been fully corrected and any maintenance repairs have been completed. Include the system validation protocol, the complete test results, and the final validation report. Include the summary of all improvements made to system design, as well as the program for ongoing control and maintenance.\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of potential contamination from residual moisture after cleaning. For each production line, assess (b)(4) cleaning and (b)(4) drying cycles, identify specific equipment parts which remain within the (b)(4) and RABS after cleaning, and address the potential for (b)(4) to remain stagnant within equipment between production operations. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture products intended to be sterile.\nBased upon the cleaning effectiveness assessment, provide a CAPA detailing improvements to your cleaning and disinfection program including enhancements to cleaning effectiveness, improved ongoing verification of proper cleaning and disinfection execution for all products and equipment, and all other needed remediations.\nA comprehensive assessment of the design and control of your firm’s manufacturing operations with a detailed and thorough review of all microbiological hazards.\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\nA comprehensive evaluation of your ongoing (b)(4) maintenance program.\no Address elements including, but not limited to, frequency of integrity tests (e.g., at least (b)(4)), (b)(4) testing procedure and methodology, and appropriate practices to reduce the occurrence of invalid tests.\no Conduct an analysis of the various failure scenarios that have occurred during your (b)(4) leak testing (e.g., device set-up problems, failure to meet initial pressure, employee interference). Also include further clarity on whether supervisors will be notified immediately, prior to initiation of a retest, of any instance of a (b)(4) integrity test failure.\no Include a product impact assessment.\no Provide associated CAPA.\nA comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities. A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\nA risk assessment addressing the use of shedding material within your critical ISO 5 production areas. Include a detailed summary of how you determined that your interim controls are adequate to prevent the contamination of products. Include details of your investigation such as evaluation of particle generation, particle size distribution, and the likelihood of detection by visual inspection. Discuss your investigation into potentially impacted lots of product including your evaluation of quality indicators such as complaints and deviations. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\n2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\nYour (b)(4) cycles were inadequately validated to ensure that they were capable of consistently decontaminating all interior surfaces of your (b)(4) and multiple RABS lines in preparation for aseptic production.\nBiological Indicator Recoveries\nInadequacies in your (b)(4) process were demonstrated through a trend of routine recoveries of biological indicator (BI) growth at completion of validation cycles executed in your (b)(4) since 2022.\nNotably, your acceptance criteria were inappropriate in that they allowed routine recovery of multiple BI survivors. For example, positive BIs (upwards of 8 recoveries) were identified in nearly all validation cycles ((b)(4) of (b)(4)) between 2022 and 2025 on your lines (b)(4) lines. These positive BIs occurred at various locations within each line. However, based upon your inappropriate acceptance criteria, only two of the (b)(4) validation cycles were found to be unacceptable.\nFurthermore, you attributed recent validation failures in 2025 to “rogue” phenomenon in a BI lot, but this fails to recognize the multiple positive BIs that occurred with other BI lots in the same year. You also failed to acknowledge your long-term trend of routine BI positives in most of your (b)(4) validation studies.\nInadequate (b)(4) Validation\nYour (b)(4) validation did not demonstrate reliable decontamination cycle capability. For example:\n(b)(4) were not (b)(4) during the (b)(4) validation cycles such that (b)(4) were present in the (b)(4). Your validation instruction, PPVA VA 48074e\u002F03, appears to permit (b)(4) to rest on the bottom of (b)(4), creating an occluded surface which undermines the ability of (b)(4) to decontaminate this critical location.\nYou did not document or adequately specify each location of BI placement. You also lacked scientific evidence to support the triplicate BIs being representative of each location.\nYou allowed repetition of validation cycles without proper investigation in each instance of observed BI growth. Your (b)(4) validation cycle was repeated in your (b)(4) after initially failing to meet its acceptance criteria for positive BIs ((b)(4) out of (b)(4)).\nIn your response, you committed to assessing your (b)(4) for surface exposure and implementing remediations based on your findings where possible, increasing BIs in (b)(4) with (b)(4) for (b)(4) decontamination process validation, updating your procedures to address failed validation cycles, reducing the allowable BI growth, implementing investigational requirements for any BI growth, and optimizing the (b)(4) cycle in your (b)(4).\nYour response is inadequate. You failed to address multiple years of consistent recoveries of positive BIs across multiple locations within your (b)(4) during previous validation cycles. Recurrent failures are indicative of poor cycle robustness and require further investigation. Furthermore, your commitment to increase the number of BIs in (b)(4) does not address setup and configuration adaptations that can ensure consistent exposure of all interior surfaces to (b)(4).\nIncomplete exposure of interior surfaces to (b)(4) compromises decontamination effectiveness and places the (b)(4) and RABS environment at risk. Furthermore, as discussed above, the inconsistent removal of residual moisture prior to (b)(4) treatment of your (b)(4) and RABS could further compromise (b)(4) decontamination efficacy.\nIn response to this letter, provide:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification and ongoing monitoring of variation to ensure a continuing state of control.\nA comprehensive, independent review of the adequacy of (b)(4) cycles. Place special attention on (b)(4) cycle stages including (b)(4). Provide a timeline for a detailed report on the findings of the independent review and associated CAPA activities (e.g., cycle parameter changes such as an increased decontamination phase duration; optimized airflow; improved surface exposure).\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your decontamination cycles that includes vigilant monitoring to ensure an ongoing state of control. Also, include your program for assuring ongoing state of control throughout your facility and equipment infrastructure.\nProcedures to ensure residual (b)(4) is appropriately removed from RABS and (b)(4) units before execution of (b)(4) cycles.\nRequest for a Meeting with FDA\nAfter you submit your response to this warning letter, we recommend you reach out to this office to arrange for a teleconference to discuss your corrective actions and preventive actions in detail. Please direct your request to Patricia Warren at patricia.warren@fda.hhs.gov and cc: CDER-OC-OMQ-Communications@fda.hhs.gov.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Simtra Deutschland GmbH located at Kantstr. 2, 33790 Halle\u002FWestphalia, Germany, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3002806419 and ATTN: Samantha Bradley.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nCC:\nRémi Helmig\nSite Director\nSimtra Deutschland GmbH\nKantstr. 2\n33790 Halle\u002FWestphalia\nGermany\nrhelmig@simtra.com\n_____________________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Simtra BioPharma Solutions","simtra-biopharma-solutions-720436-03032026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsimtra-biopharma-solutions-720436-03032026","2026-10-26T08:09:57.988668+00:00","2026-03-10","720436","Franco Negron","2026-08-19T04:52:12.655+00:00","320-26-49",{"id":330,"raw":331,"subject":337,"body_html":338,"body_text":339,"firm_name":340,"letter_id":341,"created_at":266,"fei_number":19,"letter_url":342,"updated_at":343,"action_type":22,"case_status":23,"posted_date":344,"marcs_cms_no":345,"product_type":346,"closeout_date":19,"issuing_office":335,"recipient_name":347,"body_fetched_at":348,"delivery_method":137,"recipient_title":19,"reference_number":19,"action_taken_date":349,"medical_device_id":19,"response_letter_date":19},2624,[332,333,334,335,336,13,13,13],"\u003Ctime datetime=\"2022-06-14T13:20:00Z\">06\u002F14\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-05-16T04:00:00Z\">05\u002F16\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fequine-podiatry-solutions-llc-633259-05162022\">Equine Podiatry Solutions, LLC\u003C\u002Fa>","Center for Veterinary Medicine","Unapproved New Animal Drug Products\u003Cbr \u002F>\r\n","Unapproved New Animal Drug Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Derrick Cooke\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Equine Podiatry Solutions, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>105 Burkhalter Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Claxton\u003C\u002Fspan>, \u003Cspan>GA\u003C\u002Fspan> \u003Cspan>30417\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:derrick@beatlaminitis.com\"> derrick@beatlaminitis.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>May 16, 2022\u003C\u002Fp>\n\n\u003Cp>RE: [633259]\u003C\u002Fp>\n\n\u003Cp>Dear Derrick Cooke:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s marketing of unapproved veterinary products for the treatment of disease in animals, including but not limited to, Desmosphyrine. The U.S. Food and Drug Administration (FDA) has reviewed your website at the Internet address www.beatlaminitis.com in October 2021, November 2021, and March 2022 and has determined that you distribute this product there. We have also reviewed your social media websites at www.facebook.com\u002Fequine-podiatry-solutions-llc and https:\u002F\u002Fwww.youtube.com\u002Fchannel\u002FUCR9waBp-xd02qG5ugsHJ-oQ where you direct consumers to your website at www.beatlaminitis.com to purchase products. The claims on your website and social media websites establish that your “Desmosphyrine” product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) [21 U.S.C. § 321(g)(1)(B)] because it is intended for the use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals. As explained further below, this product is an unapproved new animal drug and introducing or delivering this product for introduction into interstate commerce violates the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>You can find the FD&amp;C Act and FDA regulations through links on FDA’s homepage at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Examples of claims FDA observed on your website and social media that show the intended uses of your “Desmosphyrine” product includes, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>From your website www.beatlaminitis.com: Webpage titled – “Guide to Laminitis: Treatment Solutions for Horses”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Desmosphyrine is the first product that effectively treats acute laminitis before it becomes chronic.”\u003C\u002Fli>\n\t\u003Cli>“Desmosphyrine is the only treatment available that directly addresses the underlying cause of laminitis and stops the matrix metalloproteinase from digesting collagen. This treatment has been successful in clinical trials at treating acute laminitis when applied early.”\u003C\u002Fli>\n\t\u003Cli>“Desmosphyrine is a new method of treatment that helps prevent MMP from activating and digesting the collagen of a hoof.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From your website www.beatlaminitis.com: Webpage titled – “How Important Time Is To Preventing Chronic Laminitis”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Desmosphyrine is the first effective product for treating acute laminitis…”\u003C\u002Fli>\n\t\u003Cli>Radiographs labeled as “BEFORE” and “AFTER” with the accompanying statement, “Evidence of effectiveness of product as shown through before and after radiographs.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From your website www.beatlaminitis.com: Webpage titled – “\u003Cstrong>(b)(6)\u003C\u002Fstrong> Success with Beating Laminitis – Equine Podiatry Solutions”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Under a header “DESMOSPHYRINE”, your website states “A man named Derrick from Equine Podiatry Solutions LLC reached out to \u003Cstrong>(b)(6)\u003C\u002Fstrong> and her owner with a donation of Desmosphyrine that was meant to help treat \u003Cstrong>(b)(6)\u003C\u002Fstrong> acute laminitis. Fortunately, after the application of treatment, …, she began to improve.\"\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From your website www.beatlaminitis.com: Webpage titled – “Client Reviews”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“\u003Cstrong>(b)(6)\u003C\u002Fstrong> was treated with Desmosphyrine on November 5, 6, and 7. He was back under the saddle on December 28, 2015.”\u003C\u002Fli>\n\t\u003Cli>“Desmosphyrine is the first effective product for treating Acute Laminitis…”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From your social media website www.facebook.com\u002FBeatLaminitis: Webpage titled – “Equine Podiatry Solutions LLC – Home | Facebook”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>On your February 10, 2022 post: “We are committed to preventing permanent damage to horses after Acute laminitis &amp; stopping euthanasia from the disease. We are proud to be the industry leader and standard for treating acute laminitis. At Equine Podiatry Solutions, our passion for seeing horses healthy and at peak performance drives our mission to provide healing.”\u003C\u002Fli>\n\t\u003Cli>On your March 10, 2022 post: “In order for this treatment to be effective, it must be applied as soon as signs of acute laminitis are present!\"\u003C\u002Fli>\n\t\u003Cli>On your February 2, 2022 post: “Join the growing number of clinics using Desmosphyrine to treat laminitis, and engage with the community making a difference in the second leading killer of horses.”\u003C\u002Fli>\n\t\u003Cli>On your February 18, 2022 post that has a link to a youtube.com video titled “Springtime Laminitis”: “We are proud to be the industry leader and standard for treating acute laminitis.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From your Equine Podiatry Solutions, LLC YouTube channel, https:\u002F\u002Fwww.youtube.com\u002Fchannel\u002FUCR9waBp-xd02qG5ugsHJ-oQ:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>March 15, 2021 YouTube video titled “Springtime Laminitis”, posted on the webpage: https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=gG2WBcNG474]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o “We hope you don’t have to use our product, Desmosphyrine. Our product is now available… We are pretty excited about this product. It helps these horses that undergo the acute phase of laminitis.” [from 01:01 – 01:27]\u003Cbr>\n&nbsp; &nbsp; o “We are glad that this product not only helps them survive the acute phase of laminitis with their life, but they’re actually able to go back to work in a relatively short period, most of the time it’s about two months.” [from 01:58 - 02:13]\u003C\u002Fp>\n\n\u003Cp>This product is a new animal drug, as defined by section 201(v) of the FD&amp;C Act, [21 U.S.C. § 321(v)], because it is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&amp;C Act [21 U.S.C. §§ 360b, 360ccc, and 360ccc-1]. This product is not approved or index listed by FDA, and therefore, the product is unsafe within the meaning of section 512(a) of the FD&amp;C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&amp;C Act [21 U.S.C. § 351(a)(5)]. The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all the requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify this office, in writing, within fifteen (15) working days of the receipt of this letter of the steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete the corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your product is not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent via e-mail to Dr. Vic Boddie at CVMUnapprovedDrugs@fda.hhs.gov. If you have any questions about this letter, please contact Dr. Boddie at that address.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Neal Bataller, ME, DVM\u003Cbr>\nDirector, Division of Drug Compliance\u003Cbr>\nOffice of Surveillance &amp; Compliance\u003Cbr>\nCenter for Veterinary Medicine\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nAnimal & Veterinary\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDerrick Cooke\n\nRecipient Title\n\nCEO\n\nEquine Podiatry Solutions, LLC\n\n105 Burkhalter Road\n\nClaxton, GA 30417\n\nUnited States\n\nderrick@beatlaminitis.com\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWARNING LETTER\n\nMay 16, 2022\n\nRE: [633259]\n\nDear Derrick Cooke:\n\nThis letter concerns your firm’s marketing of unapproved veterinary products for the treatment of disease in animals, including but not limited to, Desmosphyrine. The U.S. Food and Drug Administration (FDA) has reviewed your website at the Internet address www.beatlaminitis.com in October 2021, November 2021, and March 2022 and has determined that you distribute this product there. We have also reviewed your social media websites at www.facebook.com\u002Fequine-podiatry-solutions-llc and https:\u002F\u002Fwww.youtube.com\u002Fchannel\u002FUCR9waBp-xd02qG5ugsHJ-oQ where you direct consumers to your website at www.beatlaminitis.com to purchase products. The claims on your website and social media websites establish that your “Desmosphyrine” product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) [21 U.S.C. § 321(g)(1)(B)] because it is intended for the use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals. As explained further below, this product is an unapproved new animal drug and introducing or delivering this product for introduction into interstate commerce violates the FD&C Act.\n\nYou can find the FD&C Act and FDA regulations through links on FDA’s homepage at www.fda.gov.\n\nExamples of claims FDA observed on your website and social media that show the intended uses of your “Desmosphyrine” product includes, but may not be limited to, the following:\n\nFrom your website www.beatlaminitis.com: Webpage titled – “Guide to Laminitis: Treatment Solutions for Horses”\n\n“Desmosphyrine is the first product that effectively treats acute laminitis before it becomes chronic.”\n\n“Desmosphyrine is the only treatment available that directly addresses the underlying cause of laminitis and stops the matrix metalloproteinase from digesting collagen. This treatment has been successful in clinical trials at treating acute laminitis when applied early.”\n\n“Desmosphyrine is a new method of treatment that helps prevent MMP from activating and digesting the collagen of a hoof.”\n\nFrom your website www.beatlaminitis.com: Webpage titled – “How Important Time Is To Preventing Chronic Laminitis”\n\n“Desmosphyrine is the first effective product for treating acute laminitis…”\n\nRadiographs labeled as “BEFORE” and “AFTER” with the accompanying statement, “Evidence of effectiveness of product as shown through before and after radiographs.”\n\nFrom your website www.beatlaminitis.com: Webpage titled – “(b)(6) Success with Beating Laminitis – Equine Podiatry Solutions”:\n\nUnder a header “DESMOSPHYRINE”, your website states “A man named Derrick from Equine Podiatry Solutions LLC reached out to (b)(6) and her owner with a donation of Desmosphyrine that was meant to help treat (b)(6) acute laminitis. Fortunately, after the application of treatment, …, she began to improve.\"\n\nFrom your website www.beatlaminitis.com: Webpage titled – “Client Reviews”:\n\n“(b)(6) was treated with Desmosphyrine on November 5, 6, and 7. He was back under the saddle on December 28, 2015.”\n\n“Desmosphyrine is the first effective product for treating Acute Laminitis…”\n\nFrom your social media website www.facebook.com\u002FBeatLaminitis: Webpage titled – “Equine Podiatry Solutions LLC – Home | Facebook”:\n\nOn your February 10, 2022 post: “We are committed to preventing permanent damage to horses after Acute laminitis & stopping euthanasia from the disease. We are proud to be the industry leader and standard for treating acute laminitis. At Equine Podiatry Solutions, our passion for seeing horses healthy and at peak performance drives our mission to provide healing.”\n\nOn your March 10, 2022 post: “In order for this treatment to be effective, it must be applied as soon as signs of acute laminitis are present!\"\n\nOn your February 2, 2022 post: “Join the growing number of clinics using Desmosphyrine to treat laminitis, and engage with the community making a difference in the second leading killer of horses.”\n\nOn your February 18, 2022 post that has a link to a youtube.com video titled “Springtime Laminitis”: “We are proud to be the industry leader and standard for treating acute laminitis.”\n\nFrom your Equine Podiatry Solutions, LLC YouTube channel, https:\u002F\u002Fwww.youtube.com\u002Fchannel\u002FUCR9waBp-xd02qG5ugsHJ-oQ:\n\nMarch 15, 2021 YouTube video titled “Springtime Laminitis”, posted on the webpage: https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=gG2WBcNG474]\n\no “We hope you don’t have to use our product, Desmosphyrine. Our product is now available… We are pretty excited about this product. It helps these horses that undergo the acute phase of laminitis.” [from 01:01 – 01:27]\n\no “We are glad that this product not only helps them survive the acute phase of laminitis with their life, but they’re actually able to go back to work in a relatively short period, most of the time it’s about two months.” [from 01:58 - 02:13]\n\nThis product is a new animal drug, as defined by section 201(v) of the FD&C Act, [21 U.S.C. § 321(v)], because it is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&C Act [21 U.S.C. §§ 360b, 360ccc, and 360ccc-1]. This product is not approved or index listed by FDA, and therefore, the product is unsafe within the meaning of section 512(a) of the FD&C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&C Act [21 U.S.C. § 351(a)(5)]. The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all the requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and\u002For injunction.\n\nPlease notify this office, in writing, within fifteen (15) working days of the receipt of this letter of the steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete the corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your product is not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent via e-mail to Dr. Vic Boddie at CVMUnapprovedDrugs@fda.hhs.gov. If you have any questions about this letter, please contact Dr. Boddie at that address.\n\nSincerely,\n\n\u002FS\u002F\n\nNeal Bataller, ME, DVM\n\nDirector, Division of Drug Compliance\n\nOffice of Surveillance & Compliance\n\nCenter for Veterinary Medicine","Equine Podiatry Solutions, LLC","equine-podiatry-solutions-llc-633259-05162022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fequine-podiatry-solutions-llc-633259-05162022","2026-10-26T08:08:36.056915+00:00","2022-06-14","633259","Animal & VeterinaryDrugs","Derrick Cooke","2026-08-20T01:50:13.583+00:00","2022-05-16",{"id":351,"raw":352,"subject":60,"body_html":357,"body_text":358,"firm_name":359,"letter_id":360,"created_at":65,"fei_number":19,"letter_url":361,"updated_at":362,"action_type":22,"case_status":131,"posted_date":363,"marcs_cms_no":364,"product_type":70,"closeout_date":365,"issuing_office":59,"recipient_name":366,"body_fetched_at":367,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":368,"medical_device_id":19,"response_letter_date":19},3281,[353,354,355,59,60,13,356,13],"\u003Ctime datetime=\"2021-07-06T13:20:00Z\">07\u002F06\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-06-28T04:00:00Z\">06\u002F28\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fworld-packaging-solutions-llc-612824-06282021\">World Packaging Solutions, LLC\u003C\u002Fa>","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fworld-packaging-solutions-llc-612824-09272021\">\u003Ctime datetime=\"2021-10-07T04:00:00Z\">10\u002F07\u002F2021\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jim Sonsalla\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>World Packaging Solutions, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3901 NW 79th Ave, Suite 245-1468\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Miami\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33166\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:js@wpkgs-ppe.com\"> js@wpkgs-ppe.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>DATE:&nbsp;June 28, 2021\u003Cbr>\n\u003Cbr>\nRe: “Purvigor KN95 Mask”\u003C\u002Fp>\n\n\u003Cp>Dear Jim Sonsalla:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) has reviewed your website at the Internet address https:\u002F\u002Fwpkgs-ppe.com\u002Fpurvigor-kn95-masks\u002F on May 18, 2021. The FDA has observed that your website offers the “Purvigor KN95 Mask” for sale in the United States. Based on our review, the product is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>FDA’s review of your website revealed the following statements that establish that the products are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, including but not limited to:\u003C\u002Fp>\n\n\u003Cp>• Representing that the Purvigor KN95 Mask is intended for use in offering an “anti-infection layer to help protect”, “anti-flu”, “anti-bacterial”, and “PFE [Particle FiltrationEfficiency] ≥ 95% BFE [Bacterial Filtration Efficiency] ≥ 95%” [https:\u002F\u002Fwpkgs-ppe.com\u002Fproduct\u002Fpurvigor-kn95-mask]\u003C\u002Fp>\n\n\u003Cp>The Purvigor KN95 Mask, which your website indicates is manufactured by “Guangdong Fei Fan Mstar Technology Ltd.” (Guangdong), is offered for sale in the United States without marketing approval, clearance, or authorization from the FDA. Accordingly, the product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). The product is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003Cbr>\n\u003Cbr>\nIn addition, the Purvigor KN95 Mask is misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because its labeling is false or misleading. FDA registration of a device establishment or assignment of a registration number does not denote FDA approval of the establishment or the device. Thus, references to Guangdong’s establishment registration and registration number that create an impression of official FDA approval, clearance, authorization, certification, endorsement or other evaluation of the establishment or the devices are misleading and constitute misbranding. See 21 CFR 807.39.\u003C\u002Fp>\n\n\u003Cp>Your website contains a number of false and\u002For misleading representations, including but not limited to:\u003C\u002Fp>\n\n\u003Cp>• Stating that the Purvigor KN95 Masks are “FDA Registered – NIOSH Tested – CDC Listed.” [https:\u002F\u002Fwpkgs-ppe.com\u002Fpurvigor-kn95-masks\u002F]\u003Cbr>\n• Stating “Approved, FDA EUA Appendix A List” alongside Purvigor KN95 Mask product information. [https:\u002F\u002Fwpkgs-ppe.com\u002Fproduct\u002Fpurvigor-kn95-mask\u002F]\u003Cbr>\n• Displaying the FDA logo\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> on the Purvigor KN95 Mask packaging. [https:\u002F\u002Fwpkgs-ppe.com\u002Fproduct\u002Fpurvigor-kn95-mask\u002F]\u003Cbr>\n• Displaying a “Certification of Registration”, issued by “Shenzhen CTB Testing Technology Co., Ltd” (Shenzhen Certificate) under the “Certification” page on your website. The Shenzhen Certificate “certifies that Guangdong Fei Fan Mstar Technology Ltd. … has completed the FDA Establishment Registration and Device Listing with the US Food &amp; Drug Administration…” The Shenzhen Certificate has the look of an official government document and incorporates unauthorized use of the FDA logo1 and an illustration of an eagle and a U.S. flag (or a similar flag). [https:\u002F\u002Fwpkgs-ppe.com\u002Fcertifications\u002F]\u003Cbr>\n• Displaying a screenshot of what appears to be a previous entry for Guangdong Fei Fan Mstar Technology Ltd in FDA’s Establishment Registration &amp; Device Listing Database. [https:\u002F\u002Fwpkgs-ppe.com\u002Fcertifications\u002F]\u003C\u002Fp>\n\n\u003Cp>Taken together, display of the Shenzhen Certificate, bearing the FDA logo, stating the product is “FDA Registered” and “Approved, FDA EUA Appendix A List,”\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and displaying a screenshot from FDA’s Establishment Registration &amp; Device Listing Database positioned near images of and information about the Purvigor KN95 Mask are misleading because they imply FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishment based on the representations that Guangdong Fei Fan Mstar Technology Ltd is or was registered with FDA and that the firm is or was in possession of a registration number. Although the Shenzhen Certificate for Guangdong contains language that appears to be intended to function as a disclaimer, including a statement that the Certification does not denote FDA endorsement or approval, statements that FDA does not issue or recognize certificates of registration, and a statement that quotes 21 CFR 807.39, the small font size and overall placement of the language could be easily overlooked and do not limit or otherwise mitigate the misleading impression created by the use of the Certification. Such representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the product has been reviewed and approved by FDA.\u003C\u002Fp>\n\n\u003Cp>We remind you that FDA’s Center for Devices and Radiological Health (CDRH) does not issue device registration certificates to medical device establishments, including to sellers and manufacturers. When an establishment registers and lists its devices, the resulting entry in FDA’s Establishment Registration &amp; Device Listing Database merely denotes that the establishment has provided certain information to FDA.\u003C\u002Fp>\n\n\u003Cp>This letter is not meant to be an all-inclusive list of violations that exist in connection with the product(s) or your operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your website, product labels, and other labeling and promotional materials to ensure that you do not make representations that misbrand the product in violation of the Act.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. Please notify this office in writing within fifteen 15 business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of any actions your firm has taken. If your firm’s planned actions will occur over time, please include a timetable for implementation of those activities. Your firm’s response should be comprehensive and address all violations included in this letter. If you believe that the product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to:\u003C\u002Fp>\n\n\u003Cp>Food and Drug Administration\u003Cbr>\nCenter for Devices and Radiological Health\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nDivision of Regulatory Programs 2: Establishment Support\u003Cbr>\nRegulatory Inspections and Audits Team\u003Cbr>\nWhite Oak Building 66\u003Cbr>\n10903 New Hampshire Ave.\u003Cbr>\nSilver Spring, MD 20993\u003Cbr>\n\u003Cbr>\nRefer to the Document number CMS Case Number 612824 or CTS Number CPT2000983 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Assistant Director, Paola Barnett at 301-796-5462 or Paola.Barnett@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Donna Engleman, MS, BSN\u003Cbr>\nDirector Division of Market Intelligence\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003Cbr>\n\u003Cbr>\nCc:\u003Cbr>\nShiyuan Wang\u003Cbr>\nGuangdong Fei Fan Mstar Technology Ltd\u003Cbr>\nA1 workshop, No.10, Dongnan Xincun Avenue, Zone 2,\u003Cbr>\nCaobian No.3 Industrial Zone,Dali Town, Nanhai District\u003Cbr>\nFoshan Guangdong, CN 528200\u003C\u002Fp>\n\n\u003Cp>Shenzhen CTB Testing Technology\u003Cbr>\nFirst floor, E building, Huayang\u003Cbr>\nTechnology Industry Park,\u003Cbr>\nGushu Village, Bao'an District,\u003Cbr>\nShenzhen City, P.R.C\u003C\u002Fp>\n\n\u003Cp>_______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The FDA logo is for official use by FDA and not for private use on labeling of FDA-regulated products. See FDA Logo Policy (available at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy\">https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy\u003C\u002Fa>)\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The Purvigor KN95 Face Mask offered for sale on your website appears to be the KN95 model manufactured by Guangdong Fei Fan Mstar Technology Ltd., which was removed from Appendix A of the Emergency Use Authorization (EUA) for Imported, Non-NIOSH Approved Respirators Manufactured in China (updated February 18, 2021) on May 7, 2020. As indicated in the EUA, a respirator model that has been removed from Appendix A is included in a list of respirator models whose authorization has been revoked. The list of removed respirators is maintained on FDA’s EUA webpage (\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fcoronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices\u002Fpersonal-protective-equipment-euas#nolongerauth\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fcoronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices\u002Fpersonal-protective-equipment-euas#nolongerauth\u003C\u002Fa>).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJim Sonsalla\n\nWorld Packaging Solutions, LLC\n\n3901 NW 79th Ave, Suite 245-1468\n\nMiami, FL 33166\n\nUnited States\n\njs@wpkgs-ppe.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDATE: June 28, 2021\n\nRe: “Purvigor KN95 Mask”\n\nDear Jim Sonsalla:\n\nThis is to advise you that the United States Food and Drug Administration (FDA) has reviewed your website at the Internet address https:\u002F\u002Fwpkgs-ppe.com\u002Fpurvigor-kn95-masks\u002F on May 18, 2021. The FDA has observed that your website offers the “Purvigor KN95 Mask” for sale in the United States. Based on our review, the product is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nFDA’s review of your website revealed the following statements that establish that the products are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, including but not limited to:\n\n• Representing that the Purvigor KN95 Mask is intended for use in offering an “anti-infection layer to help protect”, “anti-flu”, “anti-bacterial”, and “PFE [Particle FiltrationEfficiency] ≥ 95% BFE [Bacterial Filtration Efficiency] ≥ 95%” [https:\u002F\u002Fwpkgs-ppe.com\u002Fproduct\u002Fpurvigor-kn95-mask]\n\nThe Purvigor KN95 Mask, which your website indicates is manufactured by “Guangdong Fei Fan Mstar Technology Ltd.” (Guangdong), is offered for sale in the United States without marketing approval, clearance, or authorization from the FDA. Accordingly, the product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). The product is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\n\nIn addition, the Purvigor KN95 Mask is misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because its labeling is false or misleading. FDA registration of a device establishment or assignment of a registration number does not denote FDA approval of the establishment or the device. Thus, references to Guangdong’s establishment registration and registration number that create an impression of official FDA approval, clearance, authorization, certification, endorsement or other evaluation of the establishment or the devices are misleading and constitute misbranding. See 21 CFR 807.39.\n\nYour website contains a number of false and\u002For misleading representations, including but not limited to:\n\n• Stating that the Purvigor KN95 Masks are “FDA Registered – NIOSH Tested – CDC Listed.” [https:\u002F\u002Fwpkgs-ppe.com\u002Fpurvigor-kn95-masks\u002F]\n\n• Stating “Approved, FDA EUA Appendix A List” alongside Purvigor KN95 Mask product information. [https:\u002F\u002Fwpkgs-ppe.com\u002Fproduct\u002Fpurvigor-kn95-mask\u002F]\n\n• Displaying the FDA logo1 on the Purvigor KN95 Mask packaging. [https:\u002F\u002Fwpkgs-ppe.com\u002Fproduct\u002Fpurvigor-kn95-mask\u002F]\n\n• Displaying a “Certification of Registration”, issued by “Shenzhen CTB Testing Technology Co., Ltd” (Shenzhen Certificate) under the “Certification” page on your website. The Shenzhen Certificate “certifies that Guangdong Fei Fan Mstar Technology Ltd. … has completed the FDA Establishment Registration and Device Listing with the US Food & Drug Administration…” The Shenzhen Certificate has the look of an official government document and incorporates unauthorized use of the FDA logo1 and an illustration of an eagle and a U.S. flag (or a similar flag). [https:\u002F\u002Fwpkgs-ppe.com\u002Fcertifications\u002F]\n\n• Displaying a screenshot of what appears to be a previous entry for Guangdong Fei Fan Mstar Technology Ltd in FDA’s Establishment Registration & Device Listing Database. [https:\u002F\u002Fwpkgs-ppe.com\u002Fcertifications\u002F]\n\nTaken together, display of the Shenzhen Certificate, bearing the FDA logo, stating the product is “FDA Registered” and “Approved, FDA EUA Appendix A List,”2 and displaying a screenshot from FDA’s Establishment Registration & Device Listing Database positioned near images of and information about the Purvigor KN95 Mask are misleading because they imply FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishment based on the representations that Guangdong Fei Fan Mstar Technology Ltd is or was registered with FDA and that the firm is or was in possession of a registration number. Although the Shenzhen Certificate for Guangdong contains language that appears to be intended to function as a disclaimer, including a statement that the Certification does not denote FDA endorsement or approval, statements that FDA does not issue or recognize certificates of registration, and a statement that quotes 21 CFR 807.39, the small font size and overall placement of the language could be easily overlooked and do not limit or otherwise mitigate the misleading impression created by the use of the Certification. Such representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the product has been reviewed and approved by FDA.\n\nWe remind you that FDA’s Center for Devices and Radiological Health (CDRH) does not issue device registration certificates to medical device establishments, including to sellers and manufacturers. When an establishment registers and lists its devices, the resulting entry in FDA’s Establishment Registration & Device Listing Database merely denotes that the establishment has provided certain information to FDA.\n\nThis letter is not meant to be an all-inclusive list of violations that exist in connection with the product(s) or your operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your website, product labels, and other labeling and promotional materials to ensure that you do not make representations that misbrand the product in violation of the Act.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. Please notify this office in writing within fifteen 15 business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of any actions your firm has taken. If your firm’s planned actions will occur over time, please include a timetable for implementation of those activities. Your firm’s response should be comprehensive and address all violations included in this letter. If you believe that the product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to:\n\nFood and Drug Administration\n\nCenter for Devices and Radiological Health\n\nOffice of Regulatory Programs\n\nDivision of Regulatory Programs 2: Establishment Support\n\nRegulatory Inspections and Audits Team\n\nWhite Oak Building 66\n\n10903 New Hampshire Ave.\n\nSilver Spring, MD 20993\n\nRefer to the Document number CMS Case Number 612824 or CTS Number CPT2000983 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Assistant Director, Paola Barnett at 301-796-5462 or Paola.Barnett@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nDonna Engleman, MS, BSN\n\nDirector Division of Market Intelligence\n\nOffice of Regulatory Programs\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCc:\n\nShiyuan Wang\n\nGuangdong Fei Fan Mstar Technology Ltd\n\nA1 workshop, No.10, Dongnan Xincun Avenue, Zone 2,\n\nCaobian No.3 Industrial Zone,Dali Town, Nanhai District\n\nFoshan Guangdong, CN 528200\n\nShenzhen CTB Testing Technology\n\nFirst floor, E building, Huayang\n\nTechnology Industry Park,\n\nGushu Village, Bao'an District,\n\nShenzhen City, P.R.C\n\n_______________________\n\n1 The FDA logo is for official use by FDA and not for private use on labeling of FDA-regulated products. See FDA Logo Policy (available at: https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy)\n\n2 The Purvigor KN95 Face Mask offered for sale on your website appears to be the KN95 model manufactured by Guangdong Fei Fan Mstar Technology Ltd., which was removed from Appendix A of the Emergency Use Authorization (EUA) for Imported, Non-NIOSH Approved Respirators Manufactured in China (updated February 18, 2021) on May 7, 2020. As indicated in the EUA, a respirator model that has been removed from Appendix A is included in a list of respirator models whose authorization has been revoked. The list of removed respirators is maintained on FDA’s EUA webpage (https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fcoronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices\u002Fpersonal-protective-equipment-euas#nolongerauth).","World Packaging Solutions, LLC","world-packaging-solutions-llc-612824-06282021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fworld-packaging-solutions-llc-612824-06282021","2026-10-26T08:10:33.293711+00:00","2021-07-06","612824","2021-10-07","Jim Sonsalla","2026-08-20T03:00:08.891+00:00","2021-06-28",{"id":370,"raw":371,"subject":12,"body_html":375,"body_text":376,"firm_name":377,"letter_id":378,"created_at":128,"fei_number":19,"letter_url":379,"updated_at":380,"action_type":22,"case_status":23,"posted_date":381,"marcs_cms_no":382,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":383,"body_fetched_at":384,"delivery_method":137,"recipient_title":19,"reference_number":19,"action_taken_date":385,"medical_device_id":19,"response_letter_date":19},2395,[372,373,374,11,12,13,13,13],"\u003Ctime datetime=\"2022-10-18T13:20:00Z\">10\u002F18\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-09-06T04:00:00Z\">09\u002F06\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-cleaning-solutions-632881-09062022\">American Cleaning Solutions\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Ronald C. Ingber\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>American Cleaning Solutions\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3930 Review Ave.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Long Island City\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11101\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter CMS #: 632881\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 6, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Ingber:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, American Cleaning Solutions, FEI 3001587133, at 3930 Review Avenue, Long Island City, Ny from March 7 to March 28, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your March 29, 2022, response to our Form FDA 483 in detail. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP. We acknowledge your commitment to deregistering and your decision to cease manufacturing hand sanitizer drug products permanently.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures over-the-counter (OTC) hand sanitizer\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> drug products including Secure Gel Hand Rub and Secure Hand Rub, as well as non-drug products including insecticides and industrial cleaners. It is unacceptable as a matter of CGMP to continue manufacturing drugs using the same equipment that you use to manufacture pesticides or other non-pharmaceutical products due to the risk of cross-contamination. Our investigator also observed inadequate cleaning and maintenance of your drug manufacturing equipment, specifically:\u003C\u002Fp>\n\n\u003Cp>Your firm lacks an adequate cleaning and maintenance procedure. Your cleaning procedure states that your production tanks are cleaned with hot water and allowed to air dry. Your procedure does not list or describe the use of cleaning agents, sampling requirements, or testing specifications. During the inspection you stated that you document cleaning activities on the drug product batch records. However, no evidence of cleaning was observed on the batch records of your drug products, and you confirmed that your firm does not have cleaning or equipment use logs.\u003C\u002Fp>\n\n\u003Cp>In addition, your equipment used to manufacture your drug products were observed to be in a state of disrepair. For example, rust-like residue and other substances were observed on the product contact surfaces of your production and mixing vessels. An accumulation of dirt, debris, and grease-like residues was also observed throughout the facility and on production equipment used to manufacture drug products such as your pumps and filling lines.\u003C\u002Fp>\n\n\u003Cp>Inadequate removal of active ingredients and product residues from surfaces of non-dedicated manufacturing equipment can lead to contamination of drug products subsequently manufactured on that equipment.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100(a) and (b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm has not established that your processes used to manufacture hand sanitizer drug products are validated. You also confirmed that equipment qualification has not been performed on this equipment.\u003C\u002Fp>\n\n\u003Cp>Further, your batch records do not accurately or consistently reflect your formulation for hand sanitizer drug products. For example, the formulation for your hand sanitizer drug products calls for the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong>% isopropanol as the active ingredient. However, examples from the batch records of these products manufactured in 2020, included a mixture of both isopropanol and ethanol as active ingredients. However, ethanol was not listed as an ingredient on your hand sanitizer drug product labels. In addition, your labels list “Purified Water USP” as an ingredient. However, your formulation calls for the use of “\u003Cstrong>(b)(4)\u003C\u002Fstrong> water” and you confirmed to our investigators that your firm is unable to manufacture purified water, and that you use \u003Cstrong>(b)(4)\u003C\u002Fstrong> water as an ingredient in the manufacturing of your drug products.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and (2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately test your incoming components for identity before using the components to manufacture your drug products. Additionally, you relied on certificates of analysis from unqualified suppliers for specifications such as purity, strength, and quality. By not adequately analyzing your components for identity, purity, strength, and quality, you failed to ensure that your incoming components meet appropriate specifications.\u003C\u002Fp>\n\n\u003Cp>You stated to our investigators that you only test raw materials arriving in tankers. However, you were unable to provide evidence that any testing was performed on your incoming raw materials. In addition, you were unable to provide evidence that you have ever qualified the suppliers of your raw materials.\u003C\u002Fp>\n\n\u003Cp>You manufactured drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID- 19)\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ethanol at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>As a manufacturer, you have a responsibility to sample, test, and examine drug components before use to assure adequate quality, including testing for the presence of methanol in ethanol, before use in production.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Appropriate testing for the identity and strength of the active ingredients was performed and reviewed before release for each batch of drug product (21 CFR 211.165(a)).\u003C\u002Fli>\n\t\u003Cli>Thorough investigations for out-of-specifications results, complaints, deviations, and other discrepant results per an adequate written and approved procedure (21 CFR 211.192).\u003C\u002Fli>\n\t\u003Cli>Appropriate documentation and assessment of production and process control changes (21 CFR 211.100(a)).\u003C\u002Fli>\n\t\u003Cli>Establishment of an adequate, ongoing stability program (21 CFR 211.166(a)).\u003C\u002Fli>\n\t\u003Cli>Performance of annual product reviews (21 CFR 211.180(e)).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>An adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>501(d) Adulteration Violations - Substitution\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Secure Hand Sanitizer, listed as being manufactured at your facility, is labeled to contain 70% v\u002Fv of the active ingredient Isopropyl Alcohol (IPA). However, you confirmed to our investigator and provided production records of batches of this product which contained the addition of ethanol. Therefore, this hand sanitizer drug product is adulterated under section 501(d)(2) of the FD&amp;C Act in that the active ingredient, isopropanol, was substituted wholly or in part with ethanol.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Repeat Observations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In a previous inspection conducted in 2016, FDA cited similar CGMP observations. You proposed specific remediation for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Production Ceased\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>While we acknowledge your commitment to cease production of drugs at this facility, we note that you provided a similar commitment in your response to your 2016 FDA inspection.\u003C\u002Fp>\n\n\u003Cp>If you plan to resume manufacturing drugs, notify this office before resuming your operations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to ORAPHARM1_RESPONSES@fda.hhs.gov. Your written notification should refer to Warning Letter CMS # 632881 and include FEI: 3001587133.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the content of this letter, please contact Samina Khan, Compliance Officer, at samina.khan@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003Cbr>\nNerizza Guerin\u003Cbr>\nActing Program Division Director\u002FDistrict Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations Division I\u002F\u003Cbr>\nNew Jersey District\u003C\u002Fp>\n\n\u003Cp>___________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, the FDA published the Guidance for Industry: \u003Cem>\u003Cstrong>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fstrong>\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (\u003Cem>86 Fed Reg at 56960\u003C\u002Fem>). This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepared alcohol- based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance were present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. Because American Cleaning Solutions hand sanitizer drug products were not consistent with the formulations described in these guidances, they did not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Ronald C. Ingber\n\nRecipient Title\n\nPresident\n\nAmerican Cleaning Solutions\n\n3930 Review Ave.\n\nLong Island City, NY 11101\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nWarning Letter CMS #: 632881\n\nSeptember 6, 2022\n\nDear Mr. Ingber:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, American Cleaning Solutions, FEI 3001587133, at 3930 Review Avenue, Long Island City, Ny from March 7 to March 28, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your March 29, 2022, response to our Form FDA 483 in detail. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP. We acknowledge your commitment to deregistering and your decision to cease manufacturing hand sanitizer drug products permanently.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish and follow written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b).\n\nYour firm manufactures over-the-counter (OTC) hand sanitizer1 drug products including Secure Gel Hand Rub and Secure Hand Rub, as well as non-drug products including insecticides and industrial cleaners. It is unacceptable as a matter of CGMP to continue manufacturing drugs using the same equipment that you use to manufacture pesticides or other non-pharmaceutical products due to the risk of cross-contamination. Our investigator also observed inadequate cleaning and maintenance of your drug manufacturing equipment, specifically:\n\nYour firm lacks an adequate cleaning and maintenance procedure. Your cleaning procedure states that your production tanks are cleaned with hot water and allowed to air dry. Your procedure does not list or describe the use of cleaning agents, sampling requirements, or testing specifications. During the inspection you stated that you document cleaning activities on the drug product batch records. However, no evidence of cleaning was observed on the batch records of your drug products, and you confirmed that your firm does not have cleaning or equipment use logs.\n\nIn addition, your equipment used to manufacture your drug products were observed to be in a state of disrepair. For example, rust-like residue and other substances were observed on the product contact surfaces of your production and mixing vessels. An accumulation of dirt, debris, and grease-like residues was also observed throughout the facility and on production equipment used to manufacture drug products such as your pumps and filling lines.\n\nInadequate removal of active ingredients and product residues from surfaces of non-dedicated manufacturing equipment can lead to contamination of drug products subsequently manufactured on that equipment.\n\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100(a) and (b)).\n\nYour firm has not established that your processes used to manufacture hand sanitizer drug products are validated. You also confirmed that equipment qualification has not been performed on this equipment.\n\nFurther, your batch records do not accurately or consistently reflect your formulation for hand sanitizer drug products. For example, the formulation for your hand sanitizer drug products calls for the use of (b)(4)% isopropanol as the active ingredient. However, examples from the batch records of these products manufactured in 2020, included a mixture of both isopropanol and ethanol as active ingredients. However, ethanol was not listed as an ingredient on your hand sanitizer drug product labels. In addition, your labels list “Purified Water USP” as an ingredient. However, your formulation calls for the use of “(b)(4) water” and you confirmed to our investigators that your firm is unable to manufacture purified water, and that you use (b)(4) water as an ingredient in the manufacturing of your drug products.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\n3. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and (2)).\n\nYou failed to adequately test your incoming components for identity before using the components to manufacture your drug products. Additionally, you relied on certificates of analysis from unqualified suppliers for specifications such as purity, strength, and quality. By not adequately analyzing your components for identity, purity, strength, and quality, you failed to ensure that your incoming components meet appropriate specifications.\n\nYou stated to our investigators that you only test raw materials arriving in tankers. However, you were unable to provide evidence that any testing was performed on your incoming raw materials. In addition, you were unable to provide evidence that you have ever qualified the suppliers of your raw materials.\n\nYou manufactured drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID- 19) to help you meet the CGMP requirements when manufacturing drugs containing ethanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload.\n\nAs a manufacturer, you have a responsibility to sample, test, and examine drug components before use to assure adequate quality, including testing for the presence of methanol in ethanol, before use in production.\n\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\n\nAppropriate testing for the identity and strength of the active ingredients was performed and reviewed before release for each batch of drug product (21 CFR 211.165(a)).\n\nThorough investigations for out-of-specifications results, complaints, deviations, and other discrepant results per an adequate written and approved procedure (21 CFR 211.192).\n\nAppropriate documentation and assessment of production and process control changes (21 CFR 211.100(a)).\n\nEstablishment of an adequate, ongoing stability program (21 CFR 211.166(a)).\n\nPerformance of annual product reviews (21 CFR 211.180(e)).\n\nAn adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\n501(d) Adulteration Violations - Substitution\n\nSecure Hand Sanitizer, listed as being manufactured at your facility, is labeled to contain 70% v\u002Fv of the active ingredient Isopropyl Alcohol (IPA). However, you confirmed to our investigator and provided production records of batches of this product which contained the addition of ethanol. Therefore, this hand sanitizer drug product is adulterated under section 501(d)(2) of the FD&C Act in that the active ingredient, isopropanol, was substituted wholly or in part with ethanol.\n\nRepeat Observations at Facility\n\nIn a previous inspection conducted in 2016, FDA cited similar CGMP observations. You proposed specific remediation for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\n\nDrug Production Ceased\n\nWhile we acknowledge your commitment to cease production of drugs at this facility, we note that you provided a similar commitment in your response to your 2016 FDA inspection.\n\nIf you plan to resume manufacturing drugs, notify this office before resuming your operations.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to ORAPHARM1_RESPONSES@fda.hhs.gov. Your written notification should refer to Warning Letter CMS # 632881 and include FEI: 3001587133.\n\nIf you have questions regarding the content of this letter, please contact Samina Khan, Compliance Officer, at samina.khan@fda.hhs.gov.\n\n\u002FS\u002F\n\nNerizza Guerin\n\nActing Program Division Director\u002FDistrict Director\n\nOffice of Pharmaceutical Quality Operations Division I\u002F\n\nNew Jersey District\n\n___________________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, the FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepared alcohol- based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance were present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. Because American Cleaning Solutions hand sanitizer drug products were not consistent with the formulations described in these guidances, they did not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act.","American Cleaning Solutions","american-cleaning-solutions-632881-09062022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-cleaning-solutions-632881-09062022","2026-10-26T08:07:54.694061+00:00","2022-10-18","632881","Mr. Ronald C. Ingber","2026-08-20T01:30:05.513+00:00","2022-09-06",{"id":387,"raw":388,"subject":392,"body_html":393,"body_text":394,"firm_name":395,"letter_id":396,"created_at":128,"fei_number":19,"letter_url":397,"updated_at":398,"action_type":22,"case_status":23,"posted_date":399,"marcs_cms_no":400,"product_type":26,"closeout_date":19,"issuing_office":206,"recipient_name":19,"body_fetched_at":401,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":402,"medical_device_id":19,"response_letter_date":19},2166,[389,390,391,206,392,13,13,13],"\u003Ctime datetime=\"2023-03-14T13:20:00Z\">03\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-03-02T05:00:00Z\">03\u002F02\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Felectrx-and-health-solutions-llc-614251-03022023\">ElectRx and Health Solutions, LLC\u003C\u002Fa>","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>ElectRx and Health Solutions, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cdiv>\n\u003Cp>FROM: The United States Food and Drug Administration\u003C\u002Fp>\n\n\u003Cp>RE: Causing the Introduction of Unapproved and Misbranded Drugs into Interstate Commerce\u003C\u002Fp>\n\n\u003Cp>DATE: March 2, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The United States (U.S.) Food and Drug Administration (FDA) has observed that ElectRx and Health Solutions, LLC (“ElectRx”) causes the introduction of unapproved new drugs and misbranded drugs into interstate commerce in violation of sections 301(a), 301(d), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. §§ 331(a), 331(d), and 355(a)].\u003C\u002Fp>\n\n\u003Cp>There are inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Accordingly, FDA requests that ElectRx cease causing the introduction of unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from potential harm.\u003C\u002Fp>\n\n\u003Cp>ElectRx contracts with public and private sector employers throughout the U.S. to provide select prescription drugs to employees. ElectRx acts as a broker between foreign pharmacies and the employee-sponsored health insurance plans to provide enrolled employees with prescription drugs. ElectRx accepts the employee’s U.S. prescription and facilitates the dispensing of the prescription drug by a foreign pharmacy. The foreign pharmacy then ships the drug directly to the employee in the U.S. Invoices for prescription drugs purchased through ElectRx state, “You may have noticed that the medication which has been shipped to you is different in name or presentation to that which you may have received in the past. IF YOU HAVE ORDERED A BRANDED DRUG the name may appear different to the one you are used to. The reason for this is that you have been supplied internationally branded product and for various reasons drug companies market their products under different names and packaging in different countries.” Additionally, several of ElectRx’s formularies include the statement, “Please note that the medications ordered from the ElectRx formulary are sourced internationally, and may be marketed with a different name or a different strength to medications in the USA.” These statements demonstrate that ElectRx has designed its business to operate in a manner that substitutes the FDA-approved drugs prescribed by the U.S. healthcare provider with unapproved drugs. This distribution scheme is particularly concerning, as employees are likely inclined to trust that they will receive safe and effective drugs through their employer’s “insurance” plan and may not question their legitimacy.\u003C\u002Fp>\n\n\u003Cp>The substitution of FDA-approved prescription drugs with unapproved drugs poses significant health risks to U.S. consumers. For example, ElectRx offers certain drugs on its formularies for which the FDA-approved version is subject to a Risk Evaluation and Mitigation Strategy (REMS)\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> program, has a narrow therapeutic index (NTI)\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>, is a controlled substance, and\u002For is indicated to treat serious conditions such as HIV, cancer, or hepatitis. ElectRx also offers maintenance medications that are indicated for conditions such as high blood pressure, high cholesterol, and acid reflux. Substituting an unapproved drug for the FDA-approved drug prescribed by a patient’s healthcare practitioner can negatively affect patient outcomes because the healthcare practitioner may unknowingly make subsequent treatment decisions based on the patient's response to the unapproved drug. This can also cause potentially dangerous drug interactions with the patient’s other medications. This is of particular concern for drugs subject to REMS programs and NTI drugs. Moreover, the substitution of FDA-approved prescription drugs with unapproved versions that may have substantially different risk profiles can pose serious health risks to consumers, especially in vulnerable patient populations that suffer from serious conditions.\u003C\u002Fp>\n\n\u003Cp>Prescription medicines that are approved for use in the United States have been reviewed by FDA for safety, effectiveness, and quality and are subject to FDA-regulated manufacturing controls and FDA inspections of manufacturing facilities. Unapproved foreign drugs circumvent these safeguards, which are designed to protect patients. Unapproved drugs do not have the same assurance of safety and efficacy as drugs subject to FDA oversight and may be subpotent, superpotent, or adulterated with unknown active ingredients. Treatment with drugs that may be subpotent, superpotent, or adulterated can lead to drug resistance and\u002For therapeutic failures, and jeopardize the effectiveness of alternative drug therapies on patient outcomes.\u003C\u002Fp>\n\n\u003Cp>FDA has also established processes to recall unsafe, substandard, and poor-quality drugs within the legitimate U.S. drug supply chain. No such safeguards exist for unapproved drugs illegally distributed in the U.S. from foreign sources such as those provided through ElectRx. In addition, the unapproved versions of FDA-approved drugs offered by ElectRx may have different trade names and\u002For strengths in their labeling than their FDA-approved counterparts. Such differences can cause patient confusion and lead to medication errors.\u003C\u002Fp>\n\n\u003Cp>Examples of drugs offered on ElectRx’s formularies and a general description of their respective indications are depicted in the table below. These include drugs that are for vulnerable patient populations with serious medical conditions. This is not an exhaustive list of the drugs offered on ElectRx formularies.\u003C\u002Fp>\n\n\u003Ctable>\n\t\u003Ctbody>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>Advair Diskus (asthma, COPD)\u003C\u002Ftd>\n\t\t\t\u003Ctd>Invirase (HIV)\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>Afinitor (cancer)\u003C\u002Ftd>\n\t\t\t\u003Ctd>Opsumit (pulmonary arterial hypertension)\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>Astagraf XL (organ rejection)\u003C\u002Ftd>\n\t\t\t\u003Ctd>Tasigna (cancer)\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>Descovy (HIV)\u003C\u002Ftd>\n\t\t\t\u003Ctd>Truvada (HIV)\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>Epivir‐HBV (hepatitis)\u003C\u002Ftd>\n\t\t\t\u003Ctd>Vemlidy (hepatitis)\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>Gilotrif (cancer)\u003C\u002Ftd>\n\t\t\t\u003Ctd>Vimpat (epilepsy)\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>Inlyta (cancer)\u003C\u002Ftd>\n\t\t\t\u003Ctd>Zortress (organ rejection)\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As described above, ElectRx causes the introduction of unapproved new drugs from foreign sources into interstate commerce in the United States in violation of the FD&amp;C Act by substituting the FDA-approved drugs prescribed by a patient’s physician with unapproved drugs sourced from foreign pharmacies. Because these products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For affect the structure or function of the body, these products are drugs within the meaning of section 201(g)(1) of the FD&amp;C Act [21 U.S.C. § 321(g)(1)]. These products are also new drugs as defined by section 201(p) of the FD&amp;C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions that do not apply here, new drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act [21 U.S.C. § 355(a)]. No FDA-approved applications pursuant to section 505 of the FD&amp;C Act [21 U.S.C. § 355] are in effect for these products. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act [21 U.S.C. §§ 331(d) and 355(a)].\u003C\u002Fp>\n\n\u003Cp>For example, one of the drugs provided via ElectRx is tacrolimus extended-release capsules, manufactured by Astellas and marketed as “Advagraf.” While there are FDA-approved versions of tacrolimus extended-release capsules on the market in the U.S., including “Astagraf XL” manufactured by Astellas, there are no approved drug applications pursuant to section 505 of the FD&amp;C Act in effect for the “Advagraf” provided by ElectRx. Extended-release capsules of tacrolimus administered orally are NTI drugs. FDA-approved tacrolimus extended-release capsules are indicated for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants in adult and pediatric patients who can swallow capsules intact. FDA-approved tacrolimus extended-release capsules bears a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses an increased risk for developing serious infections and malignancies with tacrolimus or other immunosuppressants that may lead to hospitalization or death, and increased mortality in female liver transplant patients.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drugs:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Prescription drugs, as defined in section 503(b)(1) of the FD&amp;C Act [21 U.S.C. § 353(b)(1)] include those that, because of their toxicity or other potentiality for harmful effect, and\u002For the method of their use, and\u002For the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&amp;C Act, can be used safely only at the direction, and under the supervision, of a licensed practitioner. Because ElectRx advises consumers that their U.S. prescriptions are being filled with less expensive, foreign drugs, ElectRx concedes that these drugs are prescription drugs.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the FD&amp;C Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). The drugs offered by ElectRx are prescription drugs intended to treat conditions that are not amenable to self-diagnosis and treatment by persons who are not medical practitioners. Therefore, adequate directions for use cannot be written for these drugs, and they must qualify for one of the exemptions to section 502(f)(1) to avoid being misbranded. The exemption to section 502(f)(1) found at 21 CFR § 201.100 does not apply to unapproved new drugs because that exemption requires that such drugs bear “the labeling authorized by the approved new drug application.” In addition, because these drugs are not approved in the U.S., they are also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&amp;C Act. Because none of the exemptions to section 502(f)(1) apply, these drugs are misbranded under section 502(f)(1).\u003C\u002Fp>\n\n\u003Cp>By causing these products to be shipped to U.S. consumers, ElectRx is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>FDA is sending this Warning Letter to ElectRx because of the risks posed by its conduct in causing the importation of unapproved new drugs and misbranded drugs to U.S. consumers. FDA’s regulation and oversight of the drug approval process protects consumers by requiring rigorous scientific standards for new drug approval, labeling review for accuracy and completeness, and manufacturing procedures and testing performed under closely controlled conditions at FDA-registered and inspected facilities.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to identify all the ways in which your activities might be in violation of U.S. law. You should promptly cease causing the distribution of unapproved new drugs and misbranded drugs to U.S. consumers and correct any other violations of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within 15 working days of receipt of this letter describing the specific steps you have taken or will take to address any violations and to prevent their recurrence. Include an explanation of each step being taken to remedy and prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately address this matter may result in legal action, including but not limited to, seizure, injunction, and\u002For temporary restraining order without further notice. If the corrective action(s) cannot be completed within 15 working days, state the reason for the delay and the time within which the corrections will be completed. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration within 15 working days. Please direct your response, and any inquiries concerning this letter, to FDA at CDERDrugSupplyChainIntegrity@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nS. Leigh Verbois, Ph.D.\u003Cbr>\nDirector, Office of Drug Security, Integrity, and Response\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> A REMS is a drug safety program that the U.S. Food and Drug Administration (FDA) can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. REMS are designed to reinforce medication use behaviors and actions that support the safe use of that medication.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Narrow therapeutic index (NTI) drugs are drugs where small differences in dose or blood concentration may lead to serious therapeutic failures and\u002For adverse drug reactions that are life-threatening or result in persistent or significant disability or incapacity.\u003C\u002Fp>\n\u003C\u002Fdiv>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nElectRx and Health Solutions, LLC\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nFROM: The United States Food and Drug Administration\n\nRE: Causing the Introduction of Unapproved and Misbranded Drugs into Interstate Commerce\n\nDATE: March 2, 2023\n\nWARNING LETTER\n\nThe United States (U.S.) Food and Drug Administration (FDA) has observed that ElectRx and Health Solutions, LLC (“ElectRx”) causes the introduction of unapproved new drugs and misbranded drugs into interstate commerce in violation of sections 301(a), 301(d), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 331(a), 331(d), and 355(a)].\n\nThere are inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Accordingly, FDA requests that ElectRx cease causing the introduction of unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from potential harm.\n\nElectRx contracts with public and private sector employers throughout the U.S. to provide select prescription drugs to employees. ElectRx acts as a broker between foreign pharmacies and the employee-sponsored health insurance plans to provide enrolled employees with prescription drugs. ElectRx accepts the employee’s U.S. prescription and facilitates the dispensing of the prescription drug by a foreign pharmacy. The foreign pharmacy then ships the drug directly to the employee in the U.S. Invoices for prescription drugs purchased through ElectRx state, “You may have noticed that the medication which has been shipped to you is different in name or presentation to that which you may have received in the past. IF YOU HAVE ORDERED A BRANDED DRUG the name may appear different to the one you are used to. The reason for this is that you have been supplied internationally branded product and for various reasons drug companies market their products under different names and packaging in different countries.” Additionally, several of ElectRx’s formularies include the statement, “Please note that the medications ordered from the ElectRx formulary are sourced internationally, and may be marketed with a different name or a different strength to medications in the USA.” These statements demonstrate that ElectRx has designed its business to operate in a manner that substitutes the FDA-approved drugs prescribed by the U.S. healthcare provider with unapproved drugs. This distribution scheme is particularly concerning, as employees are likely inclined to trust that they will receive safe and effective drugs through their employer’s “insurance” plan and may not question their legitimacy.\n\nThe substitution of FDA-approved prescription drugs with unapproved drugs poses significant health risks to U.S. consumers. For example, ElectRx offers certain drugs on its formularies for which the FDA-approved version is subject to a Risk Evaluation and Mitigation Strategy (REMS)1 program, has a narrow therapeutic index (NTI)2, is a controlled substance, and\u002For is indicated to treat serious conditions such as HIV, cancer, or hepatitis. ElectRx also offers maintenance medications that are indicated for conditions such as high blood pressure, high cholesterol, and acid reflux. Substituting an unapproved drug for the FDA-approved drug prescribed by a patient’s healthcare practitioner can negatively affect patient outcomes because the healthcare practitioner may unknowingly make subsequent treatment decisions based on the patient's response to the unapproved drug. This can also cause potentially dangerous drug interactions with the patient’s other medications. This is of particular concern for drugs subject to REMS programs and NTI drugs. Moreover, the substitution of FDA-approved prescription drugs with unapproved versions that may have substantially different risk profiles can pose serious health risks to consumers, especially in vulnerable patient populations that suffer from serious conditions.\n\nPrescription medicines that are approved for use in the United States have been reviewed by FDA for safety, effectiveness, and quality and are subject to FDA-regulated manufacturing controls and FDA inspections of manufacturing facilities. Unapproved foreign drugs circumvent these safeguards, which are designed to protect patients. Unapproved drugs do not have the same assurance of safety and efficacy as drugs subject to FDA oversight and may be subpotent, superpotent, or adulterated with unknown active ingredients. Treatment with drugs that may be subpotent, superpotent, or adulterated can lead to drug resistance and\u002For therapeutic failures, and jeopardize the effectiveness of alternative drug therapies on patient outcomes.\n\nFDA has also established processes to recall unsafe, substandard, and poor-quality drugs within the legitimate U.S. drug supply chain. No such safeguards exist for unapproved drugs illegally distributed in the U.S. from foreign sources such as those provided through ElectRx. In addition, the unapproved versions of FDA-approved drugs offered by ElectRx may have different trade names and\u002For strengths in their labeling than their FDA-approved counterparts. Such differences can cause patient confusion and lead to medication errors.\n\nExamples of drugs offered on ElectRx’s formularies and a general description of their respective indications are depicted in the table below. These include drugs that are for vulnerable patient populations with serious medical conditions. This is not an exhaustive list of the drugs offered on ElectRx formularies.\n\nAdvair Diskus (asthma, COPD)\nInvirase (HIV)\n\nAfinitor (cancer)\nOpsumit (pulmonary arterial hypertension)\n\nAstagraf XL (organ rejection)\nTasigna (cancer)\n\nDescovy (HIV)\nTruvada (HIV)\n\nEpivir‐HBV (hepatitis)\nVemlidy (hepatitis)\n\nGilotrif (cancer)\nVimpat (epilepsy)\n\nInlyta (cancer)\nZortress (organ rejection)\n\nUnapproved New Drugs:\n\nAs described above, ElectRx causes the introduction of unapproved new drugs from foreign sources into interstate commerce in the United States in violation of the FD&C Act by substituting the FDA-approved drugs prescribed by a patient’s physician with unapproved drugs sourced from foreign pharmacies. Because these products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For affect the structure or function of the body, these products are drugs within the meaning of section 201(g)(1) of the FD&C Act [21 U.S.C. § 321(g)(1)]. These products are also new drugs as defined by section 201(p) of the FD&C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions that do not apply here, new drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]. No FDA-approved applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] are in effect for these products. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act [21 U.S.C. §§ 331(d) and 355(a)].\n\nFor example, one of the drugs provided via ElectRx is tacrolimus extended-release capsules, manufactured by Astellas and marketed as “Advagraf.” While there are FDA-approved versions of tacrolimus extended-release capsules on the market in the U.S., including “Astagraf XL” manufactured by Astellas, there are no approved drug applications pursuant to section 505 of the FD&C Act in effect for the “Advagraf” provided by ElectRx. Extended-release capsules of tacrolimus administered orally are NTI drugs. FDA-approved tacrolimus extended-release capsules are indicated for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants in adult and pediatric patients who can swallow capsules intact. FDA-approved tacrolimus extended-release capsules bears a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses an increased risk for developing serious infections and malignancies with tacrolimus or other immunosuppressants that may lead to hospitalization or death, and increased mortality in female liver transplant patients.\n\nMisbranded Drugs:\n\nPrescription drugs, as defined in section 503(b)(1) of the FD&C Act [21 U.S.C. § 353(b)(1)] include those that, because of their toxicity or other potentiality for harmful effect, and\u002For the method of their use, and\u002For the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act, can be used safely only at the direction, and under the supervision, of a licensed practitioner. Because ElectRx advises consumers that their U.S. prescriptions are being filled with less expensive, foreign drugs, ElectRx concedes that these drugs are prescription drugs.\n\nA drug is misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). The drugs offered by ElectRx are prescription drugs intended to treat conditions that are not amenable to self-diagnosis and treatment by persons who are not medical practitioners. Therefore, adequate directions for use cannot be written for these drugs, and they must qualify for one of the exemptions to section 502(f)(1) to avoid being misbranded. The exemption to section 502(f)(1) found at 21 CFR § 201.100 does not apply to unapproved new drugs because that exemption requires that such drugs bear “the labeling authorized by the approved new drug application.” In addition, because these drugs are not approved in the U.S., they are also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&C Act. Because none of the exemptions to section 502(f)(1) apply, these drugs are misbranded under section 502(f)(1).\n\nBy causing these products to be shipped to U.S. consumers, ElectRx is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n\nFDA is sending this Warning Letter to ElectRx because of the risks posed by its conduct in causing the importation of unapproved new drugs and misbranded drugs to U.S. consumers. FDA’s regulation and oversight of the drug approval process protects consumers by requiring rigorous scientific standards for new drug approval, labeling review for accuracy and completeness, and manufacturing procedures and testing performed under closely controlled conditions at FDA-registered and inspected facilities.\n\nThis letter is not intended to identify all the ways in which your activities might be in violation of U.S. law. You should promptly cease causing the distribution of unapproved new drugs and misbranded drugs to U.S. consumers and correct any other violations of the FD&C Act.\n\nPlease notify this office in writing within 15 working days of receipt of this letter describing the specific steps you have taken or will take to address any violations and to prevent their recurrence. Include an explanation of each step being taken to remedy and prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately address this matter may result in legal action, including but not limited to, seizure, injunction, and\u002For temporary restraining order without further notice. If the corrective action(s) cannot be completed within 15 working days, state the reason for the delay and the time within which the corrections will be completed. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration within 15 working days. Please direct your response, and any inquiries concerning this letter, to FDA at CDERDrugSupplyChainIntegrity@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nS. Leigh Verbois, Ph.D.\n\nDirector, Office of Drug Security, Integrity, and Response\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\n_____________________\n\n1 A REMS is a drug safety program that the U.S. Food and Drug Administration (FDA) can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. REMS are designed to reinforce medication use behaviors and actions that support the safe use of that medication.\n\n2 Narrow therapeutic index (NTI) drugs are drugs where small differences in dose or blood concentration may lead to serious therapeutic failures and\u002For adverse drug reactions that are life-threatening or result in persistent or significant disability or incapacity.","ElectRx and Health Solutions, LLC","electrx-and-health-solutions-llc-614251-03022023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Felectrx-and-health-solutions-llc-614251-03022023","2026-10-26T08:08:34.115705+00:00","2023-03-14","614251","2026-08-20T01:12:06.472+00:00","2023-03-02",35,{"510k":405,"classification":406,"enforcement":407,"event":408,"event_backfill":409,"pma":410,"warning_letter":411},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]